<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     tm2037742d1_10k.htm     <description>      FORM 10-K      <text>       <title>       </title>       <p style="margin: 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         UNITED STATES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SECURITIES AND EXCHANGE COMMISSION        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        Washington, D.C. 20549       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         FORM 10-K        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Wingdings">         x        </font>        <b>         ANNUAL REPORTPURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        For the fiscal year ended September 30,2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Wingdings">         ¨        </font>        <b>         TRANSITIONREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        For the transition period from _____ to_____       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Commission File Number        <b>         001-36745        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        (Exact name of registrant as specified in its charter)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 23%">          </td>          <td style="width: 28%; border-bottom: black 1pt solid; text-align: center">           <b>            Delaware           </b>          </td>          <td style="width: 1%">          </td>          <td style="width: 25%; border-bottom: black 1pt solid; text-align: center">           <b>            59-2262718           </b>          </td>          <td style="width: 23%">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">           (State or other jurisdiction of          </td>          <td>          </td>          <td style="text-align: center">           (I.R.S. Employer          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">           incorporation or organization)          </td>          <td>          </td>          <td style="text-align: center">           Identification No.)          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 34%; text-align: center">           <b>            50 Health Sciences Drive,           </b>          </td>          <td style="width: 1%">          </td>          <td style="width: 32%">          </td>          <td style="width: 1%">          </td>          <td style="width: 32%">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid; text-align: center">           <b>            Stony Brook, New York           </b>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <b>            11790           </b>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <b>            (631) 240-8800           </b>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           (Address of principal executive offices)          </td>          <td>          </td>          <td style="text-align: center">           (Zip Code)          </td>          <td>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            (Registrant’s telephone number,           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            including area code)           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Securities registered pursuant to Section 12(b) ofthe Act:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="width: 34%; border-bottom: black 1pt solid; text-align: center">           <font style="color: #231F20">            <b>             Title of each class            </b>           </font>          </td>          <td style="width: 1%; padding-bottom: 1pt; text-align: center">          </td>          <td style="width: 32%; border-bottom: black 1pt solid; text-align: center">           <font style="color: #231F20">            <b>             Trading             <br/>             Symbol(s)            </b>           </font>          </td>          <td style="width: 1%; padding-bottom: 1pt; text-align: center">          </td>          <td style="width: 32%; border-bottom: black 1pt solid; text-align: center">           <font style="color: #231F20">            <b>             Name of each exchange on which             <br/>             registered            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           Common Stock, $0.001 par value          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           APDN          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           The Nasdaq Capital Market          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Securities registered pursuant to Section 12(g) ofthe Act: None       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark if the registrantis a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.25in">        <font style="font-family: Wingdings">         ¨        </font>        Yes        <font style="font-family: Wingdings">         x        </font>        No       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark if the registrantis not required to file reports pursuant to Section 13 or Section 15(d) of the Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">        <font style="font-family: Wingdings">         ¨        </font>        Yes        <font style="font-family: Wingdings">         x        </font>        No       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant (1) has filedall reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">        <font style="font-family: Wingdings">         x        </font>        Yes        <font style="font-family: Wingdings">         ¨        </font>        No       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant has submittedelectronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">        <font style="font-family: Wingdings">         x        </font>        Yes        <font style="font-family: Wingdings">         ¨        </font>        No       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant is a large acceleratedfiler, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitionsof “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerginggrowth company” in Rule 12b-2 of the Exchange Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 25%">           Large accelerated filer           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td style="width: 20%">           Accelerated filer           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td style="width: 23%">           Non-accelerated filer           <font style="font-family: Wingdings">            x           </font>          </td>          <td style="width: 32%">           Smaller reporting company           <font style="font-family: Wingdings">            x           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 100%">           Emerging growth company           <font style="font-family: Wingdings">            ¨           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If an emerging growth company, indicate by a check mark if theregistrant has elected to not use the extended transition period of complying with any new or revised financial accounting standardsprovided pursuant to Section 13(a) of the Exchange Act.        <font style="font-family: Wingdings">         ¨        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant has filed a reporton and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting underSection 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared orissued its audit report.        <font style="font-size: 10pt">        </font>        <font style="font-family: Wingdings">         ¨        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant is a shell company(as defined in Rule 12b-2 of the Act).        <font style="font-family: Wingdings">         ¨        </font>        Yes        <font style="font-family: Wingdings">         x        </font>        No       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="margin: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        The aggregate market value of the Registrant’s votingand non-voting common stock held by non-affiliates of the Registrant, based upon the last sale price of the common stock reportedon The Nasdaq Capital Market as of the last business day of the Registrant’s most recently completed second fiscal quarter(March 31, 2020), was approximately $13.5 million. Shares of the Registrant’s common stock held by each executive officerand director and by each entity or person that, to the Registrant’s knowledge, owned 5% or more of the Registrant’soutstanding common stock as of March 31, 2020 have been excluded in that such persons may be deemed to be affiliates of theRegistrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of December 10, 2020, the Registranthad outstanding 5,661,330 shares of common stock, par value $0.001 per share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <u>          DOCUMENTS INCORPORATED BY REFERENCE         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Part III of this Annual Report on Form 10-K will be incorporatedby reference from certain portions of the Registrant's definitive Proxy Statement for its 2021 Annual Meeting of Shareholders,or will be included in an amendment hereto, to be filed not later than 120 days after the close of the fiscal year ended September30, 2020. Except with respect to information specifically incorporated by reference in the Annual Report on Form 10-K, theProxy Statement is not deemed to be filed as part hereof.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         TABLE OF CONTENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">           <b>            Page           </b>          </td>         </tr>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top">           PART I          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; width: 10%; padding-left: 9pt">           <a href="#a_001">            ITEM 1.           </a>          </td>          <td style="vertical-align: bottom; width: 80%; padding-left: 9pt; text-indent: -9pt">           <a href="#a_001">            BUSINESS           </a>          </td>          <td style="vertical-align: bottom; width: 10%; text-align: right">           <a href="#a_001">            5           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_002">            ITEM 1A.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_002">            RISK FACTORS           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_002">            25           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_004">            ITEM 1B.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_004">            UNRESOLVED STAFF COMMENTS           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_004">            38           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_005">            ITEM 2.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_005">            PROPERTIES           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_005">            38           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_006">            ITEM 3.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_006">            LEGAL PROCEEDINGS           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_006">            39           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_007">            ITEM 4.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_007">            MINE SAFETY DISCLOSURES           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_007">            39           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top">           PART II          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_008">            ITEM 5.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_008">            MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS    AND ISSUER PURCHASES OF EQUITY SECURITIES           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_008">            40           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_009">            ITEM 6.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_009">            SELECTED FINANCIAL DATA           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_009">            40           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_010">            ITEM 7.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_010">            MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL    CONDITION AND RESULTS OF OPERATIONS           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_010">            40           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_011">            ITEM 7A.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_011">            QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET    RISK           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_011">            49           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_012">            ITEM 8.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_012">            FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_012">            49           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_013">            ITEM 9.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_013">            CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON    ACCOUNTING AND FINANCIAL DISCLOSURE           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_013">            49           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_014">            ITEM 9A.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_014">            CONTROLS AND PROCEDURES           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_014">            50           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_015">            ITEM 9B.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_015">            OTHER INFORMATION           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_015">            50           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top">           PART III          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_016">            ITEM 10.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_016">            DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_016">            51           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_017">            ITEM 11.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_017">            EXECUTIVE COMPENSATION           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_017">            51           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_018">            ITEM 12.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_018">            SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND    MANAGEMENT AND RELATED STOCKHOLDER MATTERS           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_018">            51           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_019">            ITEM 13.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_019">            CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND    DIRECTOR INDEPENDENCE           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_019">            51           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_020">            ITEM 14.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_020">            PRINCIPAL ACCOUNTING FEES AND SERVICES           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_020">            51           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top">           PART IV          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-left: 9pt">          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 9pt">           <a href="#a_021">            ITEM 15.           </a>          </td>          <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt">           <a href="#a_021">            EXHIBITS AND FINANCIAL STATEMENT SCHEDULES           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#a_021">            51           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         PART I        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Forward-looking Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This Annual Report on Form 10-K (includingbut not limited to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”)contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended(the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”), that are intended to qualify for the “safe harbor” created by those sections. In addition, we may makeforward-looking statements in other documents filed with or furnished to the Securities and Exchange Commission (“SEC”),and our management and other representatives may make forward-looking statements orally or in writing to analysts, investors, representativesof the media and others. Forward-looking statements can generally be identified by the fact that they do not relate strictly tohistorical or current facts and include, but are not limited to, statements using terminology such as “can”, “may”, “could”, “should”, “assume”, “forecasts”, “believe”, “designatedto”, “will”, “expect”, “plan”, “anticipate”, “estimate”, “potential”, “position”, “predicts”, “strategy”, “guidance”, “intend”, “budget”, “seek”, “project” or “continue”, or the negative thereof or other comparable terminology regardingbeliefs, plans, expectations or intentions regarding the future, including        <font style="color: #212529; background-color: white">         risksrelating to the continuing outbreak of the coronavirus (COVID-19)        </font>        . You should read statements that contain these words carefullybecause they:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           discuss our future expectations;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           contain projections of our future results of operations or of our financial condition; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           state other “forward-looking” information.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe it is important to communicate our expectations.However, forward-looking statements are based on our current expectations, assumptions, estimates and projections about our businessand our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our actual results andthe timing of certain events may differ materially from those expressed or implied in such forward-looking statements due to avariety of factors and risks, including, but not limited to, those set forth under Item 1, “Business,” Item 1A, “RiskFactors,” Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,”and our consolidated financial statements and notes thereto included in this report, those set forth from time to time in our otherfilings with the SEC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our forward-looking statements address, among other things:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           our expectations of future revenues, expenditures, capital or other funding requirements;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           the adequacy of our cash and working capital to fund present and planned operations and growth;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           our business strategy and the timing of our expansion plans;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           our expectations concerning product candidates for our technologies;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           our expectations concerning existing or potential development and license agreements for third-party collaborations and joint ventures;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           our expectations of when different phases of clinical activity may commence and conclude;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           the effect of governmental regulations generally;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           our expectations of when regulatory submissions may be filed or when regulatory approvals may be received; and;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           our expectations of when commercial sales of our products may commence and when actual revenue from the product sales may be received.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="padding-bottom: 6pt">          </td>          <td style="padding-bottom: 6pt; text-align: justify">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 3; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Any or all of our forward-looking statementsmay turn out to be wrong. They may be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties.Actual outcomes and results may differ materially from what is expressed or implied in our forward-looking statements. Among thefactors that could affect future results are:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           the inherent uncertainties of product development based on our new and as yet not fully proven technologies;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           the risks and uncertainties regarding the actual effect on humans of seemingly safe and efficacious formulations and treatments when tested clinically;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           the inherent uncertainties associated with clinical trials of product candidates;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           the inherent uncertainties associated with the process of obtaining regulatory approval to market product candidates;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           the inherent uncertainties associated with commercialization of products that have received regulatory approval;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           economic and industry conditions generally and in our specific markets;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           the volatility of, and decline in, our stock price; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; padding-bottom: 6pt">           •          </td>          <td style="padding-bottom: 6pt; text-align: justify">           our current lack of financing for operations and our ability to obtain the necessary financing to fund our operations and effect our strategic development plan.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All forward-looking statements and risk factors included inthis Annual Report on Form 10-K are made as of the date hereof, or in the case of documents incorporated by reference, theoriginal date of any such documents, based on information available to us as of such date, and we assume no obligations to updateany forward-looking statement or risk factor, unless we are required to do so by law. If we do update one or more forward-lookingstatements, no inference should be drawn that we will make updates with respect to other forward-looking statements or that wewill make any further updates to those forward-looking statements at any future time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Any of the assumptions underlying the forward-looking statementscontained in this Annual Report on Form 10-K could prove inaccurate and, therefore, we cannot assure you that the resultscontemplated in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent in theseforward-looking statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee byus that our objectives or plans will be achieved, and we caution you against relying on any of the forward-looking statements containedherein.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our trademarks currently used in the United States include AppliedDNA Sciences®, SigNature® molecular tags, SigNature® T molecular tags, fiberTyping®, DNAnet®, SigNify®,Beacon®, CertainT®, LinearDNA        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        , Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19Assay Kit and safeCircle        <sup>         TM        </sup>        Surveillance Program. We do not intend our use or display of other companies’ tradenames or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks,service marks and trade names included or incorporated by reference in this Annual Report on Form 10-K are the property oftheir respective owners, including, without limitation, the PimaCott        <sup>         ®        </sup>        , HomeGrown        <sup>         ®        </sup>        , LoneStar™and HomeGrown Acala™ marks owned by Himatsingka America, Inc. and/or its affiliates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 4; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_001">           </a>           <b>            ITEM 1.           </b>          </td>          <td>           <b>            BUSINESS.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our proprietary PCR-based DNA LinearDNA        <sup>         TM        </sup>        manufacturingplatform produces large quantities of DNA for use in the nucleic acid-based in vitro medical diagnostics and preclinicalnucleic acid-based drug development and manufacturing markets (“Biotherapeutic Contract Research and Manufacturing”)and for supply chain security, anti-counterfeiting and anti-theft technology purposes (“Non-Biologic Tagging”). Inresponse to the COVID-19 pandemic, the Company developed a PCR-based molecular diagnostic test for COVID-19, which was grantedEmergency Use Authorization (EUA) by the U.S. Food and Drug Administration (“FDA”) in May 2020. The Company currentlymanufactures and sells its EUA authorized COVID-19 molecular diagnostic test kit under the Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19Assay Kit trademark (“COVID-19 Diagnostic Testing”). In addition, and in further response to the COVID-19 pandemic,the Company developed and is currently offering non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19in defined populations. The Company’s COVID-19 pooled surveillance testing services are currently offered under the safeCircle        <sup>         TM        </sup>        trademark (“COVID-19 Surveillance Testing”). The Company is also developing an invasive circulating tumor cell captureand identification technology (“iCTC Technology”) which uses a patented functional assay to capture live invasive circulatingtumor cell and associated lymphocytes that can be identified and expanded for further analysis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Applied DNA’s LinearDNA        <sup>         TM        </sup>        PCRplatform is capable of producing large scale DNA, which we believe offers many benefits over the limitations of other large scaleDNA manufacturing systems, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 98%; text-align: justify">           Speed – Production of DNA via the LinearDNA           <sup>            TM           </sup>           platform can be measured in terms of hours, not days and weeks like other large scale DNA manufacturing platforms.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           Scale – The LinearDNA           <sup>            TM           </sup>           platform is flexible and can be adapted to encompass large quantity production.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 98%; text-align: justify">           Purity – DNA produced via PCR is pure, resulting in only large quantities of the target DNA sequence. Unwanted DNA sequences such as bacterially-derived DNA are not present.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           Customization – DNA produced via PCR can be easily chemically modified to suit specific customer applications.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Corporate History        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are a Delaware corporation, which was initially formed in1983 under the laws of the State of Florida as Datalink Systems, Inc. In 1998, we reincorporated in the State of Nevada, andin 2002, we changed our name to our current name, Applied DNA Sciences, Inc. In December 2008, we reincorporated fromNevada to the State of Delaware. LineaRx (“LRx”), Inc. was incorporated in Delaware on September 11, 2018.Applied DNA Clinical Labs, LLC (“ADCL”) was formed in Delaware on June 12, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our corporate headquarters are located at the Long Island HighTechnology Incubator at Stony Brook University in Stony Brook, New York, where we established laboratories for the manufactureof molecular tags, product prototyping, molecular tag authentication, bulk DNA production, as well the manufacture of our Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19Assay Kit and the performance of our COVID-19 Surveillance Testing. The address of our corporate headquarters is 50 Health SciencesDrive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800. We maintain a website at        <i>         www.adnas.com        </i>        wheregeneral information about us is available. The information on, or that may be accessed through, our website is not incorporatedby reference into and should not be considered a part of this report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 5; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Industry Background        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Biotherapeutic Contract Researchand Manufacturing         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our patented continuous flow PCR systemsand other proprietary PCR-based production technology and post-processing systems that comprise the LinearDNA        <sup>         TM        </sup>        platformallows for the large-scale production of specific DNA sequences. The LinearDNA        <sup>         TM        </sup>        platform is currently being usedfor customers to manufacture DNA as components of in vitro diagnostic tests and for preclinical nucleic acid-based drugdevelopment in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies,clustered regularly interspaced short palindromic repeats (CRISPR) based therapies and gene therapies. We believe our LinearDNA        <sup>         TM        </sup>        platformconfers a distinct competitive advantage in cost, cleanliness, and time-to-market as compared to other DNA manufacturing systems.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company provides preclinical contractresearch and manufacturing services for the nucleic acid-based therapeutic markets. We work with biotech and pharmaceutical companiesto convert plasmid-based and/or viral transduction-based preclinical biotherapeutics into PCR-produced linear DNA-based forms thatcan be produced on our LinearDNA        <sup>         TM        </sup>        platform. In addition, we provide contract research services to RNA based drugand biologic customers for preclinical studies. These services include the design, development and manufacture of PCR-producedDNA templates for RNA. In addition, we also use our LinearDNA        <sup>         TM        </sup>        platform to produce very large gram-scale quantitiesof DNA for the in vitro diagnostic market where our DNA is used for both commercially available diagnostics and diagnostics underdevelopment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We also seek to develop, acquire, and commercialize,ourselves or with partners, a diverse portfolio of nucleic acid-based therapeutics based on PCR-produced linear DNA to improveexisting nucleic acid-based therapeutics or to create new nucleic acid-based therapeutics that address unmet medical needs. Weare currently directly engaged in preclinical drug candidate development activities focusing on therapeutically-relevant DNA constructsmanufactured via our LinearDNA        <sup>         TM        </sup>        platform in the fields of DNA-based anti-viral and anti-cancer vaccines, CAR-Tcell immunotherapy and the manufacture of rAAV vectors for gene therapy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are also engaged in preclinical andanimal drug candidate development activities focusing on therapeutically relevant DNA constructs manufactured via our PCR-basedproduction platform. We seek to develop, acquire and commercialize, alone or with partners, a diverse portfolio of nucleic acid-basedtherapeutics based on PCR-produced linear DNA which we believe will improve existing nucleic acid-based therapeutics or createnew nucleic acid-based therapeutics that address unmet medical needs. To this end, we are currently working with our developmentpartners Takis S.R.L. and Evvivax S.R.L. (“Takis/Evvivax”) to develop an amplicon-based linear DNA vaccine for COVID-19that would be manufactured on our LinearDNA        <sup>         TM        </sup>        platform. Together with our development partners, our amplicon-basedlinear COVID-19 vaccine candidate has shown efficacy in preclinical cell and small animal studies. In September 2020, we enteredinto an Animal Clinical Trial Agreement with Takis/Evvivax and with Veterinary Oncology Services, PLLC, an affiliate of GuardianVeterinary Specialists (“GVS”), a multi-specialty veterinary hospital. In November 2020, we, together with Takis/Evvivaxand GVS, announced receipt of approvals from the New York State Department of Agriculture and Markets and the U.S. Department ofAgriculture (“USDA”) on an advanced clinical strategy to conduct a veterinary trial of a vaccine candidate. Our jointly-developedamplicon-based DNA vaccine for COVID-19 is expected to start veterinary clinical trials in domestic feline cats by early 2021,with the end goal of applying for a USDA Animal and Plant Health Inspection Service conditional license to enable commercial veterinarysales for domestic felines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          COVID-19 Diagnostic Testing         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 13, 2020 we received an EUAfrom the FDA for the clinical use of the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit for the qualitative detection of nucleic acid fromSARS-CoV-2 in respiratory specimens including anterior nasal swabs, self-collected at a healthcare location or collected by a healthcareworker, and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates,and bronchoalveolar lavage specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by their healthcareprovider. Under the EUA, testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. §263a (“CLIA”), that meet requirements to perform high complexity tests, which certification we haveapplied for but have not yet obtained. Subsequently, during July and November 2020, we were granted EUA amendments thatexpand the installed base of PCR equipment platforms on which our Linea        <sup>         TM        </sup>        COVID-19 Assay Kit can be processed andsignificantly increased the daily testing capacity of the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit through the use of automation.The scope of the EUA, as amended, is expressly limited to use consistent with the Instructions for Use by authorized laboratories,certified under CLIA to perform high complexity tests. The EUA will be effective until the declaration that circumstances existjustifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminatedor until the EUA’s prior termination or revocation. Our Linea        <sup>         TM        </sup>        COVID-19 Assay Kit has not been FDA clearedor approved, and the EUA’s limited authorization is only for the detection of nucleic acid from SARS-CoV-2, not for any otherviruses or pathogens. We currently manufacture the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit at our facilities in Stony Brook, NewYork.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 6; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          COVID-19 Surveillance Testing         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Starting in July 2020, the Companyunder its ADCL subsidiary, began offering COVID-19 pooled surveillance testing to customers as a Testing-as-a-Service (TaaS) offeringbranded under the safeCircle        <sup>         TM        </sup>        trademark. Unlike diagnostic testing, which looks for the occurrence of COVID-19 at theindividual level, safeCircle        <sup>         TM        </sup>        surveillance testing looks for infections within a defined population or community andcan be used for making health management decisions at the population level. safeCircle        <sup>         TM        </sup>        surveillance testing uses high-sensitivitypooled COVID-19 testing utilizing the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit. Under the safeCircle        <sup>         TM        </sup>        surveillance testingservice, pooled test results are returned to the sponsoring organization in the aggregate only, not directly to the participatingindividuals, and may be performed without CLIA certification. Once potentially infected portions of a defined population are identifiedby the safeCircle        <sup>         TM        </sup>        surveillance testing service, the individuals comprising the potentially infected portions of thedefined population are referred to follow on diagnostic testing at a clinical lab to obtain individual results. ADCL is offeringits safeCircle        <sup>         TM        </sup>        surveillance testing in compliance with current CDC, FDA, CMS and New York State Department of Healthrecommendations. The use of pooled sampling procedures for the safeCircle        <sup>         TM        </sup>        surveillance testing service has been internallyvalidated by ADCL in compliance with current CDC guidance. The use of pooled sampling procedures is not included in the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit EUA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We seek to commercialize the safeCircle        <sup>         TM        </sup>        surveillance testing TaaS offering with institutional clients such as schools, colleges and businesses. We currently provide safeCircle        <sup>         TM        </sup>        surveillance testing to several private schools, New York State-based small enterprises and college athletic programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Clinical Testing Laboratory        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        Under our ADCL subsidiary, we haveapplied to the New York State Department of Health for all necessary licensing to operate a New York State clinical diagnosticslaboratory. These applications are currently pending. The New York State Department of Health performed its initial inspectionof our clinical laboratory and identified deficiencies in the clinical standard of practice. These deficiencies need to be rectifiedbefore we can submit a request for re-inspection. We are working to rectify these deficiencies now. Through ADCL, we seek to furthercommercialize our EUA authorized Linea COVID-19 Assay Kit and our iCTC Technology. ADCL is also performing testing services insupport of the Company’s safeCircle        <sup>         TM        </sup>        surveillance testing services in accordance with current CDC, FDA, CMS andNew York State Department of Health recommendations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          iCTC Technology         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We seek to further develop, manufactureand commercialize our Vita-Assay        <sup>         TM        </sup>        iCTC Technology recently acquired from Vitatex, Inc. in August 2019.Our iCTC Technology uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytesthat can be identified and expanded for further analysis, including genetic sequencing. We believe our iCTC Technology can be usedas an early cancer diagnostic tool, to facilitate cancer disease progression monitoring, to assess metastatic tumor risk and todiscover epitopes to serve as targets for nucleic-acid based immunotherapies. Our iCTC Technology has been used and is currentlybeing used in a human cancer drug candidate clinical trial to monitor cancer disease progression in the trial subjects as a ResearchUse Only diagnostic assay. We believe our iCTC Technology has several advantages over existing in vitro        <i>        </i>        circulatingtumor cell diagnostic technologies that do not capture live iCTC cells. The Company seeks to further develop and commercializethis technology and to potentially integrate aspects of the iCTC Technology with the LinearDNA        <sup>         TM        </sup>        platform for cancerresearch and nucleic-acid based drug development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          Non-Biologic Tagging and Security         </u>        </b>        <u>         <b>          Productsand Services         </b>        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our supply chain security business allowsour customers to use non-biologic DNA (molecular) tags manufactured on our LinearDNA        <sup>         TM        </sup>        platform to mark objectsin a unique manner and then identify these objects by detecting the absence or presence of the molecular tag. We believe our moleculartags are not economically feasible nor practical to replicate, and that our disruptive tracking platform offers broad commercialrelevance across many industry verticals.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The underlying strategy in our taggingbusiness is to become an authenticity and traceability platform provider for large complex supply chains, particularly in processindustries in which contracts for our products and services are typically larger and recurring over longer duration as comparedto our historic norms, where the benefits to customers and consumers are more significant, and where our forensic security andtraceability offer a unique and protected value. Using our tagging products and technology, manufacturers, brands, and other stakeholderscan ensure authenticity and protect against diversion throughout a product’s journey from manufacturer to use.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        SigNature® Molecular Tags, SigNature®T Molecular Tags, fiberTyping®, SigNify® Beacon® and CertainT® comprise our principal Non-Biologic tagging andsecurity technology platform.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 7; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Signature Molecular Tags         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        SigNature® molecular tags manufactured via our LinearDNA        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        platformform the core of our supply chain security technology platform. They provide forensic power and protection for a wide array ofapplications. Highly secure, robust and durable, SigNature® molecular tags are an ingredient that can be used to fortify brandprotection efforts; strengthen supply chain security; and mark, track and convict criminals. Through our SigNature® moleculartags, custom DNA sequences can be embedded into a wide range of host carriers including natural and synthetic materials such ascotton, leather, cannabis, ink, varnish, thread, metal coatings, and pharmaceuticals and nutraceuticals. SigNature® moleculartag formulations are made to be resistant to challenging environments such as heat, cold, vibration, abrasion, organic solvents,chemicals, UV radiation and other extreme environmental conditions, and can be identified for numerous years after being embeddeddirectly into or on an item. The sequence of each individual molecular tag is recorded and stored in a secure database so thatwe can later detect it to obtain definitive proof of the presence or absence of a specific molecular tag using a simple in-fieldtest, or in our laboratories. Our in-lab forensic testing capability delivers Certificate of DNA Authentication (“CODA”)or an expert witness report, with expert witness services for some cases. Because DNA can be amplified with high fidelity, onlyminute quantities of our molecular tags extracted from our customers’ goods are necessary for successful analysis and authentication.As a result, SigNature® molecular tags can fold seamlessly into production and logistics workflows at extremely low concentrations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our SigNature® molecular tags canbe uniquely designed for specific industries. For example, our SigNature® T molecular tags, designed for textiles andapparel industry, are specially engineered to adhere tenaciously to textile substrates, which make them resistant to standardtextile production conditions. The result is an enduring forensic level molecular tag that remains present from the fiberstage through to the finished product. Overall SigNature® molecular tags now exist on hundreds of millions of commoditygoods ranging from consumer product packaging to microcircuits to cotton and synthetic fibers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          SigNify®         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        SigNify® IF portable DNA readers andSigNify        <b>         <i>          ®         </i>        </b>        consumable reagent test kits provide definitive real-time authentication of molecular tags in thefield, providing a front-line solution for supply chain integrity backed with forensic-level molecular tag authentication.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          CertainT®         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The CertainT® trademark indicates theuse of our tagging, testing and tracking platforms and solutions, enabling manufacturers, brands and trade organizations to conveyproof of their product claims.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        CertainT® and other customer applicationsinclude the use of a software platform that enables customers to manage the security of company-marked goods from point of markingto point of authentication or validation to end of life. The base platform is configurable to customer requirements. Basic functionsoffered include molecular tag inventory management, program training and communications, a database of marked items information,associated documents and images, chain of custody and location tracking, sample authentication processing and CODA downloads, andother administrative functions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Our Strategy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our products and services are offered in the United States,Europe and Asia. At the present time, we are focusing our efforts on DNA manufacturing services for        <i>         in vitro        </i>        medicaldiagnostics, preclinical biotechnology research, preclinical biotherapeutic candidates and PCR-produced linear DNA products, ,the manufacturing and sale of our Linea        <sup>         TM        </sup>        COVID-19 Assay Kit, our testing as a service offerings, primarily as it relatesto our COVID-19 Surveillance Testing, and our supply chain security business, primarily in the areas of textile and apparel, pharmaceuticalsand nutraceuticals The basic technology we use in various markets is very similar, and we believe our solutions are adaptable formany types of products and markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        To date, the substantial portion of our revenues has been generatedfrom sales of our SigNature® and SigNature® T molecular tags, our principal supply chain security and product authenticationsolutions. We expect to grow revenues from sales of our  Linea™ COVID-19 Assay Kit, our COVID-19 Surveillance Testing,clinical diagnostic services (upon receipt of necessary certifications) and the manufacturing of DNA products for the biotechnologyand        <i>         in vitro        </i>        diagnostic markets. To a lesser extent, we expect to grow revenues from the sale of SigNature® moleculartags, SigNature® T molecular tags, SigNify® and CertainT® offerings as we work with companies and governments to securesupply chains for various types of products and product labeling throughout the world. We are also seeking to establish a revenuestream from our iCTC Technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 8; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            8            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Pursue Strategic Acquisitions and Alliances         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We intend to pursue strategic acquisitions of companies andtechnologies that strengthen and complement our core technologies, improve our competitive positioning, allow us to penetrate newmarkets, and grow our customer base. We also intend to work in collaboration with potential strategic partners in order to continueto market and sell new product lines derived from, but not limited to, biotherapeutics and        <i>         in vitro        </i>        diagnostics, non-biologicDNA tagging technologies and other supply chain provenance technologies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Markets         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Diagnostics and Reagents         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="background-color: white">         DNA-based diagnosticsis an emerging application area in the in-vitro diagnostics industry. DNA–protein adducts are popular across the medicaldiagnostics industry, where these molecules aid in the determination of the incidence of a suspected disease caused by an organismor pathogen. Based on the amount of target DNA present, probes can be used either directly to detect target DNA, facilitate theperformance of targeting proteins or indirectly to target DNA through amplification that creates a number of copies of a specificnucleotide. Increased automation of diagnostic tests, discovery of new diagnostic markets, rising investments in pharmaceuticaland pharmacogenomics research, and advancements in DNA array technologies are major growth facilitators for the DNA probes-baseddiagnostic products market.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="background-color: white">         According to anarticle from BCC Research, (“DNA Diagnostics Market to Almost Double by 2022 with 14.3% CAGR”), the DNADiagnostics market will reach $23.8 billion in 2022. The potential to provide accurate diagnosis and cost effectiveness overalternative        </font>        diagnostic techniques are factors that supplement the growth of the DNA diagnostics market. According toestimates from the International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases and9.5 million cancer deaths worldwide. By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3million cancer deaths.        <font style="font-family: Times New Roman, Times, Serif; font-size: 13.5pt; color: #1E1E23; background-color: white">        </font>        <font style="background-color: white">         Thesenumbers, we believe, are set to increase consistently; however, advanced automated DNA diagnostics technologies such as nextgeneration sequencing could play a crucial role in diagnosing and curbing these diseases. In addition, the Global Covid-19diagnostics market generated $73.19 million in the first quarter of calendar 2020 and is anticipated to hit $9.94 billion bythe fourth quarter of calendar 2020 (Allied Market Research, “Global Covid-19 Diagnostics Market to Garner $9.94Billion by Fourth Quarter of 2020” (November 2, 2020)        </font>        ).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our Market Response         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="background-color: white">         Our PCR-produced linearDNA is used by customers who provide patient diagnosis through the         <i>          in vitro         </i>         examination of specimens, such as blood. Allof the linear DNA we provide to our         <i>          in vitro         </i>         diagnostic customers is produced through our large-scale PCR process, usingour proprietary technology, with optimized performance for the final diagnostic assay. In addition to performance optimization,we believe that the production of linear DNA in large lots with quantifiable reproducibility improves the efficiency of our customer’squality control for incoming raw materials and improve the overall quality, accuracy and reproducibility of their diagnostic products.        </font>        Cell-based DNA production methods are often complicated by impurities. In contrast, we believe our PCR-based productionmethod offers a high degree of purity and efficiency. In April 2017, we were awarded a five-year supply agreement with FUJIFILMWako Pure Chemical Corp. (formerly Wako Pure Chemical Industries, Ltd.) for the manufacture of bulk DNA for in vitro medicaldiagnostics. This supply agreement includes quarterly DNA shipments and optional three-year renewals. Under this multi-year contract,our DNA is utilized in a medical diagnostic tool that aids in assessing disease. We currently also have a number of new linearDNA amplicons being evaluated by customers for potential use in the        <i>         in vitro        </i>        diagnostic market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On August 8, 2019 we announced that LRx acquired the assetsand intellectual property of Vitatex, Inc, which included the iCTC Technology. As part of the Vitatex, Inc. asset acquisition,we entered into an Amended and Restated License Agreement with the Research Foundation for the State University of New York relatingto a patent estate covering the iCTC Technology. See “Collaboration and Licensing Agreements.” We seek to further develop,manufacture and commercialize the iCTC Technology to address the growing circulating tumor cell        <i>         in vitro        </i>        diagnostics market.The acquired iCTC Technology uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytesthat can be identified and expanded for further analysis, including genetic sequencing. We believe our recently acquired iCTC technologycan be used as an early cancer diagnostic tool, to facilitate cancer disease progression monitoring and to assess metastatic tumorrisk. The acquired iCTC Technology has been used in a human cancer drug candidate clinical trial to monitor cancer disease progressionin the trial subjects. We believe the acquired iCTC Technology has several advantages over existing        <i>         in vitro        </i>        circulatingtumor cell diagnostic technologies that do not capture live iCTC cells.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 9; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            9            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have also developed a patent-pending nucleic acid-based invitro diagnostic, (Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19 Assay Kit) to detect the presence of SARS-CoV-2(the virus that causes COVID-19) RNA in patient specimens. During April 2020, we entered into an agreement with Stony BrookUniversity Hospital for the validation of our Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19 Assay Kit.On May 13, 2020, we received an EUA from the FDA for the clinical use of the Linea COVID-19 Assay Kit for the qualitativedetection of nucleic acid from SARS-CoV-2 in respiratory specimens including anterior nasal swabs, self-collected at a healthcarelocation or collected by a healthcare worker, and nasopharyngeal  and oropharyngeal swabs, mid-turbinate nasal swabs,nasopharyngeal washes/aspirates or nasal aspirates, and bronchoalveolar lavage specimens collected by a healthcare worker fromindividuals who are suspected of COVID-19 by their healthcare provider. Under the EUA, testing is limited to laboratories certifiedunder CLIA that meet requirements to perform high complexity tests which certification the Company has applied for but has notyet obtained.  Subsequently, during July and November 2020, the Company was granted EUA amendments that expandthe installed base of PCR equipment platforms on which the Company’s Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19Assay Kit can be processed and increases the throughput of the Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19Assay Kit through the use of automated RNA extraction. The scope of the EUA, as amended, is expressly limited to use consistentwith the Instructions for Use by authorized laboratories, certified under the CLIA to perform high complexity tests. The EUA willbe effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnosticsfor detection and/or diagnosis of COVID-19 is terminated or until the EUA’s prior termination or revocation. The Company’sLinea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19 Assay Kit has not been FDA cleared or approved, and the EUA’slimited authorization is only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. We currentlymanufacture the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit at our facilities in Stony Brook, New York. On September 29, 2020 weannounced that we had entered into a Master Services Agreement with Stony Brook University Hospital to supply the Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19Assay Kit and related automation systems.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, starting inJuly 2020, the Company through its ADCL subsidiary, began offering COVID-19 pooled surveillance testing to customers asa Testing-as-a-Service (TaaS) offering branded under the safeCircle        <sup>         TM        </sup>        trademark. Unlike diagnostic testing, whichlooks for the occurrence of COVID-19 at the individual level, safeCircle        <sup>         TM        </sup>        surveillance testing looks forinfections within a defined population or community and can be used for making health management decisions at the populationlevel. safeCircle        <sup>         TM        </sup>        surveillance testing uses high-sensitivity pooled COVID-19 testing utilizing theLinea        <sup>         TM        </sup>        COVID-19 Assay Kit. Under the safeCircle        <sup>         TM        </sup>        surveillance testing service, pooled test resultsare returned to the sponsoring organization in the aggregate only, not directly to the participating individuals, and may beperformed without CLIA certification. Once potentially infected portions of a defined population are identified by thesafeCircle        <sup>         TM        </sup>        surveillance testing service, the individuals comprising the potentially infected portions of thedefined population are referred to follow on diagnostic testing at a clinical lab to obtain individual results. ADCL isoffering its safeCircle        <sup>         TM        </sup>        surveillance testing in compliance with current CDC, FDA, CMS and New York StateDepartment of Health recommendations. The use of pooled sampling procedures for the safeCircle        <sup>         TM        </sup>        surveillancetesting service has been internally validated by ADCL in compliance with current CDC guidance. The use of pooled samplingprocedures is not included in the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit EUA. We currently provide safeCircle        <sup>         TM        </sup>        surveillance testing to several private schools, New York State-based small enterprises and college athletic programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 10; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            10            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Biotherapeutic Contract Research and Manufacturing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Nucleic acid-based drugs and biologics have emerged as a newclass of treatments for unmet medical needs. Through LRx, we are currently pursuing several types of nucleic acid-based therapeuticapplications for PCR-produced DNA. These applications include: (i) adoptive cell therapy; (ii) DNA vaccines; (iii) RNA-basedtherapeutics and (iv) gene therapies. To date, the most prominent use of adoptive cell therapy is for CAR T-cell immuno-oncologytherapies, wherein autologous or allogeneic cells are collected and genetically modified to kill cancer cells. At least two CART-cell therapies have recently been approved by the FDA for treatment of B-cell malignancies. These approved therapies have demonstratedhigh efficacy in published studies. Current CAR T-cell therapies are manufactured via bacterial plasmid and viral vector-basedmethods. We believe these manufacturing methods are extremely expensive, time-consuming and may have public health concerns. Webelieve that production of CAR T-cell therapies via a PCR-based platform, without plasmid or viral vectors, may lead to reducedmanufacturing times, reduced costs and mitigation of public health concern.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        DNA vaccines may we believe hold numerous advantages over conventionalvaccination methods. DNA vaccines are able to trigger a wide range of immune responses, leading to broad applications. DNA vaccineswe believe are cheaper and easier to manufacture when compared to convention vaccines. Current DNA vaccines are manufactured viabacterial plasmids. Production via our PCR-based platform may reduce DNA vaccine costs and manufacturing timeframes.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 11; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            11            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There are two types of RNA therapeutics. mRNA-based therapeutics,which result in protein production, and antisense/interfering RNA-based therapeutics, which interfere with or inhibit gene expression.This dual functionality allows RNA-based therapeutics to target a wide range of indications. RNA-based therapeutics are typicallymanufactured from a DNA template obtained from a bacterial plasmid. We believe creating RNA-based therapeutics from a DNA templateobtained from our PCR-based platform may reduce RNA-based therapeutic costs and manufacturing timeframes.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Gene therapy is designed to introduce genetic material intoa subject’s cells to compensate for abnormal genes or to make a beneficial protein. Currently, gene therapy is accomplishedthrough the viral transduction of a subject’s cells via the use of a recombinant viral vector manufactured from plasmid-derivedDNA. Recently, several gene therapies have been approved for use in the United States. We believe recombinant viral vectors manufacturedin whole or in part from PCR-produced DNA may reduce manufacturing complexities, timelines and costs.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our Market Response         </i>        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During September 2018, we formed a new, majority ownedsubsidiary LineaRx, Inc. (LRx) to develop and commercialize our extensive experience in the design, manufacture and chemicalmodification of DNA via our large scale PCR-based LinearDNA        <sup>         TM        </sup>        production platform in the fields of nucleic acid-basedtherapeutics, including drugs and biologics. We believe our PCR-produced linear DNA products and services are made cleaner andfaster than historical manufacturing methods. We are also engaged in preclinical and animal drug candidate development, directlyand with collaborators focusing on therapeutically relevant DNA constructs manufactured via our LinearDNA        <sup>         TM        </sup>        productionplatform. We seek to develop, acquire and commercialize, previously alone and now along with partners, a diverse portfolio of nucleicacid-based therapeutics based on PCR-produced linear DNA to improve existing nucleic acid-based therapeutics or to create new nucleicacid-based therapeutics that address unmet medical needs.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In September 2018, LRx signed a Joint DevelopmentAgreement with Takis/Evvivax to develop PCR-produced DNA expression vectors for two of Takis/Evvivax’s DNA-basedanti-cancer vaccine candidates. Under the Joint Development Agreement, PCR-produced-linear DNA amplicons carrying the DNAsequences for Takis/Evvivax vaccine candidates will be delivered to preclinical and animal models via Takis/Evvivax’sproprietary electroporation technology. Antigen-specific immune responses aimed at achieving therapeutic effects will bestudied. See “Collaboration and Licensing Agreements.” During February 2020 we expanded our existing JointDevelopment Agreement (JDA) with Takis/Evvivax to include the preclinical development of five linear DNA vaccine candidatesagainst COVID-19. Together with our development partners, our amplicon-based linear COVID-19 vaccine candidates have shownpromising efficacy in preclinical cell and small animal studies. In addition, on September 16, 2020, we announced theinitiation of a veterinary clinical trial of one of the Company’s five amplicon-based linear COVID-19 vaccinecandidates. In November 2020, we, together with Takis/Evvivax and our clinical research partner GVS, announced receiptof approvals from the New York State Department of Agriculture and Markets and the USDA on an advanced clinical strategy toconduct a veterinary trial of a vaccine candidate. Our jointly-developed amplicon-based DNA vaccine for COVID-19 is expectedto start veterinary clinical trials in domestic feline cats by early 2021. The goal of the veterinary clinical trial is toevaluate the vaccine candidate as a strategy for the prevention of SARS-CoV-2 (COVID-19) (a zoonotic disease) infections incompanion felines of humans. This veterinary clinical trial will seek to understand the immune response in cats by utilizinga vaccination strategy of interest in people that could yield valuable data for both cats and humans, with the end goal ofapplying for a USDA Animal and Plant Health Inspection Service conditional license to enable commercial veterinary sales fordomestic felines.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Non-Biologic Tagging         </i>        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Pharmaceutical and Nutraceutical Supply Chain         </i>        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        The pharmaceutical industry faces majorproblems relative to counterfeit, diluted, or falsely labeled drugs that make their way through healthcare systems worldwide, posinga health threat to patients and a financial threat to drug makers and distributors. Counterfeit prescription pharmaceuticals area growing trend, widely recognized as a public health risk and a serious concern to public health officials, private companies,and consumers. According to a        <font>         2017 report by PricewaterhouseCoopers        </font>        (“Fighting counterfeitpharmaceuticals: New defenses for an underestimated - and growing – menace” (June 2017)), the counterfeit drugmarket earns between $163 billion to $217 billion per year, making it one of the most lucrative types of illegally-copied goods.The National Association of Boards of Pharmacy estimates that counterfeit drugs account for 1% of all drugs sold in the UnitedStates. The global anti-counterfeit packaging market size is projected to grow from USD 106.3 billion in 2020 to USD 188.2 billionby 2025, at a CAGR of 12.09% from 2020 to 2025. The market is driven by factors such as strong growth in the demand from the food &amp;beverage and pharmaceutical &amp; healthcare sectors. The growing pharmaceutical &amp; healthcare industry and rise incounterfeit products in the market are the major drivers of the anti-counterfeit packaging market. Applied DNA’s use of moleculartagging on both the packaging and directly embedded into the dosage itself is targeted at this market segment.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 12; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            12            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        Nearly 40 percent of the drugs Americanstake are made outside of the United States, and about 80 percent of manufacturing sites of active pharmaceutical ingredients (APIs)used in drugs manufactured in the United States are located outside our borders—in more than 150 countries, many with lesssophisticated manufacturing and regulatory systems than our own. In addition to the sheer volume of imports and foreign facilities,there has been an increase in the variety of sources, shippers, methods of transportation, and supply chain complexity of products.Combined, these factors create great challenges to the FDA and industry in ensuring that all drugs and drug components are highquality and travel safely throughout their complex supply chains. A joint report issued by the Organization for Economic Cooperationand Development (OECD) and the European Union’s Intellectual Property Office (EUIPO) in April 2020 identified the mostfrequently counterfeited drug products from 2014 to 2016. Most did not contain the active ingredients in the correct proportions,and many contained undeclared substances that are potentially harmful. The study noted that forensic tests of samples suggest that90% of counterfeit medicines can cause harm to patients. The report also found that 96% of websites offering pharmaceuticals areoperating illegally, and that more than 50% and 33% of fake medicines seized in recent years have come from India and China, respectively.The COVID-19 pandemic is exacerbating this situation. Interpol, during its annual Operation Pangea in March (the sameweek that the WHO declared the novel coronavirus outbreak a pandemic) seized over $14 million worth of dangerous pharmaceuticalsin just seven days.        <sup>         1        </sup>        (“The COVID-19 Pandemic Magnifies Pharmaceutical Supply Chain Issues”(September 2020)).       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our Market Response         </i>        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="background-color: white">         On March 31, 2018,we entered into a License and Cooperation Agreement and a related Supply Agreement with Colorcon, Inc. (“Colorcon”)for the use of our molecular tags in Colorcon’s product offerings and access to our associated authentication technologies.Under the terms of the Agreements, we granted Colorcon exclusive worldwide right to use our molecular tags and associated authenticationtechnologies in film coatings for solid oral dosage form (“SOD”) applications, for which Colorcon is the largest globalsupplier, and non-exclusive rights to use our technologies in inks and colorants for SOD applications. Pursuant to the Agreements,we will supply taggant and authentication materials to Colorcon in exchange for long-term royalties on the sale of Colorcon productsincorporating our molecular tags and on the sale of authentication services related thereto. Further, the first of two milestonepayments was paid to us at the signing of the Agreements. We will receive the second milestone payment upon initial approval bya regulatory authority for application in a Solid Oral Dosage Form (SODF) pharmaceutical or nutraceutical product application.The Agreements generally expire on the later of October 1, 2032 or the last expiration date of any patent licensed pursuantto the Agreements.        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In April 2018, we filed our Drug Master File with the U.S.FDA to allow confidential information about the chemistry, manufacturing and controls processes of our product to be made availableto the FDA for inspection should an end-user company choose to have the FDA review the addition of SigNature molecular tag to theirproduct. In May 2018, the FDA acknowledged receipt of our filing. In April 2020, we were accepted to participate in theFDA’s Emerging Technology Program for guidance in regulatory activities with customers.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We continue to expand the formulation of our SigNature®tags with Colorcon into coatings and inks for targeted pharmaceutical companies, following the October 2011, the FDA FinalGuidance document on the use of so called “Physical-Chemical Identifiers” (PCIDs). The FDA Guidance stipulates thata PCID should be pharmacologically inactive and present no risk of adverse reaction. The PCID cannot affect the efficacy of thedrug. In addition, 11 categories of information about the PCID must be satisfactorily addressed. We believe SigNature® DNAmay be able to fulfill these requirements. In addition, DNA identifier molecular taggants can be embedded at parts per billiononto film coatings that cover many of the world’s leading brands of tablets. By integrating the Applied DNA molecular tagswithin already utilized film coatings of tablets, we believe we will be able to offer a seamless solution for pharmaceutical companycustomers.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 13; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            13            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On February 19, 2020 we entered into a multi-year MasterServices Agreement and a Trademark Licensing Agreement (the “Agreements”) with Nutrition21, LLC (“Nutrition21”)to cover commercial production of Nitrosigine®, as well as potential expansion to other products within the Nutrition21 portfolio.Separately, a Broker Agreement was also signed between the parties to enable Nutrition21 to represent Applied DNA’s CertainTplatform throughout its extensive network in the dietary supplement market. Shipments of SigNature tags for        <font style="background-color: white">         Nitrosiginecommercial production are now in their second production cycle, with shipments for a second product, nooLVL        </font>        ®        <font style="background-color: white">         nowin progress. We are providing authentication services for both products on a periodic basis.        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Textiles and Apparel         </i>        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        Textile identity and the authenticationof a product’s origin, are issues of global significance, important to brand owners for quality assurance and compliance,and to governments that must regulate international trade, enforce textile labeling, and protect consumers. We believe that CertainT®,an integrated platform to Tag, Test, and Track fiber, yarn, fabrics all the way to finished goods, enables brands and manufacturersto preserve the integrity authenticity and quality of the source materials in a global supply chain. As a result, consumers willhave confidence that claims and ingredients listed on the label are proven in the finished product. CertainT® molecular businesssolutions are relevant to natural fibers like cotton, wool, cashmere, down and feather, and leather, as well as man-made fiber,recycled polyester, viscose and other synthetic products used in apparel, footwear and home textiles globally.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <b>         <i>          Our Market Response         </i>        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        As part of the CertainT® platform,our patented SigNature® T molecular tag technology for molecular tagging and authentication has been proven to be scalableand commercially applicable in integrated textile supply chains, in cotton as well as recycled polyester and is currently in useby our customers. Our SigNature® T molecular tag commercial program involves the creation of unique SigNature® T moleculartags that can be used to tag a customer’s cotton fiber at the ginning stage. Our fully automated, secure DNA Transfer Systemsallow for traceability and monitoring of all molecularly-tagged cotton at multiple gins in Arkansas and California.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        Once tagged, the cotton fiber may beauthenticated for textile identity from grower to ginner to spinner to manufacturer to distributor to retailer. At each step ofthe process, its textile identity can be tested to link the original cotton fiber to finished product, preserving the authenticityof the product and the integrity of the supply chain. SigNature® T DNA tags are being used to mark premium Pima cotton fiber,known as PimaCott® and are also used to mark Upland cotton under the HomeGrown™ trademark. As the cotton ginning in theU.S. takes place sometime between September and March each year, it is possible that revenues from this business willbe seasonal. In particular, due to the impacts of the COVID-19 global pandemic, the Company did not recognize revenue for the shipmentof DNA concentrate relating to its cotton customer contract during the twelve months ended September 30, 2020.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 14; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            14            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In June 2017, we entered into a new licensing agreementwith Himatsingka America, Inc., which is part of the Himatsingka Group. (“Himatsingka America”), a leading supplierof home textiles. Under the terms of the Agreement, Himatsingka America will be solely responsible for promoting, marketing andselling on a worldwide basis the Company’s technology with respect to finished and unfinished cotton products. The Agreementgrants Himatsingka America an exclusive license to use our technology in respect of cotton, subject to certain carve-outs includinggovernmental users, non-commercial trade associations and others. The Agreement has a term that continues until June 23, 2042,except in the case of patents, in which case the term continues with respect to a patent until such patent is no longer in effect.The Agreement also provides that Himatsingka America will make royalty payments on a quarterly basis in arrears in the event thatour technology is used on non-home products. Himatsingka America is responsible for the inspection and compliance within the supplychain.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Himatsingka America is generally required to use ourtechnology during the term of the Agreement, subject, among other things, to their customers’ requirements. We haveestablished an independent testing laboratory in Ahmedabad, India, which is required by the agreement. Finished productsmade from this tagged fiber have been offered for sale under the PimaCott®, HomeGrown        <sup>         ®        </sup>        , and HomeGrownAcala™ content branded labels. The Agreement includes customary mutual indemnification provisions. See also theinformation under the caption “—Distribution of our Products and Commercial Agreements—HimatsingkaAmerica.”       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <b>         Sales and Marketing        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have eight employees engaged in sales and marketing, of whichfive are directly involved with sales.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Research and Development        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In our Biotherapeutic Contract Research and Manufacturing business,our research and development efforts are focused on the development of PCR-produced linear DNA expression vectors for use in nucleicacid-based therapies including drugs and biologics and associated PCR-based methods of linear DNA expression vector manufacture.Methods for viral free transfection, high-level cellular expression and linear DNA based rAAV manufacture are under development.In addition, we are developing several linear DNA based COVID-19 and cancer vaccine candidates in collaboration with Takis/Evvivax.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Under our COVID-19 Diagnostic and Surveillance Testing business,our research and development efforts are focused on the development of high-throughput high-sensitivity molecular diagnostic assaysfor COVID-19 and other pathogens.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our research and development efforts for our Non-Biologic Taggingbusiness are primarily focused on incorporating DNA molecular tags into carriers such as ink, textiles, thermoplastics and pharmaceuticalsand then authenticating DNA obtained from those marked products both in our laboratories and in the field, with the use of portableinfield DNA readers and proprietary reagents. As part of this effort, we typically conduct feasibility and pilot testing to ensurethat DNA tagging methods are compatible with the customer’s manufacturing and logistic processes, and that they can be implementedin a cost-effective manner. In some cases, the DNA incorporation methods may undergo wash-out and/or adherence tests to ensurethat DNA can be authenticated on a product even if it is subjected to aggressive processing techniques. We also continue developmentin the area of genotyping of cotton, down to the cultivar level to detect more specific information about cotton type. In short,we have considerable experience working with DNA in a wide range of carriers and substrates and authenticating them even yearsafter they have been applied onto the surface or inside of product materials. We believe that our continued development of newand enhanced technologies relating to our core business is essential to our future success.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We incurred approximately $3.3 million and $3.0 million on researchand development activities for the fiscal years ended September 30, 2020 and 2019, respectively       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Raw Materials and Suppliers        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our sources of raw materials include synthesized sources ofDNA which we are able to replicate to use in our product offerings and that are available from multiple sources.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Manufacturing        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have the capability to manufacture specific sequences ofSigNature DNA molecular tags and DNA for biopharma applications using PCR at large scale and to produce all of the resulting finishedproducts at our laboratories in Stony Brook. We manufacture COVID-19 diagnostic assay kits. We also have in-house capabilitiesto complete all authentications in our Stony Brook location and textile authentications in our India location.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 15; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Distribution of our Products and Commercial Agreements        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our products are distributed in the following ways:       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 24px">          </td>          <td style="text-align: justify; width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           directly to the customer;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           through channel partners; and          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           through licensed distributors.          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have entered into the following agreements and arrangementsfor the distribution of our products, among others:       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <b>         <i>          Tyme Technologies.         </i>        </b>        DuringNovember 2019, the Company’s majority-owned subsidiary, LRx signed a definitive agreement with Tyme Technologies, Inc.to supply the Company’s Vita-AssayTM invasive Circulating Tumor Cell (iCTC) capture assay and associated services foruse in the pivotal stage of the TYME-88-PANC clinical trial for patients with third-line pancreatic cancer.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        Under the terms of the Agreement, TYMEhas the option to purchase from the Company up to 3,000 Vita-Assay kits and associated iCTC analytical and storage services overthe course of treatment of up to 250 patients.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 16; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            16            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Collaboration and Licensing Agreements        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Takis S.R.L. and Evvivax S.R.L.        </b>        During September 2018we signed a joint development agreement with Takis/Evvivax, biotechnology companies focused on the discovery and development ofDNA based anti-cancer vaccines for the human and animal targets, respectively. Under the terms of the agreement, we will jointlydevelop linear DNA expression vectors for two of Takis/Evvivax’s anti-cancer vaccines candidates utilizing our linear DNAtechnology. Linear DNA amplicons carrying the DNA sequences for Takis/Evvivax’s vaccine candidates will be delivered to preclinicalanimal models via Takis/Evvivax’s proprietary electroporation technology. Antigen-specific immune responses aimed at achievingtherapeutic effects will be studied. During February 2020 we expanded our existing Joint Development Agreement (JDA) withTakis/Evvivax to include the preclinical development of a linear DNA vaccine against COVID-19. In addition, on September 16,2020, we announced the initiation of a veterinary clinical trial of one of the Company’s five LineaDNA™ vaccine candidates.In November 2020, we, together with Takis/Evvivax and our clinical research partner GVS, announced receipt of approvals fromthe New York State Department of Agriculture and Markets and the USDA on an advanced clinical strategy to conduct a veterinarytrial of a vaccine candidate. The goal of the vaccine trial is to evaluate the vaccine candidate as a strategy for the preventionof SARS-CoV-2 (COVID-19) (a zoonotic disease) infections in companion felines of humans. This veterinary clinical trial will seekto understand the immune response in cats by utilizing a vaccination strategy of interest in people that could yield valuable datafor both cats and humans. Our jointly-developed amplicon-based DNA vaccine for COVID-19 is expected to start veterinary clinicaltrials in domestic feline cats by early 2021, with the end goal of applying for a USDA Animal and Plant Health Inspection Serviceconditional license to enable commercial veterinary sales for domestic felines.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         iCell Gene Therapeutics, Inc.        </b>        During October 2018,we entered into an exclusive North American licensing agreement and a research services agreement with iCell Gene Therapeutics, Inc.(“iCell”) under which iCell licensed to us an anti-CD19 CAR T therapy candidate for non-viral delivery. We intend toutilize our non-viral, plasmid free platform, along with the in-licensed anti-CD19 CAR T therapy to develop, manufacture and commercializeLinCART19, a non-viral, plasmid free anti-CD19 CAR T therapeutic candidate. During April 2019, we announced that LRx had improvedexpression levels and survival rates of linear DNA constructs delivered without viruses or plasmids to human T cells. In collaborationwith Avectas, a cell engineering technology business enabling the manufacture of cell therapies, LRx has achieved a greater thanfour-fold increase in cell survival and a more than 50% increase in linear gene expression of a model amplicon. Results were presentedby Avectas at the Cell &amp; Gene Meeting on the Mediterranean in April 2019, which was attended by more than 50 companies.The Company expects to continue its preclinical research relating to LinCART19 with its partners to increase cellular expressionwithout the use of viral transduction.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Customer Concentration        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our revenues earned from sale of products and services for thefiscal year ended September 30, 2020 includes 13%, 12%, 11% and 10% respectively from four customers. At September 30,2020, four customers accounted for 74% of our accounts receivable. Our revenues earned from sale of products and services for thefiscal year ended September 30, 2019 includes 27%, 26% and 15%, respectively from three customers. At September 30, 2019,one customer accounted for 77% of our accounts receivable. Generally, our customers do not have an obligation to make purchasesfrom us and may stop ordering our products and services or may terminate existing orders or contracts at any time with little orno financial penalty. The loss of any of our significant customers, any substantial decline in sales to these customers, or anysignificant change in the timing or volume of purchases by our customers, could result in lower revenues and could harm our business,financial condition or results of operations.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Competition        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Some of our competitors that operate in the nucleic-acid basedtherapeutic, biologics and DNA manufacturing markets include: Precigen, Inc., Aldevron, LLC, Cobra Biologics, Limited, IntegratedDNA Technologies, Inc., Ziopharm Oncology, Inc., MaxCyte, Inc., Touchlight Genetics Ltd., Novartis AG, Kite Pharma, Inc.and Juno Therapeutics, Inc.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Some of our competitors that operate in the in vitro diagnosticsand/or clinical laboratory markets include: Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, PerkinElmer, Inc.,Roche Molecular Systems, Inc., Thermo Fisher Scientific Inc., Hologic, Inc., Becton, Dickinson and Company, Abbott MolecularInc., Canon Inc. and Bio-Rad Laboratories, Inc.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Some of our competitors that operate in the anti-counterfeitingand fraud prevention markets include: AlpVision Sa, Authentix, Inc., Brandwatch Technologies, Inc., Chromologic LLC,Collectors Universe, Inc., DataDot Technology Limited, De La Rue Plc., Digimarc Corporation, DNA Technologies, Inc.,Haelixa Ltd., ICA Bremen GmbH, IEH Corporation, Informium AG, opSec Security Group plc., MicroTag Temed Ltd., NanotechSecurity Corp., Nokomis, Inc., Oritain Global Limited, SafeTraces, Inc., Selectamark Security Systems plc, SmartWaterTechnology, Inc., Sun Chemical Corporation, TraceTag International Ltd., TruTag Technologies, Inc., Tailorlux gmbH andYottaMark, Inc.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 17; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We expect competition with our products and services to continueand intensify in the future. We believe competition in our principal markets is primarily driven by:       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 24px">          </td>          <td style="text-align: justify; width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           product performance, features and liability;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           price;          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 24px">          </td>          <td style="text-align: justify; width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           timing of product introductions;          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 24px">          </td>          <td style="text-align: justify; width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           ability to develop, maintain and protect proprietary products and technologies;          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 24px">          </td>          <td style="text-align: justify; width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           sales and distribution capabilities;          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 24px">          </td>          <td style="text-align: justify; width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           technical support and service;          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 24px">          </td>          <td style="text-align: justify; width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           brand loyalty; and          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 24px">          </td>          <td style="text-align: justify; width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           applications support.          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If a competitor develops superior technology or cost-effectivealternatives to our products, our business, financial condition and results of operations could be significantly harmed.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Proprietary Rights        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that our approximately 87issued patents, 42 patent applications,  34 trademark registrations, and 8  trademark applications, and our trade secrets,copyrights and other intellectual property rights are important assets for us. Our patents will expire at various timesbetween 2021 and 2037. The duration of our trademark registrations varies from country to country. However, trademarks aregenerally valid and may be renewed indefinitely as long as they are in use and/or their registrations are properlymaintained.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On August 7, 2019 we entered into an Amended and RestatedExclusive Licensing Agreement with The Research Foundation for the State University of New York (the “RF”) for a patentestate relating to the iCTC Technology. Under the terms of the Amended and Restated Exclusive Licensing Agreement, LRx is providedexclusive world-wide rights to the iCTC Technology patent estate that was previously licensed from the RF by Vitatex, Inc.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        However, there are events that are outside of our control thatpose a threat to our intellectual property rights as well as to our products and services. For example, effective intellectualproperty protection may not be available in every country in which our products and services are distributed. The efforts we havetaken to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our intellectual propertyrights could harm our business or our ability to compete. Protecting our intellectual property rights is costly and time consuming.Any increase in the unauthorized use of our intellectual property could make it more expensive to do business and harm our operatingresults. Although we seek to obtain patent protection for our innovations, it is possible we may not be able to protect some ofthese innovations. Given the costs of obtaining patent protection, we may choose not to protect certain innovations that laterturn out to be important. There is always the possibility that the scope of the protection gained from one of our issued patentswill be insufficient or deemed invalid or unenforceable. We also seek to maintain certain intellectual property as trade secrets.This secrecy could be compromised by third parties, or intentionally or accidentally by our employees, which would cause us tolose the competitive advantage resulting from these trade secrets.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Litigation regarding patents and other intellectual propertyrights is extensive in the biotechnology industry. In the event of an intellectual property dispute, we may be forced to litigate.This litigation could involve proceedings instituted by the U.S. Patent and Trademark Office or the International Trade Commission,as well as proceedings brought directly by affected third parties. Intellectual property litigation can be extremely expensive,and these expenses, as well as the consequences should we not prevail, could seriously harm our business. If a third party claimsan intellectual property right to technology we use, we might need to discontinue an important product or product line, alter ourproducts and processes, pay license fees or cease our affected business activities. Although we might under these circumstancesattempt to obtain a license to this intellectual property, we may not be able to do so on favorable terms, or at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 18; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            18            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Government Approvals of Commercial Non-Biologic Products        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We do not require any governmental approvals of our currentlycommercialized non-biologic products or services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Government Regulations for COVID-19 Diagnostic and SurveillanceTesting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For our Linea        <sup>         TM        </sup>        COVID-19 Assay Kit we received EUAfrom the FDA for the clinical use of the LineaTM COVID-19 Assay Kit for the qualitative detection of nucleic acid from SARS-CoV-2in respiratory specimens including anterior nasal swabs, self-collected at a healthcare location or collected by a healthcareworker, and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates,and bronchoalveolar lavage specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by theirhealthcare provider. Under the EUA, testing is limited to laboratories certified under CLIA that meet requirements to performhigh complexity tests. In July and November 2020, we were granted amendments to our EUA that expand the installed baseof PCR equipment platforms on which our Linea        <sup>         TM        </sup>        COVID-19 Assay Kit can be processed and significantly increasedthe daily testing capacity of the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit through the use of robotic automation. Our EUA andother information relating to our Linea        <sup>         TM        </sup>        COVID-19 Assay Kits can be found at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitrodiagnostics-euas.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Surveillance testing is not regulated by the FDA and CMShas stated that CLIA certification is not required to conduct surveillance testing. ADCL is offering itssafeCircle        <sup>         TM        </sup>        surveillance testing in compliance with current CDC, FDA, CMS and New York State Department of Healthrecommendations. The use of pooled sampling procedures for the safeCircle        <sup>         TM        </sup>        surveillance testing service has beeninternally validated by ADCL in compliance with current CDC guidance. The use of pooled sampling procedures is not includedin the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit EUA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Government Approvals of Drug and Biologic Products        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Some of our products may be incorporatedinto drug and biologic products which are subject to extensive regulation by FDA and other regulatory agencies in the United Statesand by comparable authorities in foreign countries. Biologics include a wide range of products such as vaccines, gene therapy,and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins or nucleic acids or complex combinations ofthese substances. They may also be living entities such as cells or tissue. Some of our products may be incorporated into drugsand biologics that are or will be subject to regulation as described in the next section. Some of our products may be drugs orbiologics that are subjected themselves to regulation as described in the following section. In either case, we are unlikely toreceive material revenues until the related drug or biologic receives regulatory approval. The FDA and other authorities regulateamong other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion andmarketing, distribution, post-approval monitoring and reporting, sampling and import and export of drug and biologic products.Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions,such as FDA refusal to file a marketing application, to issue a Complete Response letter or to not approve pending New Drug Applications(NDA) or Biologics Licensing Applications (BLAs), or to issue warning letters, product recalls, product seizures, total or partialsuspension of production or distribution, injunctions, fines, civil penalties, litigation, government investigation and criminalprosecution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Drug and biologic products that must undergopreclinical and clinical evaluation relating to product safety and efficacy before they are approved as commercial therapeuticsproducts. The regulatory authorities having jurisdiction in the countries in which our collaborators and customers intend to markettheir products may delay or put on hold clinical trials, delay approval of a product or determine that the product is not approvable.The FDA and comparable government authorities having jurisdiction in the countries in which our customers intend to market theirproducts have the authority to withdraw product approval or suspend manufacture if there are significant problems with raw materialsor supplies, quality control and assurance, safety, efficacy or the product is deemed adulterated or misbranded.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Government Regulation of Pharmaceutical and Biologic Products        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In the United States, the FDA regulatesdrugs and biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtainingregulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requiresthe expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any timeduring the product development process, approval process or after approval, may subject an applicant to a variety of administrativeor judicial sanctions, such as the FDA’s refusal to approve pending NDAs or BLAs, withdrawal of an approval, imposition ofa clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution,injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 19; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            19            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The process required by the FDA beforea drug or biologic may be marketed in the United States generally involves the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           completion of preclinical laboratory tests, animal studies and formulation studies in compliancewith the FDA’s Good Laboratory Practice regulations;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           submission to the FDA of an Investigational New Drug Application (“IND”), which mustbecome effective before human clinical trials may begin;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           approval by an independent Institutional Review Board (“IRB”) at each clinical sitebefore each trial may be initiated;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           performance of adequate and well-controlled human clinical trials in accordance with Current GoodClinical Practices (“cGCPs”), requirements to establish the safety and efficacy of the proposed drug or biologic productfor each indication;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           submission to the FDA of a New Drug Application (“NDA”) or Biologics Licensing Application(“BLA”);          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           satisfactory completion of an FDA advisory committee review, if applicable;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           satisfactory completion of an FDA inspection of the manufacturing facility or facilities at whichthe drug or biologic product is produced to assess compliance with cGMP requirements and to assure that the facilities, methodsand controls are adequate to preserve the drug’s identity, strength, quality and purity;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           satisfactory completion of FDA audits of clinical trial sites to assure compliance with cGCPs andthe integrity of the clinical data;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           payment of user fees and securing FDA approval of the NDA or BLA; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           compliance with any post-approval requirements, including the potential requirement to implementa Risk Evaluation and Mitigation Strategy (“REMS”), and the potential requirement to conduct post-approval studies.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Preclinical Studies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Preclinical studies include laboratoryevaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. AnIND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and anyavailable clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continueeven after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that timethe FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinicalhold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Asa result, submission of an IND may not result in the FDA allowing clinical trials to initiate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Clinical Trials        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Clinical trials involve the administrationof the investigational new drug or biologic product to human subjects under the supervision of qualified investigators in accordancewith cGCP requirements, which include the requirement that all research subjects provide their informed consent in writing fortheir participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectivesof the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for eachclinical trial and any subsequent protocol amendments must be submitted to the FDA. In addition, an IRB at each institution participatingin the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. Informationabout certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for publicdissemination on their www.clinicaltrials.gov website.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Progress reports detailing the resultsof the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Furthermore,the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the researchsubjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trialat its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drugor biologic has been associated with unexpected serious harm to patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Marketing Approval        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Assuming successful completion of the requiredclinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product’schemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA or BLA requestingapproval to market the product for one or more indications. In most cases, the submission of an NDA or BLA is subject to a substantialapplication user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA hasa goal of ten months from the date of “filing” of a standard NDA or BLA, for a new molecular entity to reviewand act on the submission. This review typically takes twelve months from the date the NDA or BLA is submitted to FDA because theFDA has approximately two months to make a “filing” decision.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 20; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            20            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        After evaluating the NDA or BLA and allrelated information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturingfacilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A completeresponse letter generally contains a statement of specific conditions that must be met in order to secure final approval of theNDA or BLA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even withsubmission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteriafor approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically issue an approvalletter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Even if the FDA approves a product, itmay limit the approved indications for use of the product, require that contraindications, warnings or precautions be includedin the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assessa drug or biologic’s safety after approval, require testing and surveillance programs to monitor the product after commercialization,or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, whichcan materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing ofa product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to theapproved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to furthertesting requirements and FDA review and approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Post-Approval Requirements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Drugs or biologics manufactured or distributedpursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirementsrelating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverseexperiences with the product. After approval, most changes to the approved product, such as adding new indications or other labelingclaims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed productsand the establishments where such products are manufactured, as well as new application fees for supplemental applications withclinical data.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA may impose a number of post-approvalrequirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase4 clinical trials, and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, drug and biologic manufacturersand other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishmentswith the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliancewith cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval beforebeing implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and imposereporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use.Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintaincGMP compliance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Once an approval of a drug or biologicis granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or ifproblems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverseevents of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements,may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies orclinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA strictly regulates marketing, labeling,advertising and promotion of products that are placed on the market. Drugs or biologics may be promoted only for the approved indicationsand in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulationsprohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subjectto significant liability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In many foreign countries, drugs and biologicsare subject to regulatory requirements in addition to and sometimes different than the U.S. requirements described herein.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Laboratory Developed Tests        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA is currently exercisingenforcement discretion over the regulation of Laboratory Developed Tests (“LDTs”), such as our iCTC captureassay. If the FDA were to begin enforcement, our product would potentially be subject to extensive regulation as a medicaldevice under federal law. In order to market a medical device, a company must first receive either FDA clearance underSection 510(k) of the Federal Food, Drug and Cosmetic Act or approval of a PMA application from the FDA, unless anexemption applies. The process of obtaining PMA approval is much more rigorous, costly, lengthy and uncertain than the510(k) clearance process. In the 510(k) clearance process, the FDA must determine that a proposed device is “substantially equivalent” to a device legally on the market, known as a “predicate” device, in orderto clear the proposed device for marketing. To be “substantially equivalent,” the proposed device must have thesame intended use as the predicate device, and either have the same technological characteristics as the predicate device orhave different technological characteristics and not raise different questions of safety or effectiveness than the predicatedevice. Clinical data is sometimes required to support substantial equivalence. In the PMA approval process, the FDA mustdetermine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, butnot limited to, technical, pre-clinical, clinical trial, manufacturing, and labeling data. The PMA process is typicallyrequired for devices for which the 510(k) process cannot be used and that are deemed to pose the greatest risk.Following FDA clearance or approval, medical devices are subject to continuing regulatory requirements, including thoserelated to manufacturing, labeling, advertising and promotion, restrictions on sale, distribution and use, and surveillanceof safety issues and product complaints.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 21; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            21            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Clinical Laboratory Improvement Amendments        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The CLIA is a federal law regulating clinicallaboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis,prevention, or treatment of disease. CLIA is intended to ensure the quality and reliability of clinical laboratories in the UnitedStates by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiencytesting, patient test management, quality control, quality assurance and inspections. Clinical laboratories must be certified underCLIA in order to perform testing on human specimens, unless they fall within an exception to CLIA certification, such as researchlaboratories that test human specimens but do not report patient-specific results for the diagnosis, prevention, or treatment ofany disease or impairment of, or the assessment of the health of individual patients. CLIA certification is also required to beeligible to bill Federal and State healthcare programs, as well as many private third-party payers, for diagnostic testing andservices. In addition, proprietary tests must also be recognized as part of an accredited program under CLIA so that they can beoffered in a CLIA-certified laboratory.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Emergency Use Authorizations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA has the authority to grant an EUAto allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseasesor conditions when there are no adequate, approved, and available alternatives. When issuing an EUA, the FDA imposes conditionsof authorization, with which the company must comply. Such conditions include, but may not be limited to, compliance with labeling,distribution of materials designed to ensure proper use, reporting obligations, and restrictions on advertising and promotion.The EUA is only effective for the duration of the COVID-19 public health emergency. The FDA may revoke or terminate the EUA soonerif, for example, we fail to comply with the terms of the EUA or our test is determined to be less accurate than it was initiallybelieved to be. The FDA may revoke an EUA if there is a failure to comply with the conditions of authorization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are subject to various federal and statelaws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketingprograms for drugs and biologics. In addition, we may be subject to patient privacy regulation by both the federal government andthe states in which we conduct our business. The laws that may affect such operations include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting,receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for,either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under afederal healthcare program, such as the Medicare and Medicaid programs. The term “remuneration” has been broadly interpretedto include anything of value;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           federal false claims and civil monetary penalties laws, including the federal civil False ClaimsAct, which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federalprograms (including Medicare and Medicaid) claims for items or services that are false or fraudulent;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           provisions of federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”),which created federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraudany healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits,items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of2009 (“HITECH”) and its implementing regulations, impose certain requirements relating to the privacy, security andtransmission of individually identifiable health information; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           the federal Physician Payments Sunshine Act requirements, under the Patient Protection and theAffordable Care Act (the “ACA”), which require manufacturers of certain drugs and biologics to track and report toCenters for Medicare &amp; Medicaid Services, or CMS, payments and other transfers of value they make to U.S. physicians andteaching hospitals as well as physician ownership and investment interests in the manufacturer.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 22; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            22            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Other U.S. Regulatory Matters        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Manufacturing, sales, promotion and otheractivities following product approval for drugs and biologics are also subject to regulation by numerous regulatory authoritiesin the United States in addition to the FDA, including the Centers for Medicare &amp; Medicaid Services, other divisions ofthe Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer ProductSafety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental ProtectionAgency and state and local governments. Sales, marketing and scientific and educational programs also must comply with state andfederal fraud and abuse laws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Pricing and rebate programs must complywith the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in theACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration,additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. PoisonPrevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and stateconsumer protection and unfair competition laws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The distribution of pharmaceutical andbiologic products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storageand security requirements intended to prevent the unauthorized sale of pharmaceutical products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The failure to comply with any of theselaws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failureto meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requestsfor recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusalto allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws,even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’sattention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed byus could materially affect our business in an adverse way.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Changes in regulations, statutes or theinterpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to ourmanufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuationof our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adverselyaffect the operation of our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Coverage and Reimbursement        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Sales of our drug and biologic productswill depend, in part, on the extent to which such products will be covered by third party payors, such as government health programs,commercial insurance and managed healthcare organizations. In the United States no uniform policy of coverage and reimbursementfor drug products or biologics exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to beprovided for any of our products will be made on a payor-by-payor basis. As a result, the coverage determination process is oftena time-consuming and costly process that will require us to provide scientific and clinical support for the use of our productsto each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As noted above, the marketability of anydrug or biologic products for which we receive regulatory approval for commercial sale may suffer if the government and third-partypayors fail to provide adequate coverage and reimbursement. An emphasis on cost containment measures in the United States has increased,and we expect will continue to increase, the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursementrates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for whichwe receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, in most foreign countries,the proposed pricing for a drug or biologic must be approved before it may be lawfully marketed. The requirements governing drugand biologic pricing and reimbursement vary widely from country to country. For example, the European Union provides options forits member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursementand to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal productor it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal producton the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceuticalproducts will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched inthe European Union do not follow price structures of the United States and generally prices tend to be significantly lower.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Impact of Other Government Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We and our products are subject to regulationby various U.S. federal regulatory agencies such as the Federal Trade Commission and are subject to regulation by the OccupationalSafety and Health Administration concerning employee safety and health matters. Such regulations principally relate to the ingredients,labeling, packaging, advertising and marketing of our products. There are no significant capital expenditures for government regulationmatters either planned in the current year or expected in the near future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 23; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            23            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Compliance with Environmental Law        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We and any suppliers we currently or may in the future engageare subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements,including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous andregulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employeehealth and safety. We believe that we are in compliance with all applicable environmental law and do not have any material costsof compliance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Under certain environmental laws, we could be held responsiblefor costs relating to any contamination at our current or past facilities and at third party facilities. We also could incur significantcosts associated with civil or criminal fines and penalties. Compliance with applicable environmental laws and regulations maybe expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturingefforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes.Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to ouremployees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurancepolicies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amountexceeding our resources, and our preclinical trials, future clinical trials or regulatory approvals could be suspended, which couldhave a material adverse effect on our business, prospects, financial condition, results of operations, and prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Employees        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of September 30, 2020 we had a total of 61employees(59 fulltime and 2 part-time), consisting of 3 in executive management, 13 in research and development,  4 inforensics, 5 in quality assurance and compliance, 4 in quality control, 3 in finance and accounting,  6 in operations/production,8 in sales and marketing, 1 in human resources, 1 in shared services, 1 in investor relations, 2 in information services, 4 inproduct development,  and 6 in Applied DNA Clinical Labs, LLC.  . Expenses related to travel, marketing, salaries,and general overhead will be increased as necessary to support our growth in revenue. Any projected increase in human capital isdependent upon our ability to generate revenues and obtain sources of funding. Since June 2012, we have been working withInsperity Inc. to assist in managing many of our back-end administrative human resources, benefits, and payroll responsibilities.We are an at-will employer and generally do not enter into employment agreements requiring our employees to continue in our employmentfor any period of time, with the exception of our Chief Executive Officer, Dr. James A. Hayward. The initial term of Dr. Hayward’scurrent employment agreement was July 1, 2016 through June 30, 2017, and this employment agreement automatically renewsfor one-year periods subject to ninety days’ prior notice of non-renewal by Dr. Hayward or us in accordance with theterms of the employment agreement. As of June 30, 2020, the employment contract automatically renewed for an additional year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Available Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are subject to the informational requirements of the ExchangeAct, which requires us to file our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K,amendments to such reports and other information with the SEC. Because we file documents electronically with the SEC, you may obtainthis information by visiting the SEC’s website at:        <i>         www.sec.gov        </i>        . Our website is located at:        <i>         www.adnas.com        </i>        . Theinformation on, or that may be accessed through, our website is not incorporated by reference into and should not be considereda part of this report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 24; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            24            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_002">           </a>           <b>            ITEM 1A.           </b>          </td>          <td>           <b>            RISK FACTORS.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Summary of Risk Factors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our business is subject to numerous risksand uncertainties, discussed in more detail in the following section. These risks include, among others, the following key risks:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           The COVID-19 global pandemic may continue to materially and adversely impact our business, financial condition andresults of operations.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Our ability to continue as a going concern.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           We have a history of net losses.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           We have not produced significant revenues. This makes it difficult to evaluate our future prospects and increases the riskthat we will not be successful.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           Our opportunities in pharmaceuticals and biologics will require substantial additional funding.  We may not be successfulin our efforts to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfullyidentify, finance and develop product candidates, our commercial opportunities in pharmaceuticals and biologics may be limited.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           Our Linea           <sup>            TM           </sup>           COVID-19 Assay Kit is being sold under a FDA EUA which could be revoked or terminated by the FDAat any time and will cease to be effective once the public health emergency justifying its use ends.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           Our COVID-19 Surveillance Testing may become obsolete for a variety of reasons, including an endto the current pandemic. The utility will also be diminished if positivity rates reach levels high enough to render surveillancetesting ineffective or inefficient. Pharmaceutical and biologic products are highly complex, and if we or our collaborators andcustomers are unable to provide quality and timely offerings to our respective customers, our business could suffer.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt; text-align: justify">           <font style="font-size: 10pt">            Our Linea            <sup>             TM            </sup>            COVID-19 Assay Kits could become obsolete or their utility could be significantly diminished.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           Pharmaceutical and biologic-related revenue will be dependent on our collaborators’ and customers’demand for our manufacturing services.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           The markets for our drug and biologic candidates and linear DNA are very competitive, and we maybe unable to continue to compete effectively in these industries in the future.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           The markets for our supply chain security and product authentication solutions are very competitive,and we may be unable to continue to compete effectively in these industries in the future.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           Intellectual property litigation could harm our business, financial condition and results of operations.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           Our joint pursuit of a potential vaccine for COVID-19 is at an early stage and may be unable to produce a vaccine that successfullytreats the virus in a timely manner, if at all, and compete successfully with vaccines developed by larger companies.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Pharmaceutical and biologic-related revenue is generally dependent on regulatory approval, oversight and compliance.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming, andinherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unableto generate product revenue and our business will be substantially harmed.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           If the FDA were to begin to enforce regulation of Laboratory Developed Tests (“LDTs”), we could incur substantialcosts and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-marketrequirements.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           If we are unable to obtain laboratory licensure or we fail to comply with laboratory licensing requirements, we could losethe ability to offer our clinical testing services or experience disruptions to our business.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditionscould be adversely affected.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           We need to expand our sales, marketing and support organizations to increase market acceptance of our products and services.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           If we are unable to continue to retain the services of Dr. Hayward, we may not be able to continue our operations.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           We may have conflicts of interest with our affiliates and related parties, and in the past we have engaged in transactionsand entered into agreements with affiliates that were not negotiated at arms’ length.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           There are a large number of shares of common stock underlying our outstanding options and warrants and the sale of these sharesmay depress the market price of our common stock and cause immediate and substantial dilution to our existing stockholders.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 25; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            25            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">        In addition to the abovekey factors, as well as other variables affecting our operating results and financial condition, past financial performancemay not be a reliable indicator of future performance, and historical trends should not be used to anticipate results ortrends in future periods. The following are important factors that could cause actual results or events to differ materiallyfrom those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties describedbelow are not the only ones we face. In addition to the factors discussed elsewhere in this report and our other reports anddocuments filed with the SEC, risks and uncertainties not presently known to us or that we may currently deem immaterial alsomay impair our business, financial condition, operating results and/or stock price. If any of the following risks or suchother risks actually occurs, our business, financial condition, operating results and/or stock price could be harmed. In thefollowing factors, “volatility in our share price”, “adverse impact on the price (or value) of ourshares”, “decline in the price of our common stock” and similar terms also refer to our warrants and sharesto be received upon exercise of our warrants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Relating to Our Business:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The COVID-19 global pandemic may continue tomaterially and adversely impact our business, financial condition and results of operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our business has been and could continue to be materially andadversely affected by the outbreak of a widespread health epidemic. The present coronavirus (or COVID-19) pandemic has disruptedour operations and has affected our business, as government authorities impose mandatory closures, work-from-home orders and socialdistancing protocols or impose other restrictions that could materially adversely affect our ability to adequately staff and maintainour operations. Portions of our business are considered “essential” such as our government and pharmaceuticalcontracts, as well as our vaccine and diagnostic candidate development and our COVID-19 Surveillance Testing. However, we haveexperienced, and may continue to experience in the future, facility closures related to our “nonessential” businesses,and pursuant to the government order, the Company has reduced the scope of its operations and where possible, certain workers aretelecommuting from their homes. As a result of COVID-19 we have experienced a decline in revenues from non-biological taggingand related services. As the COVID-19 outbreak and responses to it continue to evolve, we may experience further adverse impactson our operations, including our ability to secure supplies, and our ability to access capital on favorable terms, or at all, maybe impaired. There may also be long-term effects on our customers in and the economies of affected countries. Although the durationand ultimate impact of these factors is unknown at this time, the decline in economic conditions due to COVID-19, or another disease-causingsimilar impacts, may adversely affect our business, financial condition and results of operations and such impact may be material.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="background-color: white">         <b>          <i>           There is substantialdoubt relating to our ability to continue as a going concern.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="background-color: white">         We have recurring netlosses, which have resulted in an accumulated deficit of $269,835,650 as of September 30, 2020. We have incurred a net lossof $13,028,904 for the fiscal year ended September 30, 2020. At September 30, 2020, we had cash and cash equivalentsof $7,786,743. We have concluded that these factors raise substantial doubt about our ability to continue as a going concern forone year from the issuance of the financial statements. In addition, the report from our independent registered public accountingfirm for the year ended September 30, 2020 includes an explanatory paragraph stating that our significant losses and needsto raise additional funds to meet our obligations and sustain operations raise substantial doubt about our ability to continueas a going concern. We will continue to seek to raise additional working capital through public equity, private equity or debtfinancings. If we fail to raise additional working capital, or do so on commercially unfavorable terms, it would materially andadversely affect our business, prospects, financial condition and results of operations, and we may be unable to continue as agoing concern. Future reports from our independent registered public accounting firm may also contain statements expressing substantialdoubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in thefuture and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sourcesmay be unwilling to provide additional funding to us on commercially reasonable terms, if at all.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We may not be entitled to forgivenessof our recently received Paycheck Protection Program Loan, and our application for the Paycheck Protection Program Loan could inthe future be determined to have been impermissible.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InMay 2020, we received loan proceeds of approximately $847 thousand (the “PPP Loan”) pursuant to the Paycheck ProtectionProgram under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. SmallBusiness A        </font>        <font style="background-color: white">         dministration (the “SBA”). The PPP Loan, if not forgiven,bears interest at a rate of 1.00% per annum, and is subject to the standard terms and conditions applicable to loans administeredby the SBA under the CARES Act.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 26; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            26            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Under the terms of the CARES Act, PPP Loan recipients must meetcertain eligibility criteria. Due to the size of the PPP Loan, it is subject to review by regulators. We could be granted forgivenessfor all or a portion of loans granted under the PPP. Such forgiveness will be determined based on the use of loan proceeds forpayment of payroll costs and any payments of mortgage interest, rent, and utilities. We have considered the requirements of thePPP Loan and we believe we are within the eligibility threshold and have used the loan proceeds in accordance with PPP Loan forgivenessrequirements. However, no assurance can be provided that we will obtain forgiveness for any portion of the PPP Loan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Further, if despite our actions and certificationthat we satisfied all eligibility requirements for the PPP Loan, it is later determined that we violated applicable laws or wereotherwise ineligible to receive the PPP Loan, we may be required to repay the PPP Loan in its entirety in a lump sum or be subjectto additional penalties, which could result in adverse publicity and damage to our reputation. If these events were to transpire,they could have a material adverse effect on our business, results of operations and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We have not produced significant revenues. This makesit difficult to evaluate our future prospects and increases the risk that we will not be successful.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our operations since inception have producedlimited revenues and may not produce significant revenues in the near term, or at all, which may harm our ability to obtain additionalfinancing and may require us to reduce or discontinue our operations. You must consider our business and prospects in light ofthe risks and difficulties we will encounter as a company operating in a rapidly evolving industry. We may not be able to successfullyaddress these risks and difficulties, which could significantly harm our business, operating results, and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our new emphasis on biotherapeuticcontract research and manufacturing and COVID-19 diagnostic and surveillance testing may reduce our ability to maintain and expandour existing Non-Biologic Tagging businesses         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our new emphasis on biotherapeutic contractresearch and manufacturing and COVID-19 diagnostic and surveillance testing may divert funding and our limited managerial and otherresources from our existing non-biologic tagging businesses. This may have the effect of reducing opportunities to grow or maintainrevenues in our existing businesses while at the same time we may fail in our biotherapeutic contracts research and manufacturingand COVID-19 diagnostic and surveillance testing efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our opportunities in pharmaceuticals and biologics willrequire substantial additional funding.  We may not be successful in our efforts to create a pipeline of product candidatesor to develop commercially successful products. If we fail to successfully identify, finance and develop product candidates, ourcommercial opportunities in pharmaceuticals and biologics may be limited.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have no pharmaceutical or biologic productsapproved for commercial sale and have not generated any revenue from pharmaceutical or biologic product sales. Identifying, developing,obtaining regulatory approval and commercializing pharmaceutical and biologic product candidates will require substantial additionalfunding beyond our current available resources and is prone to the risks of failure inherent in drug or biologic development. Developingproduct candidates is expensive, and we expect to spend substantial amounts as we fund our early-stage research projects, engagein preclinical development of early-stage programs and, in particular, advance program candidates through preclinical developmentand clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Investment in pharmaceutical and biologicproduct development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptablesafety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be ableto successfully advance any product candidates through the development process or, if approved, successfully commercialize anyproduct candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Even if we receive regulatory approvalto market any of our product candidates, we cannot assure you that any such product candidate will be successfully commercialized,widely accepted in the marketplace or be more effective than other commercially available alternatives.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Even if we are able to generate revenuefrom the sale of any approved pharmaceutical and biologic products, we may not become profitable and may need to obtain additionalfunding to continue operations. Our failure to become and remain profitable would decrease the value of our Company and could impairour ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of productcandidates or continue our operations, and cause a decline in the value of our common stock, all or any of which may adverselyaffect our viability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our operating results could be adversely affected by areduction in business with our significant customers.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our revenue earned from the sale of products and services forthe fiscal year ended September 30, 2020 included an aggregate of 46% of our total revenues from four customers. These fourcustomers accounted for approximately 22% of our total accounts receivable at September 30, 2020. At September 30, 2020,four customers accounted for an aggregate of 74% of our total accounts receivable. Our revenue earned from the sale of productsand services for the fiscal year ended September 30, 2019 included an aggregate of 68% of our total revenues from three customers.These three customers accounted for approximately 82% of our total accounts receivable at September 30, 2019. At September 30,2019, one customer accounted for an aggregate of 77% of our total accounts receivable. Generally, our customers do not have anobligation to make purchases from us and may stop ordering our products and services or may terminate existing orders or contractsat any time with little or no financial penalty. The loss of any of our significant customers, any substantial decline in salesto these customers, or any significant change in the timing or volume of purchases by our customers could result in lower revenuesand could harm our business, financial condition or results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 27; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            27            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Fluctuations in quarterly results may cause a declinein the price of our common stock.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our revenues and profitability aredifficult to predict due to the nature of the markets in which we compete, as well as our recent entry into new markets andproducts, such as our Linea        <font style="font-variant: small-caps">         <sup>          TM         </sup>        </font>        COVID-19 Assay Kit and ourCOVID-19 Surveillance Testing, fluctuating user demand, the uncertainty of current and future global economic conditions, andfor many other reasons, including that our operating results are highly dependent on the volume and timing of orders receivedduring a quarter, which are difficult to forecast. Customers generally order on an as-needed basis and we typically do notobtain firm, long-term purchase commitments from our customers.  The quarterly fluctuations in operating resultsdescribed above may cause a decline in the price of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Relating to Our Product Candidates, Manufacturing,Development, and Industries:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our Linea          <sup>           TM          </sup>          COVID-19Assay Kit is being sold under an FDA EUA.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our Linea        <sup>         TM        </sup>        COVID-19 AssayKit has not been cleared or approved by FDA, but has been authorized for sale under an EUA. The FDA has the authority to grantan EUA to allow unapproved medical products to be used in an emergency when there are no adequate, approved, and available alternatives.The EUA authorizes our test to be used by laboratories certified to perform high complexity testing under CLIA. The EUA includesconditions of authorization with which we must comply, including, but not limited to, compliance with labeling, distribution ofmaterials designed to ensure proper use, reporting obligations, and restrictions on advertising and promotion. Distributors ofand laboratories using our Linea        <sup>         TM        </sup>        COVID-19 Assay Kit must also comply with the relevant provisions of our EUA.The EUA is only effective for the duration of the COVID-19 public health emergency. The FDA may revoke or terminate the EUA soonerif, for example, we fail to comply with the terms of the EUA or our test is determined to be less accurate than it was initiallybelieved to be. We cannot predict how long the EUA will remain in place. If the EUA is revoked or terminated, it could significantlyharm our business, results of operations, and profits.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our safeCircle          <sup>           TM          </sup>          surveillance testing servicecould become obsolete or its utility could be significantly diminished.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Surveillance testing is not regulatedby the FDA and CMS has stated that CLIA certification is not required to conduct surveillance testing. ADCL is offering itssafeCircle        <sup>         TM        </sup>        surveillance testing in compliance with current CDC, FDA, CMS and New York State Department of Healthrecommendations. The regulatory framework or recommendations regarding COVID-19 Surveillance Testing could change at anytime. Further, our COVID-19 Surveillance Testing may become obsolete for a variety of reasons, including an end to thecurrent pandemic or the development and widespread distribution of a vaccine,including the vaccine developed by Pfizer-BioNTech for which the FDA has recently granted emergency use authorization. In addition, the utility of these services will also diminish if positivity rates reach levels high enoughto render surveillance testing ineffective or inefficient.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our Linea          <font style="font-family: Times New Roman, Times, Serif">           <sup>            TM           </sup>          </font>          COVID-19Assay Kits could become obsolete or their utility could be significantly diminished.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our Linea        <sup>         TM        </sup>        COVID-19 Assay Kits may become obsoletefor a variety of reasons, including an end to the current pandemic or the development and widespread distribution of a vaccine,including the vaccine developed by Pfizer-BioNTech for which the FDA has recently granted emergency use authorization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our joint pursuit of a potential vaccine for COVID-19is at an early stage and may be unable to produce a vaccine that successfully treats the virus in a timely manner, if at all ,and compete successfully with vaccines developed by larger companies.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In response to the global outbreak of coronavirus,we are jointly pursuing the development of linear DNA vaccine candidates in collaboration with Takis/Evvivax. Our joint developmentof vaccine candidates is in early stages, and we may be unable to produce a successful vaccine candidate in a timely manner, ifat all. Additionally, development of an effective vaccine candidate depends on the success of our and our partner’s manufacturingcapabilities, and we may face challenges in clinical trials, licensing, distribution channels, intellectual property disputes orchallenges, and the need to establish teams of people with the relevant skills worldwide. We may also face challenges with sourcinga sufficient amount of raw materials to support the demand for a vaccine. We may be unable to effectively create a supply chainfor any vaccine candidate that will adequately support demand.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We would require additional funding inorder to enable the development of vaccine candidates.  Our commitment of financial resources and personnel to the jointdevelopment of these vaccine candidates may cause delays in or otherwise negatively impact our other development programs and couldprove futile, as future demand for any successful vaccine is unknown.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, another party may be successfulin producing a more efficacious vaccine or other treatment for COVID-19 which may reduce or eliminate demand for any successfulvaccine that we may jointly develop. In particular, given the widespread media attention on the current COVID-19 pandemic, thereare efforts by public and private entities to develop a COVID-19 vaccine as fast as possible. On December 11, 2020, the FDA issuedthe first emergency use authorization to Pfizer-BioNTech for a vaccine for the prevention of COVID-19 in individuals 16 years ofage and older. The emergency use authorization allows the COVID-19 vaccine to be distributed in the U.S. In addition to the Pfizer-BioNTechvaccine, other entities, including AstraZeneca PLC, GlaxoSmithKline plc, Johnson &amp; Johnson, Moderna, Inc., and Sanofi,may develop COVID-19 vaccines that are more effective than any we may jointly develop, may develop a COVID-19 vaccine that becomesthe standard of care, may develop a COVID-19 vaccine at a lower cost or earlier than we are able to jointly develop any COVID-19vaccine, or may be more successful at commercializing a COVID-19 vaccine. These other organizations are much larger than we areand have access to larger pools of capital and broader manufacturing infrastructure. The success or failure of other entities,or perceived success or failure, may adversely impact our ability to obtain any future funding for our joint COVID-19 vaccine developmentefforts or for us to ultimately commercialize any vaccine candidate, if approved.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 28; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            28            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Pharmaceutical and biologic products are highly complex,and if we or our collaborators and customers are unable to provide quality and timely offerings to our respective customers, ourbusiness could suffer.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The process of manufacturing pharmaceuticaland biologics and their components is complex, highly-regulated and subject to multiple risks.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Manufacturing biologics is highlysusceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendoror operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the productionprocess. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defectsand other supply disruptions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our ability to generate revenue in thepharmaceutical and biologic market depends on our ability to manufacture products that meet exacting quality and safety standards.If we are unable to manufacture these products to the required levels, it could have an adverse effect on our business, financialcondition, and results of operations and may subject us to regulatory actions, including product recalls, product seizures, injunctionsto halt manufacture or distribution, restrictions on our operations, or civil sanctions, including monetary sanctions and criminalactions. In addition, we could be subject to costly litigation, including claims from our collaborators and customers for reimbursementfor the cost of our products or other related losses, the cost of which could be significant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our business also depends on the abilityof our collaborators and customers to manufacture the pharmaceutical or biologic products that incorporate our products. If theFDA determines that our collaborators and customers are not in compliance with FDA laws and regulations, including those governingcGMP regulations, the FDA may deny NDA or BLA approval until the deficiencies are corrected. Even if our collaborators or customersobtain regulatory approval for any of their product candidates, there is no assurance that they will be able to manufacture theapproved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantitiesto meet the requirements for the potential launch of the product or to meet potential future demand. If our collaborators or customersare unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired,which would have an adverse effect on our business, financial condition, results of operations and growth prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Pharmaceutical and biologic-related revenue will be dependenton our collaborators’ and customers’ demand for our manufacturing services.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The amount of customer spending on pharmaceuticaland biologic development and manufacturing will have an impact on our sales and profitability in the pharmaceutical and biologicmarket. Our collaborators and customers determine the amounts that they will spend based upon, among other things, available resources,access to capital, and their need to develop new products, which, in turn, are dependent upon a number of factors, including theircompetitors’ research, development and product initiatives and the anticipated market uptake, and clinical and reimbursementscenarios for specific products and therapeutic areas. Consolidation in the pharmaceutical and biologic industry may impact suchspending as customers integrate acquired operations, including R&amp;D departments and manufacturing operations. Any reductionin spending on pharmaceutical and biotechnology development and related services as a result of these and other factors could havea material adverse effect on our business, results of operations and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The markets for our drug and biologic candidates and linearDNA are very competitive, and we may be unable to continue to compete effectively in these industries in the future.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-size: 10pt">         The principal markets for ourdrug and biologic candidates and linear DNA are intensely competitive. We compete with many existing suppliers and new competitorscontinue to enter the market. Many of our competitors, both in the United States and elsewhere, are major pharmaceutical, chemicaland biotechnology companies, or have strategic alliances with such companies, and many of them have substantially greater capitalresources, marketing experience, research and development staff, and facilities than we do. Any of these companies could succeedin developing products that are more effective than the product candidates that we have or may develop and may be more successfulthan us in producing and marketing their existing products.        </font>        Some of our competitors that operate in the nucleic-acid basedtherapeutic, biologics and DNA manufacturing markets include: Precigen, Inc., Aldevron, LLC, Cobra Biologics, Limited, IntegratedDNA Technologies, Inc., Ziopharm Oncology, Inc., MaxCyte, Inc., Touchlight Genetics Ltd., Novartis AG, Kite Pharma, Inc.and Juno Therapeutics, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 29; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            29            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We expect this competition to continueand intensify in the future. Our competitors also compete with us in recruiting and retaining qualified scientific and managementpersonnel, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunitiescould be reduced or eliminated if our competitors develop and commercialize drug and biologic candidates or linear DNA that aresafer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any drug and biologiccandidates and linear DNA that we may develop. Our competitors also may obtain FDA or other regulatory approval for their productsmore rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market positionbefore we are able to enter the market. Additionally, drug and biologic candidates and linear DNA developed by our competitorsmay render our potential drug and biologic candidates and linear DNA uneconomical or obsolete, and we may not be successful inmarketing any drug and biologic candidates and linear DNA we may develop against competitors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        If any of these risks occur, our business,financial condition and results of operations could be significantly harmed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The markets for our supply chain security and productauthentication solutions are very competitive, and we may be unable to continue to compete effectively in these industries in thefuture.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The principal markets for our offerings are intensely competitive.We compete with many existing suppliers and new competitors continue to enter the market. Many of our competitors, both in theUnited States and elsewhere, are major pharmaceutical, chemical and biotechnology companies, or have strategic alliances with suchcompanies, and many of them have substantially greater capital resources, marketing experience, research and development staff,and facilities than we do. Any of these companies could succeed in developing products that are more effective than the productsthat we have or may develop and may be more successful than us in producing and marketing their existing products. Some of ourcompetitors that operate in the supply chain security and product authentication markets include: AlpVision Sa, Authentix, Inc.,Brandwatch Technologies, Inc., Chromologic LLC, Collectors Universe, Inc., DataDot Technology Limited, De La Rue Plc.,Digimarc Corporation, DNA Technologies, Inc., Haelixa Ltd., ICA Bremen GmbH, IEH Corporation, Informium AG,opSec Security Group plc., MicroTag Temed Ltd., Nanotech Security Corp., Nokomis, Inc., Oritain Global Limited, SafeTraces, Inc.,Selectamark Security Systems plc, SmartWater Technology, Inc., Sun Chemical Corporation, TraceTag International Ltd., TruTagTechnologies, Inc., Tailorlux gmbH and YottaMark Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We expect this competition to continueand intensify in the future        <b>         .        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our research and development efforts for new productsmay be unsuccessful.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We incur research and development expenses to develop new productsand technologies in an effort to maintain our competitive position in a market characterized by rapid rates of technological advancement.Under our COVID-19 Diagnostic and Surveillance Testing businesses, our research and development efforts are focused on the developmentof high-throughput high-sensitivity molecular assays for COVID-19. Our research and development efforts are subject to unanticipateddelays, expenses and technical problems. There can be no assurance that any of these products or technologies will be successfullydeveloped or that, if developed, will be commercially successful. In the event that we are unable to develop commercialized productsfrom our research and development efforts or we are unable or unwilling to allocate amounts beyond our currently anticipated researchand development investment, we could lose our entire investment in these new products and technologies. Any failure to translateresearch and development expenditures into successful new product introduction could have an adverse effect on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, research, development, andcommercialization of pharmaceutical and biologic products is inherently risky. We cannot give any assurance that any of our pharmaceuticaland biologic product candidates will receive regulatory approval, which is necessary before they can be commercialized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to Our Intellectual Property:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our intellectual property rights are valuable, and anyinability to protect them could reduce the value of our products, services and brand.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our patents, trademarks, trade secrets,copyrights and all of our other intellectual property rights are important assets for us. There are events that are outside ofour control that pose a threat to our intellectual property rights as well as to our products and services. For example, effectiveintellectual property protection may not be available in every country in which our products and services are distributed. Theefforts we have taken to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our intellectualproperty rights could harm our business or our ability to compete. Protecting our intellectual property rights is costly and timeconsuming. Any increase in the unauthorized use of our intellectual property could make it more expensive to do business and harmour operating results. Although we seek to obtain patent protection for our innovations, it is possible we may not be able to protectsome of these innovations. Given the costs of obtaining patent protection, we may choose not to protect certain innovations thatlater turn out to be important. There is always the possibility that the scope of the protection gained from one of our issuedpatents will be insufficient or deemed invalid or unenforceable. We also seek to maintain certain intellectual property as tradesecrets. The secrecy could be compromised by third parties, or intentionally or accidentally by our employees, which would causeus to lose the competitive advantage resulting from these trade secrets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 30; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            30            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Intellectual property litigation could harm our business,financial condition and results of operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Litigation regarding patents and otherintellectual property rights is extensive in the drug and biotechnology industry. In the event of an intellectual property dispute,we may be forced to litigate. This litigation could involve proceedings instituted by the U.S. Patent and Trademark Office or theInternational Trade Commission, as well as proceedings brought directly by affected third parties. Intellectual property litigationcan be extremely expensive, and these expenses, as well as the consequences should we not prevail, could seriously harm our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        If a third party claims anintellectual property right to technology we use, we might need to discontinue an important product or product line, alterour products and processes, pay license fees or cease our affected business activities. Although we might under thesecircumstances attempt to obtain a license to this intellectual property, we may not be able to do so on favorable terms, orat all. Furthermore, a third party may claim that we are using inventions covered by the third party’s patent rightsand may go to court to stop us from engaging in our normal operations and activities, including making or selling ourproducts. These lawsuits are costly and could affect our results of operations and divert the attention of managerial andtechnical personnel. A court may decide that we are infringing the third party’s patents and would order us to stop theactivities covered by the patents. In addition, a court may order us to pay the other party damages for having violated theother party’s patents. The drug and biotechnology industry has produced a proliferation of patents, and it is notalways clear to industry participants, including us, which patents cover various types of products or methods of use. Thecoverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are suedfor patent infringement, we would need to demonstrate that our products or methods of use either do not infringe the patentclaims of the relevant patent and/or that the patent claims are invalid, and we may not be able to do this. Provinginvalidity, in particular, is difficult since it requires a showing of clear and convincing evidence to overcome thepresumption of validity enjoyed by issued patents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Because some patent applications in theUnited States may be maintained in secrecy until the patents are issued, because patent applications in the United States and manyforeign jurisdictions are typically not published until eighteen months after filing, and because publications in the scientificliterature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technologycovered by our or our licensor’s issued patents or pending applications or that we or our licensors were the first to inventthe technology. During the ordinary course of our business, we do not conduct “prior art” searches before filing apatent application. Our competitors may have filed, and may in the future file, patent applications covering technology similarto ours. Any such patent application may have priority over our or our licensors’ patent applications and could further requireus to obtain rights to issued patents covering such technologies. If another party has filed a United States patent applicationon inventions similar to ours, we may have to participate in an interference proceeding declared by the U.S. Patent and TrademarkOffice to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it ispossible that such efforts would be unsuccessful, resulting in a loss of our United States patent position with respect to suchinventions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Some of our competitors may be able tosustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effecton our ability to raise the funds necessary to continue our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          A cybersecurity incident and other technology disruptionscould negatively affect our business and our relationships with customers.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We use technology in substantially allaspects of our business operations. The widespread use of technology, including mobile devices, cloud computing, and the internet,give rise to cybersecurity risks, including security breach, espionage, system disruption, theft and inadvertent release of information.Our business involves the storage and transmission of numerous classes of sensitive and/or confidential information and intellectualproperty, including information relating to customers and suppliers, private information about employees, and financial and strategicinformation about us and our business partners. If we fail to effectively assess and identify cybersecurity risks associated withthe use of technology in our business operations, we may become increasingly vulnerable to such risks. Additionally, while we haveimplemented measures to prevent security breaches and cyber incidents, our preventative measures and incident response effortsmay not be entirely effective. The theft, destruction, loss, misappropriation, or release of sensitive and/or confidential informationor intellectual property, or interference with our information technology systems or the technology systems of third parties onwhich we rely, could result in business disruption, negative publicity, brand damage, violation of privacy laws, loss of customers,potential liability and competitive disadvantage.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 31; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            31            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Related to Regulatory Approval of Our Pharmaceuticaland Biotherapeutic Product Candidates and Other Legal Compliance Matters:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The regulatory pathway of a potential vaccine for COVID-19is continually evolving, and may result in unexpected or unforeseen challenges.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The speed at which all parties are movingto create, test and approve a vaccine for COVID-19 is highly unusual, and evolving or changing plans or priorities at the FDA,including based on new knowledge of COVID-19 and how the disease affects the human body, may significantly affect the regulatorypathway for any of our potential vaccine candidates. For example, any results from clinical testing may raise new questions andrequire us to redesign proposed clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohortsof subjects. In addition, the FDA’s analysis of any clinical data may differ from our interpretation and the FDA may requirethat we conduct additional analyses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA has the authority to grant an EUAto allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseasesor conditions when there are no adequate, approved, and available alternatives. If we are granted an EUA for any vaccine candidate,we would be able to commercialize it prior to FDA approval. The EUA is only effective for the duration of the COVID-19 public healthemergency. The FDA may revoke or terminate the EUA sooner if, for example, we fail to comply with the terms of the EUA or our vaccineis determined to be less effective or safe than it was initially believed to be. We cannot predict how long, if ever, an EUA wouldremain in place.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Shifting enforcement priorities of federal and state lawsrelating to cannabis may create uncertainties for our business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Some of our products may be incorporatedinto cannabis products which are subject to regulation by federal and state regulatory agencies in the United States and by comparableauthorities in foreign countries. Cannabis is a Schedule I substance, as defined under federal law, and its possession and useis generally not permitted under federal law, although a number of individual states have enacted state laws to authorize possession,sale and use of cannabis for medical purposes, and in some states for recreational purposes. Revenue from the cannabis market ishighly dependent on our customers’ continuing compliance with federal and state regulations which may change over time. Ourbusiness may be materially harmed by their failure to comply with applicable regulations and may subject us to an increased riskof litigation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Pharmaceutical and biologic-related revenue is generallydependent on regulatory approval, oversight and compliance.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        All of our pharmaceutical and biologicproduct candidates, except for our Linea        <font style="font-variant: small-caps">         <sup>          TM         </sup>        </font>        COVID-19 Assay Kit andour COVID-19 Surveillance Testing, will require significant preclinical and clinical development before we can seek regulatoryapproval for them and launch a product commercially. The sale and use of our products and services in the pharmaceutical and biologicmarkets will generally be subject to regulatory approval and oversight, potentially including approval and/or oversight in variousforeign jurisdictions. In addition, our pharmaceutical and biologic products and services may be incorporated into products thatcannot be marketed in the United States or in many other jurisdictions without approval by the FDA or comparable agencies of othercountries or regions. Obtaining such regulatory approvals is costly, time-consuming, uncertain, and subject to unanticipated delays.When, if ever, such approvals will be obtained is unknown. Our revenue in the pharmaceutical and biologic markets is highly dependentupon obtaining such approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Federal agencies, including the FDA andFederal Trade Commission, as well as state, local, and foreign authorities, also exercise ongoing review and control of the manufacturing,packaging, labeling, advertising, sale, distribution, and monitoring of pharmaceutical and biologic products. If our pharmaceuticalor biologic product candidates or pharmaceutical or biologic products incorporating our products are ever approved, failure tocomply with any of these regulations or other requirements could also have an adverse effect on our revenue in the pharmaceuticaland biologic markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Pharmaceutical and biologic-related revenue will be highlydependent on our collaborators’ and customers’ success in obtaining regulatory approval and commercializing their products.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Some of our products will be incorporatedinto products in the pharmaceutical and biologic market that are subject to comprehensive regulation by the FDA and other regulatoryagencies in the United States and by comparable authorities in other countries. In the United States, to obtain approval from theFDA to market any future pharmaceutical or biologic product that incorporates our technology, our collaborators or customers willbe required to submit a NDA or BLA. Ordinarily, the FDA requires a company to support an NDA or BLA with substantial evidence ofthe product candidate’s safety and efficacy in treating the targeted indication based on data derived from adequate and well-controlledclinical trials, including Phase III safety and efficacy trials conducted in patients with the disease or condition being targeted.The process of obtaining such regulatory approvals is expensive, often takes many years if approval is obtained at all, and canvary substantially based upon the type, complexity and novelty of the product candidate involved. Changes in the regulatory approvalprocess during the development period, changes in or the enactment of additional statutes or regulations, or changes in the regulatoryreview process may cause delays in the approval or rejection of an application. There is no guarantee that our collaborators andcustomers will ever be successful in obtaining regulatory approval for any product that incorporates our products or technology.Even if regulatory approval is received, the manufacturing processes, post approval clinical data, labeling, advertising and promotionalactivities for any such product will be subject to continual requirements of and review by the FDA and other regulatory bodies.Our business may be materially harmed by our collaborators’ and customers’ failure to comply with applicable regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 32; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            32            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, we will be dependent on, andhave no control over, consumer demand for the products into which our products are incorporated. Consumer demand for our collaborators’and customers’ products could be adversely affected by, among other things, delays in health regulatory approval, the lossof patent and other intellectual property rights protection, the emergence of competing products, including generic drugs or biosimilars,the degree to which private and government drug plans subsidize payment for a particular product and changes in the marketing strategiesfor such products. The healthcare industry has changed significantly over time, and we expect the industry to continue to evolve.Some of these changes may have a material adverse effect on our collaborators and customers and thus may have a material adverseeffect on our business. If the products into which our products are incorporated do not gain market acceptance, our revenues andprofitability may be adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The regulatory approval processes of the FDA and comparableforeign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtainregulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantiallyharmed.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The time required to obtain approvalby the FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following thecommencement of clinical trials, and depends upon numerous factors, including the type, complexity and novelty of the productcandidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gainapproval may change during the course of a product candidate’s clinical development and may vary among jurisdictions,which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantialdiscretion in the approval process and may refuse to accept any application or may decide that our data are insufficient forapproval and require additional preclinical, clinical or other studies. We have not submitted for, or obtained regulatoryapproval for any product candidate, and it is possible that none of our existing product candidates or any product candidateswe may seek to develop in the future will ever obtain regulatory approval. Applications for our product candidates could failto receive regulatory approval for a variety of reasons. This lengthy approval process, as well as the unpredictability ofthe results of clinical trials, may result in our failing to obtain regulatory approval to market any of our productcandidates, which would significantly harm our business, results of operations, and prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our product candidates may cause undesirable side effectsor have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercialpotential, or result in significant negative consequences.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Adverse events or other undesirable sideeffects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trialsand could result in a more restrictive label or the delay or denial of regulatory approval by regulatory authorities. Side effectsrelated to a drug or biologic could affect patient recruitment, the ability of enrolled patients to complete the study, and/orresult in potential product liability claims.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Additionally, if one or more of our productcandidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by suchproducts, a number of potentially significant negative consequences could result. Regulatory authorities may withdraw approvalsof such product or impose restrictions on distribution. They may require additional warnings or contraindications on the productlabel that could diminish the usage or otherwise limit the commercial success of the product. We may be required to change theway the product is administered, conduct additional clinical trials or post-approval studies. We may be forced to suspend marketingof the product or required to create a REMS. In addition, our reputation may suffer. Any of these events could prevent us fromachieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business,results of operations, and prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Even if we obtain regulatory approval for a product candidate,our products will remain subject to extensive regulatory scrutiny.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        If any of our product candidates are approved,they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion,sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information,including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.Ongoing regulatory requirements include ensuring that quality control and manufacturing and production procedures conform to cGMPregulations, and we will be subject to continual review and inspections to assess compliance with cGMP regulations and adherenceto commitments made in any regulatory filings. Accordingly, we and others with whom we work must continue to expend time, money,and effort in all areas of regulatory compliance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Any regulatory approvals that we receivefor our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketedand promoted or to the conditions of approval (including the requirement to implement a REMS), or contain requirements for potentiallycostly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to theFDA and comparable foreign regulatory authorities. Any new legislation addressing drug or biologic safety issues could result indelays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, includingthe Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that theyare manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approvedlabeling. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communicationswith respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistentwith the information in the product’s approved label. As such, we may not promote our products for indications or uses forwhich they do not have approval. The holder of an approved NDA must submit new or supplemental applications and obtain approvalfor certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketingclinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketingapproval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinicaltrial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study couldresult in the withdrawal of marketing approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 33; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            33            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        If a regulatory agency discovers previouslyunknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility wherethe product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may imposerestrictions on that product or us, including, but not limited to, requiring withdrawal or recall of the product from the market,imposing civil or criminal penalties, and imposing restrictions on our operations. Any government investigation of alleged violationsof law could require us to expend significant time and resources in response, and could generate negative publicity. Any failureto comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generaterevenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our Companyand our operating results will be adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, the FDA’sregulations, policies or guidance may change and new or additional statutes or government regulations in the United Statesand other jurisdictions may be enacted that could further restrict or regulate post-approval activities. We cannot predictthe likelihood, nature or extent of adverse government regulation that may arise from pending or future legislation oradministrative action. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to marketour products and/or product candidates, which would adversely affect our ability to generate revenue and achieve or maintainprofitability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If the FDA were to begin to enforce regulation of LDTs,we could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associatedwith complying with post-market requirements.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As a LDT, our iCTC capture assay is currentlysubject to enforcement discretion by the FDA. In October 2014, the FDA issued two draft guidance documents: “Frameworkfor Regulatory Oversight of Laboratory Developed Tests,” which provides an overview of how the FDA would regulate LDTs througha risk-based approach, and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests”, which providesguidance on how the FDA intends to collect information on existing LDTs, including adverse event reports. Pursuant to the Frameworkfor Regulatory Oversight draft guidance, LDT manufacturers will be subject to medical device registration, listing, and adverseevent reporting requirements. LDT manufacturers will be required to either submit a pre-market application and receive the FDA’sapproval before an LDT may be marketed or submit a pre-market notification in advance of marketing. The Framework for RegulatoryOversight draft guidance states that within six months after the guidance documents are finalized, all laboratories will be requiredto give notice to the FDA and provide basic information concerning the nature of the LDTs offered.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On November 18, 2016, however, theFDA announced that it would not release final versions of these guidance documents and would instead continue to work with stakeholders,the new administration and Congress to determine the right approach. On January 13, 2017, the FDA released a discussion paperon LDTs outlining a possible risk-based approach for FDA and CMS oversight of LDTs. According to the 2017 discussion paper, previouslymarketed LDTs would not be expected to comply with most or all FDA oversight requirements (grandfathering), except for adverseevent and malfunction reporting. In addition, certain new and significantly modified LDTs would not be expected to comply withpre-market review unless the agency determines certain tests could lead to patient harm. Since LDTs currently on the market wouldbe grandfathered in, pre-market review of new and significantly modified LDTs could be phased-in over a four-year period, as opposedto the nine years proposed in the Framework for Regulatory Oversight draft guidance. In addition, tests introduced after the effectivedate, but before their phase-in date, could continue to be offered during pre-market review.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The discussion paper notes that the FDAwill focus on analytical and clinical validity as the basis for marketing authorization. The FDA anticipates laboratories thatalready conduct proper validation should not be expected to experience new costs for validating their tests to support marketingauthorization and laboratories that conduct appropriate evaluations would not have to collect additional data to demonstrate analyticalvalidity for FDA clearance or approval. This goal would be achieved through a precertification process. The evidence of the analyticaland clinical validity of all LDTs will be made publically available. LDTs are encouraged to submit prospective change protocolsin their pre-market submission that outline specific types of anticipated changes, the procedures that will be followed to implementthem, and the criteria that will be met prior to implementation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 34; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            34            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In March 2017, a draft bill “TheDiagnostics Accuracy and Innovation Act” (“DAIA”) was introduced in Congress. The bill would establish a newregulatory framework for the oversight of in vitro clinical tests (“IVCTs”) which include LDTs. Following review andcomment from FDA on the provisions of DAIA, a revised version of the bill, now called “The Verifying Accurate, Leading-edgeIVCT Development Act” (VALID) was introduced in Congress in December 2018. Under the bill, a risk-based approach willbe used to regulate IVCTs. Each test will be classified as high-risk or low-risk. Pre-market review will be required for high-risktests. To market a high-risk IVCT, reasonable assurance of analytical and clinical validity for the intended use must be established.Under VALID, a precertification process would be established which will allow a laboratory to establish that the facilities, methods,and controls used in the development of its IVCTs meet quality system requirements. If pre-certified, low-risk IVCTs it developswill not be subject to pre-market review. The new regulatory framework will include quality control and post-market reporting requirements.The FDA will have the authority to withdraw from the market IVCTs that present an unreasonable and substantial risk of illnessor injury when used as intended. We cannot predict whether this bill will become law. If the FDA were to require us to seek clearanceor approval for our existing product or any of our future products for clinical use, we may not be able to obtain such approvalson a timely basis or at all. Our business could be negatively impacted as a result of commercial delay that may be caused by anynew requirements. The cost of conducting clinical trials and otherwise developing data and information to support pre-market approvalmay be significant. If we are required to submit applications for our currently-marketed iCTC test, we may be required to conductadditional studies, which may be time-consuming and costly and could result in our currently-marketed test being withdrawn fromthe market. Continued compliance with the FDA’s regulations would increase the cost of conducting our business, and subjectus to heightened regulation by the FDA and penalties for failure to comply with these requirements. Failure to comply with applicableregulatory requirements can result in enforcement action by the FDA, such as fines, product suspensions, warning letters, recalls,injunctions and other civil and criminal sanctions. Any other regulatory or legislative proposals that would increase general FDAoversight of clinical laboratories and LDTs could negatively impact our business if additional requirements are imposed. We aremonitoring developments and anticipate that our products will be able to comply with requirements that are ultimately imposed bythe FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we fail to comply with laboratory licensing requirements,we could lose the ability to offer our clinical testing services or experience disruptions to our business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        CLIA is a federal law regulatingclinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for thediagnosis, prevention, or treatment of disease. CLIA is intended to ensure the quality and reliability of clinicallaboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration,and participation in proficiency testing, patient test management, quality control, quality assurance and inspections.Clinical laboratories must be certified under CLIA in order to perform testing on human specimens, unless they fall within anexception to CLIA certification, such as research laboratories that test human specimens but do not report patient-specificresults for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health ofindividual patients. CLIA certification is also required to be eligible to bill Federal and State healthcare programs, aswell as many private third-party payers, for diagnostic testing and services. Currently, we are supplying our iCTC captureassay and associated testing services under the research exception to CLIA. We also sell COVID-19 Surveillance Testingservices which, under FDA and CDC guidance, do not require an EUA or CLIA certification. If we expand our laboratory testingservices so that the research exception no longer applies to our iCTC capture assay or regulations and guidances change sothat our COVID-19 Surveillance Testing cannot be conducted without CLIA certification, we will no longer be able to offerthese services. Further, if we fail to comply with the CLIA research exception with respect to our iCTC capture assay or wefail to comply with the government’s guidance regarding COVID-19 surveillance testing, we could be found to haveviolated FDA or CLIA regulations or guidances and could have to stop offering these services and potentially be assessedsubstantial penalties. We have applied for CLIA certification but do not know when, or if, we will receive it. A delay inobtaining certification or a failure to do so could significantly harm our business, results of operations, andprospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Healthcare legislative measures aimed at reducing healthcarecosts may have a material adverse effect on our business and results of operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Third party payors are developing increasinglysophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there havebeen a number of legislative and regulatory changes to the health care system that could impact our ability to sell our productsprofitably. In particular, in the United States in 2010, the ACA was enacted. In addition, other legislative changes have beenproposed and adopted in the United States since the ACA was enacted. The repeal of or changes in some or all of the ACA and complyingwith any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a materialadverse effect on our business. Until the ACA is fully implemented or there is more certainty concerning the future of the ACA,it will be difficult to predict its full impact and influence on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There have been, and likely will continueto be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the costof healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurancecompanies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or imposeprice controls may adversely affect the demand for our product candidates, if we obtain regulatory approval, including: our abilityto receive or set a price that we believe is fair for our products; our ability to generate revenue and achieve or maintain profitability;the level of taxes that we are required to pay; and the availability of capital. We expect that the ACA, as well as other healthcarereform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding,more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receivefor any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programsmay result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficientrevenue, attain profitability or commercialize our product candidates, if approved.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 35; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            35            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our employees, independent contractors, consultants, commercialpartners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standardsand requirements.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are exposed to the risk of fraud, misconductor other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct bythese parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA and othercomparable foreign regulatory authorities; provide true, complete and accurate information to the FDA and other comparable foreignregulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws inthe United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to discloseunauthorized activities to us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        If we obtain FDA approval of any of ourproduct candidates and begin commercializing those products in the United States, our potential exposure under such laws will increasesignificantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales,marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to preventfraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range ofpricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other businessarrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course ofpatient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. Wehave adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employeesand third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknownor unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from afailure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defendingourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significantfines or other sanctions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we fail to comply with healthcare laws, we could facesubstantial penalties and our business, operations and financial conditions could be adversely affected.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Healthcare providers, physicians and payorsplay a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval.Our future arrangements with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare lawsand regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distributeany product candidates for which we may obtain marketing approval. Even though we do not and will not control referrals of healthcareservices or bill directly to Medicare, Medicaid or other third party payors, federal and state healthcare laws and regulationspertaining to fraud and abuse and patients’ rights are and will be applicable to our business. Restrictions under applicablefederal, state and foreign healthcare laws and regulations which may affect our ability to operate and expose us to areas of riskinclude: federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act; HIPAA, asamended by HITECH; the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations; federalconsumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentiallyharm consumers; and analogous state and foreign laws and regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Because of the breadth of these laws andthe narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could,despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangementswill comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authoritieswill conclude that our business practices may not comply with current or future statutes, regulations or case law interpretingapplicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we arenot successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, includingthe imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion fromparticipation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profitsand future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our businessand our results of operations. In addition, the approval and commercialization of any of our product candidates outside the UnitedStates will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to Personnel:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our failure to manage our growth in operations and acquisitionsof new product lines and new businesses could harm our business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The recent growth in our operations couldplace a significant strain on our current management resources, specifically as it relates to        <font style="font-size: 10pt">         our        </font>        Linea        <sup>         TM        </sup>        COVID-19 Assay Kit and        <u>         our        </u>        COVID-19 pooled surveillance testing offering branded under the safeCircle        <sup>         TM        </sup>        trademark. We seek to continue to commercialize the safeCircle        <sup>         TM        </sup>        surveillance testing TaaS offering with institutionalclients such as schools, colleges and businesses. In addition, we have applied to the New York State Department of Health for allnecessary licensing to operate a New York State clinical diagnostics laboratory. These applications are currently pending. TheNew York State Department of Health performed its initial inspection of our clinical laboratory and identified deficiencies inthe clinical standard of practice. These deficiencies need to be rectified before we can submit a request for re-inspection. Weare working to rectify these deficiencies now. We seek to further commercialize our EUA authorized Linea COVID-19 Assay Kit andour iCTC Technology. We are also performing testing services in support of our safeCircle        <sup>         TM        </sup>        surveillance testing servicesin accordance with current CDC, FDA, CMS and New York State Department of Health recommendations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 36; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            36            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        To manage such growth, we may need to improveour:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           operations and financial systems;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           procedures and controls; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           training and management of our employees.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we are unable to continue to retain the services ofDr. Hayward, we may not be able to continue our operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our success depends to a significant extentupon the continued service of Dr. James A. Hayward, our CEO. On July 28, 2016, we entered into an employment agreementwith Dr. Hayward. The initial term was from July 1, 2016 through June 30, 2017, with automatic one-year renewalperiods. As of June 30, 2020, the employment contract automatically renewed for an additional year. Loss of the services ofDr. Hayward could significantly harm our business, results of operations and financial condition. We do not maintain key-personinsurance on the life of Dr. Hayward.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We may have conflicts of interest with our affiliatesand related parties, and in the past we have engaged in transactions and entered into agreements with affiliates that were notnegotiated at arms’ length.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have engaged, and may in the futureengage, in transactions with affiliates and other related parties. These transactions may not have been, and may not be, on termsas favorable to us as they could have been if obtained from non-affiliated persons. While an effort has been made, and will continueto be made, to enter into transactions with affiliated persons and other related parties at rates and on terms as favorable aswould be charged by others, there will always be an inherent conflict of interest between our interests and those of our affiliatesand related parties. In August 2018 and November 2018, we issued an aggregate of $2.2 million in principal amount ofsecured convertible notes, a majority of which were owned by Dr. James A. Hayward, our CEO. Dr. Hayward and other directors,officers, and affiliates of the Company converted substantial portions of such August 2018 Notes and November 2018 Notes(in each case, as defined in Management’s Discussion and Analysis of Financial Condition and Results of Operations, below)into common stock of the Company in September 2019. During October 2020 we entered into Warrant Exercise Agreements withDillon Hill Capital, LLC and its affiliate, Dillon Hill Investment Company LLC, a greater than 5% shareholder in the Company, whereby318,000 warrants were exercised. The gross proceeds to the Company from this partial exercise of the 2019 Warrants (as definedbelow) was $1,669,500. Also during October 2020, we entered into a letter agreement with such investors for the repaymentof the secured convertible notes. The Company may be adversely impacted if any related party agreement or transaction is made onunfavorable terms        <font style="font-size: 10pt">         .        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Relating to Our Common Stock and Other Securities:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          There are a large number of shares of common stock underlyingour outstanding options and warrants and the sale of these shares may depress the market price of our common stock and cause immediateand substantial dilution to our existing stockholders.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of December 10, 2020, we had5,661,330 shares of common stock issued and outstanding, outstanding options to purchase 362,178 shares of common stock,outstanding warrants to purchase  778,118 shares of common stock, and 3,615,486 shares available for grant under our 2020Equity Incentive Plan. The issuance of shares upon exercise of our outstanding options and warrants will cause immediate andsubstantial dilution to our stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We may be required to repurchasecertain of our warrants.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Under our warrants sold privately thathave registration rights, in the event of a “Fundamental Transaction” (as defined in the related warrant agreement,which generally includes any merger with another entity, the sale, transfer or other disposition of all or substantially all ofour assets to another entity, or the acquisition by a person of more than 50% of our common stock), each warrant holder will havethe right at any time prior to the consummation of the Fundamental Transaction to require us to repurchase the warrant for a purchaseprice in cash equal to the Black Scholes value (as calculated under the warrant agreement) of the then remaining unexercised portionof such warrant on the date of such Fundamental Transaction, which may materially adversely affect our financial condition and/orresults of operations and may prevent or deter a third party from acquiring us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 37; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            37            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We will require additional financing which may in turnrequire the issuance of additional shares of common stock, preferred stock or other debt or equity securities (including convertiblesecurities) and which would dilute the ownership held by our stockholders.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We will need to raise funds through eitherdebt or the sale of our shares of our common stock in order to achieve our business goals. Any additional shares issued would furtherdilute the percentage ownership held by the stockholders. Furthermore, if we raise funds in equity transactions through the issuanceof convertible securities which are convertible at the time of conversion at a discount to the prevailing market price, substantialdilution is likely to occur resulting in a material decline in the price of your shares. Our public offerings completed in November 2014,April 2015, December 2018 and November 2019, our registered direct public offering and concurrent private placementduring November 2015, our private placements completed in November 2016, June 2017, and August 2019, and ourregistered direct offering in December 2017 resulted in dilution to investors and future offerings of securities could resultin further dilution to investors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we fail to comply with the continuing listing standardsof Nasdaq, our securities could be delisted.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our common stock is listed on Nasdaq underthe symbol “APDN”.  For our common stock to continue to be listed on Nasdaq, we must meet the current continuedlisting requirements. If we were unable to meet these requirements, our common stock could be delisted from Nasdaq. If our commonstock were to be delisted from Nasdaq, our common stock could begin to trade on one of the markets operated by OTC Markets Group,including OTCQX, OTCQB or OTC Pink (formerly known as the “pink sheets”), as the case may be. In such event, our commonstock could be subject to the “penny stock” rules which among other things require brokers or dealers to approveinvestors’ accounts, receive written agreements and determine investor suitability for transactions and disclose risks relatingto investing in the penny stock market. Any such delisting of our common stock could have an adverse effect on the market priceof, and the efficiency of the trading market for our common stock, not only in terms of the number of shares that can be boughtand sold at a given price, but also through delays in the timing of transactions and less coverage of us by securities analysts,if any. Also, if in the future we were to determine that we need to seek additional equity capital, it could have an adverse effecton our ability to raise capital in the public or private equity markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Any material weaknesses in our internal control over financialreporting in the future could adversely affect investor confidence, impair the value of our common stock and increase our costof raising capital.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Any failure to remedy deficiencies in ourinternal control over financial reporting that may be discovered or our failure to implement new or improved controls, or difficultiesencountered in the implementation of such controls, could harm our operating results, cause us to fail to meet our reporting obligationsor result in material misstatements in our financial statements. Any such failure could, in turn, affect the future ability ofour management to certify that internal control over our financial reporting is effective. Inferior internal control over financialreporting could also subject us to the scrutiny of the SEC and other regulatory bodies which could cause investors to lose confidencein our reported financial information and could subject us to civil or criminal penalties or stockholder litigation, which couldhave an adverse effect on our results of operations and the market price of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, if we or our independent registeredpublic accounting firm identify deficiencies in our internal control over financial reporting, the disclosure of that fact, evenif quickly remedied, could reduce the market’s confidence in our financial statements and harm our share price. Furthermore,deficiencies could result in future non-compliance with Section 404 of the Sarbanes-Oxley Act of 2002. Such non-compliancecould subject us to a variety of administrative sanctions, including review by the SEC or other regulatory authorities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_004">           </a>           <b>            ITEM 1B.           </b>          </td>          <td>           <b>            UNRESOLVED STAFF COMMENTS.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_005">           </a>           <b>            ITEM 2.           </b>          </td>          <td style="text-align: justify">           <b>            PROPERTIES.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our corporate headquarters is located at the Long Island HighTechnology Incubator (“LIHTI”), which is located on the campus of Stony Brook University at 50 Health Sciences Drive,Stony Brook, NY 11790. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 andexpired on May 31, 2016, with the option to extend the lease for two additional three-year periods. We have exercised ouroption to extend the lease for one additional three-year period, ending May 31, 2019. The base rent during the additionalthree-year period was $458,098 per annum. In addition to the office space, we also have 2,200 square feet of laboratory space.On January 20, 2020, we entered into an agreement to amend both of these leases, extending the term for the corporate headquartersas well as the laboratory space until January 15, 2021, with a one-year renewal option. During October 2020, we exercisedthe one-year renewal option for both of these leases. We also have a satellite testing facility in Ahmedabad, India, whichwas established during fiscal 2018. On November 17, 2017, we leased 1,108 square feet for an initial three-year term beginningNovember 1, 2017. During September 2020, we renewed this lease with a new expiration date of September 30, 2021.The base rent is approximately $6,500 per annum.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 38; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            38            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_006">           </a>           <b>            ITEM 3.           </b>          </td>          <td>           <b>            LEGAL PROCEEDINGS.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        From time to time, we may become involved in various lawsuitsand legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties,and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not awareof any such legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business,financial condition or operating results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_007">           </a>           <b>            ITEM 4.           </b>          </td>          <td>           <b>            MINE SAFETY DISCLOSURES.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 39; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            39            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         PART II        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_008">           </a>           <b>            ITEM 5.           </b>          </td>          <td>           <b>            MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Market Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our common stock is listed on The Nasdaq Capital Market underthe symbol “APDN”. Our warrants were listed on The Nasdaq Capital Market under the symbol “APDNW”. Thesewarrants expired during November 2019. There is no certainty that the common stock will continue to be listed or that anyliquidity exists for our stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Holders        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of December 10, 2020, we had approximately        <font>         124holders of record of our common stock.        </font>        The number of record holders was determined from the records of our transfer agentand does not include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers,and registered clearing agencies. The transfer agent of our common stock is American Stock Transfer &amp; Trust Company, 620115th Avenue, Brooklyn, New York 11219.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Dividends        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have never declared or paid any cash dividends on our commonstock. We do not anticipate paying any cash dividends to stockholders in the foreseeable future. In addition, any future determinationto pay cash dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, resultsof operations, capital requirements, and such other factors as the Board of Directors deem relevant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_009">           </a>           <b>            ITEM 6.           </b>          </td>          <td style="text-align: justify">           <font style="text-transform: uppercase">            <b>             Selected Financial Data.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Information requested by this Item is not applicable as we areelecting scaled disclosure requirements available to Smaller Reporting Companies with respect to this Item.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_010">           </a>           <b>            ITEM 7.           </b>          </td>          <td>           <b>            MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following Management’s Discussion and Analysis ofFinancial Condition and Results of Operations should be read in conjunction with our consolidated financial statements and therelated notes appearing elsewhere in this Annual Report on Form 10-K. This discussion and analysis includes certain forward-lookingstatements that involve risks, uncertainties and assumptions. You should review the Risk Factors section of this Form 10-Kfor a discussion of important factors that could cause actual results to differ materially from the results described in or impliedby such forward-looking statements. See “Forward-Looking Information” at the beginning of this Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All warrants, option, share and per share information in thisreport gives retroactive effect to a one-for-forty reverse stock split that was effective on November 1, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 40; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            40            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Introduction        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our proprietary PCR-based DNA LinearDNA        <sup>         TM        </sup>        manufacturingplatform produces large quantities of DNA for use in the nucleic acid-based in vitro medical diagnostics and preclinicalnucleic acid-based drug development and manufacturing markets (“Biotherapeutic Contract Research and Manufacturing”)and for supply chain security, anti-counterfeiting and anti-theft technology purposes (“Non-Biologic Tagging”). Inresponse to the COVID-19 pandemic, the Company developed a PCR-based molecular diagnostic test for COVID-19, which was grantedan EUA in May 2020. The Company currently manufactures and sells its EUA authorized COVID-19 molecular diagnostic test kitunder the Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19 Assay Kit trademark (“COVID-19 DiagnosticTesting”). In addition, and in further response to the COVID-19 pandemic, the Company developed and is currently offeringnon-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations. The Company’sCOVID-19 Surveillance Testing services are currently offered under the safeCircle        <sup>         TM        </sup>        trademark. The Company is also developingan invasive circulating tumor cell capture and identification technology (“iCTC Technology”) which uses a patentedfunctional assay to capture live invasive circulating tumor cell and associated lymphocytes that can be identified and expandedfor further analysis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Applied DNA’s LinearDNA        <sup>         TM        </sup>        PCRplatform is capable of producing large scale DNA, which we believe offers many benefits over the limitations of other large scaleDNA manufacturing systems, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 18.05pt">          </td>          <td style="width: 18pt">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Speed – Production of DNA via the LinearDNATM platform can be measured in terms of hours, not days and weeks likeother large scale DNA manufacturing platforms.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 18.05pt">          </td>          <td style="width: 18pt">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Scale – The LinearDNATM platform is flexible and can be adapted to encompass large quantity production.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Purity – DNA produced via PCR is pure, resulting in only large quantities of the target DNA sequence. Unwanted DNA sequencessuch as bacterially-derived DNA is not present.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 18.05pt">          </td>          <td style="width: 18pt">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Customization – DNA produced via PCR can be easily chemically modified to suit specific customer applications.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         General        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We seek to leverage our proprietary PCR-basedDNA LinearDNA        <sup>         TM        </sup>        manufacturing platform to further grow and monetize both our Biotherapeutic Contract Research andManufacturing and Non-Biologic Tagging businesses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        To date, the substantial portion of our revenues has beengenerated from sales pursuant to our non-biologic tagging and related services, principally related to our supply chainsecurity and product authentication solutions, including our SigNature® molecular tags produced via ourLinearDNA        <sup>         TM        </sup>        platform. We expect to grow revenues from sales of our  Linea™ COVID-19 Assay Kit, ourCOVID-19 Surveillance Testing, clinical diagnostic services (upon receipt of necessary approvals) and the manufacturing ofDNA products for the biotechnology and        <i>         in vitro        </i>        diagnostic markets. To a lesser extent, we expect to grow revenuesfrom our non-biologic tagging businesses, as we work with companies and governments to secure supply chains for various typesof products and product labeling throughout the world. We are also seeking to establish a revenue stream from our iCTCTechnology.  We have continued to incur expenses in expanding our business to meet current and anticipated futuredemand. We have limited sources of liquidity       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Critical Accounting Policies         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Financial Reporting Release No. 60, published by the SEC,recommends that all companies include a discussion of critical accounting policies used in the preparation of their financial statements.While all these significant accounting policies impact our financial condition and results of operations, we view certain of thesepolicies as critical. Policies determined to be critical are those policies that have the most significant impact on our consolidatedfinancial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from thoseestimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that given current facts and circumstances, it isunlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our consolidatedresults of operations, financial position or liquidity for the periods presented in this report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The accounting policies identified as criticalare as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Revenue recognition; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Equity based compensation.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 41; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            41            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Revenue Recognition         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We follow Financial Accounting StandardsBoard (“FASB”) issued accounting standard updates which clarify the principles for recognizing revenue arising fromcontracts with customers (“ASC 606” or “Topic 606”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The core principle of the revenue standardis that an entity recognizes revenue to depict the transfer of promised goods or services to clients in an amount that reflectsthe consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 applies a five-stepmodel for revenue measurement and recognition and also requires increased disclosures including the nature, amount, timing, anduncertainty of revenue and cash flows related to contracts with clients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        The Company measuresrevenue at the amounts that reflect the consideration to which it is expected to be entitled in exchange for transferring controlof goods and services to customers. The Company recognizes revenue either at the point in time or over the period of time thatperformance obligations to customers are satisfied. The Company’s contracts with customers may include multiple performanceobligations (e.g. taggants, maintenance, authentication services, research and development services, etc.). For such arrangements,the Company allocates revenues to each performance obligation based on their relative standalone selling price.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company recognizes revenue upon transferof control of promised goods or services to customers in an amount that reflects the consideration it expects to receive for thosegoods or services, including any variable consideration.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Due to the short-term nature of the Company’scontracts with customers, it has elected to apply the practical expedients under Topic 606 to: (1) expense as incurred, incrementalcosts of obtaining a contract and (2) not adjust the consideration for the effects of a significant financing component forcontracts with an original expected duration of one year or less.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <i>         Product Revenuesand Authentication Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s PCR-produced linearDNA products, are manufactured in accordance with contracts with customers. The Company recognizes revenue upon satisfying itspromises to transfer goods or services to customers under the terms of its contracts. These performance obligations are satisfiedat the point in time the Company transfers control of the goods to the customer, which in nearly all cases is when title to andrisk of loss of the goods transfer to the customer. The timing of transfer of title and risk of loss is dictated by customary orexplicitly stated contract terms. The Company does not consider payment terms of a performance obligation for customers with contractualterms that are one year or less and has elected the practical expedient. Nearly all of the Company’s sales contracts reflectmarket pricing at the time the contract is executed, or are one year or less, and generally provide for shipment within 30 to 60days after the price has been agreed upon with the customer. The Company invoices customers upon shipment, and its collection termsrange, on average, from 30 to 60 days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <i>         Authentication Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company recognizes revenue for authenticationservices upon satisfying its promises to provide services to customers under the terms of its contracts. These performance obligationsare satisfied at the point in time the Company services are complete, which in nearly all cases is when the authentication reportis released to the customer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 42; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            42            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Laboratory Testing Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company records revenue for its laboratory testing servicecontracts upon satisfying its promise to provide services to customers under the terms of its contracts. These performance obligationsare satisfied at the point in time that Company services are complete, which is nearly all cases is when the testing results arereleased to the customer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Research and Development Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company records revenue for its researchand development contracts using the over-time revenue recognition model. Revenue is primarily measured using the cost-to-cost method,which the Company believes best depicts the transfer of control to the customer.  Under the cost-to-cost method, theextent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expectedupon satisfying the identified performance obligation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Revenues are recorded proportionally ascosts are incurred. For contracts where the total costs cannot be estimated, revenues are recognized for the actual costs incurredduring a period until the remaining costs to complete a contract can be estimated. The Company has elected to not disclose thevalue of unsatisfied performance obligations for contracts with an original expected duration of one year or less.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Equity Based Compensation         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We account for stock-based compensationfor employees, directors and nonemployees in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires allshare-based payments, including grants of employee stock options, to be recognized in the statement of operations based on theirfair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fairvalue of the award, and are recognized as expense over the requisite service period (generally the vesting period of the equitygrant). The fair value of our common stock options are estimated using the Black Scholes option-pricing model with the followingassumptions: expected volatility, dividend rate, risk free interest rate and the expected life. We expense stock-based compensationby using the straight-line method. In accordance with ASC 740, excess tax benefits realized from the exercise of stock-based awardsare classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits ofdividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statementsof operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Use of Estimates         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The preparation of the financial statementsin conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures.Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under thecircumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities thatare not readily apparent from other sources. The most complex and subjective estimates include revenue recognition, recoverabilityof long-lived assets, including the values assigned to goodwill, intangible assets and property and equipment, fair value calculationsfor stock-based compensation and convertible promissory notes, contingencies, allowance for doubtful accounts and management’santicipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflectedin the condensed consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differfrom those estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The impact of the COVID-19 pandemic asof and for the fiscal year ended September 30, 2020 did not have a material impact on the valuation of the Company’sintangible assets or reporting units that contain goodwill. As such, we concluded that a triggering event, which would requireimpairment testing for any intangible assets, or reporting units that contain goodwill, did not occur. We will continue to evaluatethe nature and extent of impacts related to COVID-19 on our business and any impact they may have on management's estimates. Theduration and severity of the outbreak and its long-term impact on our business is uncertain at this time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Comparison of the Fiscal Year Ended September 30, 2020to the Fiscal Year Ended September 30, 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Revenues        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Product revenues         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the twelve month periods ended September 30, 2020and 2019, we generated $615,430 and $2,136,055 in revenues from product sales, respectively. Product revenue decreased by$1,520,625 or 71% for the twelve month period ended September 30, 2020 as compared to the prior fiscal year. Revenuesdecreased by $1,351,266 in textiles relating to shipments of DNA concentrate to protect the cotton supply chain. Thisdecrease in textiles revenue is primarily as result of the global shut down related to the COVID-19 pandemic adverselyimpacting the textile industry. Further decreases include $91,609 in Consumer Asset Marking due to a decrease in demand forautomobile marking in Scandinavia and $58,704 in biopharmaceuticals due to a customer having decreased demand and thereforedelaying the issuance of its annual purchase order.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 43; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            43            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Service revenues         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the twelve month periods ended September 30, 2020 and2019, we generated $1,316,067 and $3,253,034 in revenues from sales of services, respectively. Service revenues include our feasibilityprojects and any research and/or development contracts as well as our COVID-19 Surveillance Testing and fiberTyping and authenticationservices. The decrease in service revenues of $1,936,967 or 60% for the twelve month period ended September 30, 2020 as comparedto the prior fiscal year is attributable to a decrease in revenue from a cannabis licensing agreement (now terminated) of $1,000,000,as well as additional decreases of $612,890 for a government contract award that ended during the second half of fiscal 2019 and$197,446 of textile authentications and feasibility projects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Costs and Expenses        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Cost of Revenues         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Cost of revenues for the twelve month period ended September 30,2020 decreased by $156,713 or 18% from $877,613 for the twelve month period ended September 30, 2019 to $720,900 for the twelvemonth period ended September 30, 2020. Cost of revenues as a percentage of product revenues was 117% and 41% for the twelvemonth periods ended September 30, 2020 and 2019, respectively. This increase in cost of revenues as a percentage of productrevenues is due to product sales mix, as sales during the twelve month period ended September 30, 2019 included textiles sales,which are at a higher gross margin, and to a further extent, certain fixed costs, such as rent and payroll not getting fully absorbeddue to the low product revenue during the twelve month period ended September 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Selling, General and Administrative         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Selling, general and administrative expenses for the fiscalyear ended September 30, 2020 decreased by $139,942 or 1% to $10,138,103 from $10,278,045 in fiscal year 2019. The decreaseis primarily attributable to a decrease in travel of $274,000 due to the global pandemic as well as a $140,000 decrease in consultingexpense. These decreases were offset by an increase of $278,000 for the establishment of our diagnostic clinical lab (recruitmentfees, payroll, office expenses).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Research and Development         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Research and development expenses increased to $3,321,763 forthe twelve month period ended September 30, 2020 from $2,967,278 for the twelve month period ended September 30, 2019,an increase of $354,485 or 12%. This increase is primarily due to costs incurred related to the development and validation of our Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19 Assay Kit and our COVID-19 Surveillance Testing. Theincrease also relates to costs incurred on other feasibility projects in both textiles and pharmaceutical/nutraceutical markets,as well as the write-off of certain development costs for transfer units that are not expected to be used commercially in the cannabismarket. These increases were offset by a decrease related to the completion of the government contract award of approximately $400,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Depreciation and Amortization         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Depreciation and amortization decreased by $104,694 or 27% from$390,424 for the twelve month period ended September 30, 2019 to $285,730 for the twelve month period ended September 30,2020. This decrease is related primarily to items becoming fully depreciated during fiscal 2020 and therefore not having a full12 months of expense in the current fiscal year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Interest (expense)         </i>         income        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Interest (expense) income for the fiscal year ended September 30,2020, decreased to expense of $115,830 from expense of $162,432 in the same period of 2019. The decrease in interest expense wasdue to interest incurred on the secured convertible notes payable for the August 2018 and November 2018 secured convertiblenotes amended during July 2019. These notes were repaid in full at the end of fiscal 2019, as such no interest expense wasrecorded during fiscal 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 44; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            44            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Other (expense) income         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Other income (expense) for the twelve monthperiods ended September 30, 2020 and 2019, was expense of $378,075 and $43,299, respectively. The increase of $334,776 isdue to an increase in franchise taxes during the twelve month period ended September 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Loss on extinguishment of debt         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Loss on extinguishment of debt relatesto the August 2018 and November 2018 secured convertible notes amendment during July 2019 resulting in accountingfor such notes as an extinguishment of debt and issuance of new debt. The majority of these notes were subsequently converted intoequity during September 2019 and the remaining notes were paid back in full during the first quarter of fiscal 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Gain on change in fair value of securedconvertible notes payable         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Gain on change in fair value of securedconvertible notes payables relates to fair value adjustments relating to the August 2018 and November 2018 secured convertiblenotes as amended in July 2019. Due to the amendment, the Company elected the fair value option and adjusts the remaining securedconvertible notes to fair value upon conversion as well as at every quarter-end. The majority of these notes were subsequentlyconverted into equity during September 2019 and the remaining notes were paid back in full during the first quarter of fiscal2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Net Loss         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Net loss increased $4,396,458, or 51% to$13,028,904 for the fiscal year ended September 30, 2020 compared to $8,632,446 for the fiscal year ended September 30,2019, due to the factors noted above.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Recently Issued Accounting Pronouncements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        See Note C, “Recent Accounting Standards,” to theaccompanying consolidated financial statements for a description of accounting standards which may impact our consolidated financialstatements in future reporting periods.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Liquidity and Capital Resources        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our liquidity needs consist of our working capital requirementsand research and development expenditure funding. As of September 30, 2020, we had a working capital of $4,811,847. For thefiscal year ended September 30, 2020, we used cash in operating activities of $11,143,059 consisting primarily of our lossof $13,028,904 net with non-cash adjustments of $285,730 in depreciation and amortization charges, $1,001,082 in stock-based compensationexpense, $45,280 of bad debt expense and $26,019 in amortization of debt issuance costs. Additionally, we had a net decrease inoperating assets of $218,326 and a net increase in operating liabilities of $309,408. Cash used in investing activities was $1,063,698,for the purchase of property and equipment. Cash provided by financing activities was $19,434,512, which included net proceedsfrom the sale of common stock and warrants of $10,639,728, net proceeds from the exercise of warrants of $8,055,797, and net proceedsfrom promissory notes of $846,789.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have recurring net losses, which have resulted in an accumulateddeficit of $269,835,650 as of September 30, 2020. We have incurred a net loss of $13,028,904 for the fiscal year ended September 30,2020. At September 30, 2020, we had cash and cash equivalents of $7,786,743. These factors, along with the impact of the COVID-19pandemic, raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuanceof the financial statements. The ability of the Company to continue as a going concern is dependent on the Company's ability tofurther implement its business plan, raise capital, and generate revenues. The financial statements do not include any adjustmentsthat might be necessary if the Company is unable to continue as a going concern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our current capital resources include cash and cash equivalents,accounts receivable and inventories. Historically, we have financed our operations principally from the sale of equity and equity-linkedsecurities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We expect capital expenditures to beless than $1,200,000 in fiscal 2021. Our primary investments will be in laboratory equipment related to our biotherapeuticresearch and development activities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Substantially all of the real property used in our businessis leased under operating lease agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 45; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            45            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Recent Debt and Equity Financing Transactions        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Fiscal 2020         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Reverse Stock Split.        </u>        On October 31, 2019, we fileda Certificate of Amendment of our Certificate of Incorporation with the Secretary of State of the State of Delaware that effecteda one-for-forty (1:40) reverse stock split of our common stock, effective November 1, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Underwritten Public Offering.        </u>        On November 15, 2019,we closed an underwritten public offering where we issued and sold 2,285,000 shares of our common stock and 2,285,000 accompanyingcommon warrants (the “2019 Warrants”) each with the right to purchase one share of our common stock at an exerciseprice of $5.25 per share. The shares of common stock and accompanying 2019 Warrants were sold at a combined offering price of $5.25before underwriting discounts. The common warrants have an exercise price of $5.25 per share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        After deducting underwriter discounts andcommissions and other estimated expenses related to the underwritten public offering, we estimate the aggregate net proceeds tobe approximately $10.8 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We also granted the underwriter in theunderwritten offering an option to purchase an additional 342,750 shares of our common stock and/or additional 2019 Warrants topurchase 342,750 shares of our common stock to cover any over-allotments made by the underwriters in the sale and distributionof the securities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The 2019 Warrants include an adjustment provision that, subjectto certain exceptions, reduces its exercise price if we issue common stock or common stock equivalents at a price lower than thethen-current exercise price of the 2019 Warrants, subject to a minimum exercise price of $1.47 per share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Subject to limited exceptions, a holderof the 2019 Warrants will not have the right to exercise any portion of its warrant if the holder, together with its affiliates,would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstandingimmediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that upon61 days’ prior notice to us, the holder may increase the Beneficial Ownership Limitation, provided that in no event shallthe Beneficial Ownership Limitation exceed 9.99%.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The exercise price and number of the sharesof common stock issuable upon the exercise of the 2019 Warrants will be subject to adjustment in the event of any stock dividendsand splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the related warrant agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Fiscal 2019         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Private Placement of Secured Convertible Notes        </u>        . On November 29,2018, we closed a securities purchase agreement with our chairman, president and chief executive officer and one member of themanagement team, pursuant to which we issued and sold an aggregate of $550,000 in principal amount of secured convertible notesbearing interest at a rate of 6% per annum (the “November 2018 Notes”). The November 2018 Notesare substantially similar to our August 2018 Notes (as defined below) except with respect to maturity date. The November 29        <sup>         th        </sup>        Notesare secured on a pari passu basis with the same Company assets as the August 2018 Notes.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Underwritten Public Offering.        </u>        On December 21, 2018,we entered into an underwriting agreement (the “Agreement”) with Maxim Group LLC (“Maxim”), as the soleunderwriter and book running manager, with respect to the issuance and sale of an aggregate of 137,500 shares (the “Shares”)of common stock, together with warrants to purchase an aggregate of 137,500 shares of common stock (the “Warrants”)at an exercise price equal to $20.00 per share of common stock (the “Exercise Price”) in an underwritten public offering.The public offering price for each Share together with the accompanying Warrant was $20.00. Pursuant to the Agreement, we alsogranted Maxim a 45-day option to purchase an additional 20,625 Shares and/or additional Warrants to purchase 20,625 Shares to coverany over-allotments made by the underwriters in the sale and distribution of the Shares and Warrants. The gross proceeds ofthe offering, before deducting underwriter discounts and commissions and other offering expenses, were approximately $2,750,000.The offering closed on December 26, 2018. On December 26, 2018, Maxim partially exercised its overallotment option andpurchased an additional 20,000 Warrants at a price of $0.0000004 per Warrant.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        After deducting underwriting fees and otherexpenses related to the offering, the aggregate net proceeds were approximately $2,262,000.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On January 25, 2019, we closed on the underwriters’partial exercise of its over-allotment option for 12,500 shares of common stock for gross proceeds of $250,000. After deductingunderwriting fees and other expenses related to the over-allotment option, the aggregate net proceeds were approximately $201,000.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 46; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            46            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The total number of common stock and Warrants issued underthis offering, including the exercise of the over-allotment option was 150,000 and 157,500, respectively. The gross proceeds tous were $3.0 million and net proceeds after deducting underwriting expenses and other estimated offering expenses was approximately$2.5 million.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Warrants are immediately exercisable beginning on the dateof issuance (the “Initial Exercise Date”). The Warrants will be exercisable for five years from the Initial ExerciseDate, but not thereafter.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Warrants include an adjustment provision that, subjectto certain exceptions, reduces their exercise price if we issue common stock or common stock equivalents at a price lower thanthe then-current exercise price of the Warrants, subject to a minimum exercise price of $5.60 per share. The exercise price andnumber of the shares of our common stock issuable upon the exercise of the Warrants will be subject to adjustment in the eventof any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as describedtherein.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As a result of the November 2019 underwritten public offering,the exercise price of the Warrants was reduced to an exercise price of $5.60 per share in accordance with the adjustment provisioncontained in the warrant agreement.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As a result of this financing, the exercise price of the 68,375warrants issued during December 2017 was reduced to an exercise price of $17.60 per share in accordance with the adjustmentprovision contained in the warrant agreement. The incremental change in fair value of these warrants as a result of the triggeringevent was insignificant.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Private Placement of Secured Convertible Notes.        </u>        On July 16,2019, we issued $1.5 million of secured convertible notes (the “July 2019 Notes”), bearing interest at a rateof 6% per annum, in a non-brokered private placement with an accredited investor, Dillon Hill Capital, LLC (“Dillon Hill”)and simultaneously amended the terms of certain outstanding August 2018 secured convertible notes (as amended, the “August 2018Notes”) and November 2018 secured convertible notes (as amended, the “November 2018 Notes”, and togetherwith the August 2018 Notes, the “2018 Notes”, and together with the August 2018 Notes and July 2019Notes, the “Company Notes”), to, among other amendments, (i) reduce the conversion price of the 2018 Notes to$21.60 to facilitate their conversion into equity and (ii) change the maturity date of the August 2018 Notes to be November 28,2021. Dillon Hill was granted a right to participate in certain of our future financing transactions, (each a “SubsequentFinancing”) until July 16, 2020 equal to the amount required for Dillon Hill to maintain its pro rata ownership ofus as if the July 2019 Notes had been fully converted into our common stock.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company Notes contain certain events of default that arecustomarily included in financings of this nature. If an event of default occurs, the holders of the Company Notes (by an affirmativevote of the holders of the Company Notes representing at least 30% of the aggregate principal amount of the Company Notes thenoutstanding) may require us to redeem the Company Notes, in whole or in part, at a redemption price equal to the greater of (i) theiroutstanding principal balance, plus all accrued and unpaid interest, divided by the Conversion Price (as defined below), multipliedby the volume-weighted average price (“VWAP”) on the date the redemption price is either (x) demanded or otherwisedue or (y) paid in full, whichever has a higher VWAP, or (ii) 130% of the outstanding principal, plus all accrued andunpaid interest.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        After giving effect to the amendments to the 2018 Notes, theJuly 2019 Notes are substantially similar to the 2018 Notes. The July 2019 Notes are secured on a pari passu basis withthe same Company assets as the 2018 Notes. In addition, on July 19, 2019, we also amended the security agreements dated asof October 19, 2018, to among other amendments, exclude 20% of our equity interest in LRx from the assets securing the CompanyNotes. The Company Notes are convertible, in whole or in part, at any time, at the option of the purchasers, into shares of ourcommon stock, in an amount determined by dividing the principal amount of the Company Notes, together with any and all accruedand unpaid interest, by the conversion price of $21.60 (the “Conversion Price”). The Company Notes are due and payablein full on November 28, 2021. We have reserved sufficient shares of our common stock for the potential conversion of theCompany Notes.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The July Company Notes, contain certain negative covenantsthat restrict us, including prohibitions or limitations, among other things, on the incurrence of additional indebtedness, subsidiaryasset sales, intercompany loans, liens, amendments to our organization documents, dividends, and redemptions without consent ofthe Required Holders (as defined in the Company Notes).       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Private Placement of Common Stock.        </u>        On August 22, 2019, the Company issued and sold 38,704 shares of common stock at a price of $10.80 per share for totalgross proceeds of $418,000 to a group of accredited investors, including its chief executive officer, president and chairman ofthe board of directors, our chief information officer, and a 5% or greater stockholder.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Conversion of Notes.        </u>        During September 2019, approximately$2.2 million of the 2018 Notes were converted into 102,893 shares of our common stock. Included in the conversion, Dr. JamesA. Hayward, our CEO, converted approximately $1.59 million of the 2018 Notes, into approximately 72,500 shares of our common stock.In addition, other directors, officers, and affiliates of the Company converted approximately $409,000 of such 2018 Notes in September 2019into 18,929 shares of our common stock.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 47; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            47            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Subsequent Events         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Entry into Warrant Exercise Agreement         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On October 7, 2020, we entered intoWarrant Exercise Agreements (each, a “Warrant Exercise Agreement”) with Dillon Hill Capital, LLC and its affiliate,Dillon Hill Investment Company LLC (together, the “Investors”), whereby 318,000 of our 2019 Warrants were exercised.The 2019 Warrants were issued as part of the Company’s November 15, 2019 underwritten public offering. The gross proceedsto the Company from this partial exercise of the 2019 Warrants is $1,669,500.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In consideration of this partial exerciseof the 2019 Warrants and of the consent to repayment of the Notes, as described below, the Company agreed to issue, in additionto the 318,000 shares of common stock issued upon exercise of the 2019 Warrants (the “Warrant Shares”), 159,000 replacementwarrants (the “Replacement Warrants”) to the Investors, which is an amount equal to one-half the amount of the 2019Warrants exercised pursuant to the Warrant Exercise Agreements. The Replacement Warrants have an exercise price of $7.54, theclosing price on The Nasdaq Capital Market of the Company’s common stock on October 7, 2020. In addition, until January 5,2021, if the Investors exercise additional 2019 Warrants, the Company will issue to the applicable Investor additional ReplacementWarrants in an amount equal to one-half the amount of such exercised 2019 Warrants with each such Replacement Warrant having anexercise price equal to the closing price on The Nasdaq Capital Market of the Company’s common stock on such date that therelated 2019 Warrants are exercised.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Each Replacement Warrant will be exercisablebeginning on the date of issuance thereof and ending on the five year anniversary of such date. The exercise price and numberof shares of common stock issuable upon exercise of the Replacement Warrants will be subject to adjustment in the event of anystock dividend, split, recapitalization, reorganization or similar transaction, as described in the Replacement Warrant. Subjectto limited exceptions, a holder of a Replacement Warrant will not have the right to exercise any portion of its Replacement Warrantif the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of common stockoutstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided thatupon 61 days’ prior notice to the Company, the holder may elect to increase or decrease the Beneficial Ownership Limitation,although in no event may the Beneficial Ownership Limitation exceed 9.99%. Each Replacement Warrant includes an adjustment provisionthat, subject to certain exceptions, reduces its exercise price if the Company issues common stock or common stock equivalentsat a price lower than the then-current exercise price of such Replacement Warrant, subject to a minimum exercise price of 21%of such Replacement Warrant’s initial exercise price per share. Under certain limited circumstances, including that thedaily volume weighted average price of the common stock for each of 20 consecutive trading days has exceeded three times the exerciseprice of such Replacement Warrant, the Company may call for cancellation of all or any portion of such Replacement Warrant forwhich a notice of exercise has not yet been delivered for consideration equal to $0.001 per Warrant Share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Replacement Warrants will not be registerednor listed on any exchange but are the subject of registration rights agreements (each, a “Registration Rights Agreement”),entered into with each Investor concurrently with the respective Warrant Exercise Agreement, pursuant to which the Company agreesto file a registration statement by January 20, 2021 with respect to the common stock underlying the Replacement Warrants.If at the time of exercise of the Replacement Warrants there is no effective registration statement registering, or the prospectuscontained therein is not available for the issuance of the Warrant Shares to the applicable Investor, then such Replacement Warrantmay also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Investor willbe entitled to receive a number of Warrant Shares as determined by the terms of the Replacement Warrant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The private placement of the ReplacementWarrants was completed in reliance upon the exemption from registration provided for by Section 4(a)(2) of the SecuritiesAct and by Rule 506 of Regulation D promulgated under the Securities Act. Each Investor represented to the Company in itsWarrant Exercise Agreement that it is an “accredited investor” as that term is defined in Rule 501 of RegulationD.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On each of December 9 and 10, 2020, the Investors exercised100,000 of their 2019 Warrants, for an aggregate exercise of 200,000 of their 2019 Warrants, resulting in total net proceeds tothe Company of approximately $1.1 million. As a result of these exercises, we issued to the Investors an aggregate of 100,000 additionalreplacement warrants, which are substantially similar to the Replacement Warrants described above except that 50,000 of the newly-issuedreplacement warrants have an exercise price of $6.57 and 50,000 of such replacement warrants have an exercise price of $6.46.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Repayment of secured convertiblenotes         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On October 9, 2020, the Company enteredinto a letter agreement (the “Letter Agreement”) with Dillon Hill Capital, LLC (the “Noteholder”) as soleholder of the secured convertible notes (the “Notes”) for the repayment in full of the Notes, in an aggregate amountof $1,665,581 (the “Payoff Amount”), representing the outstanding principal amount of the Notes plus accrued but unpaidinterest through the scheduled maturity of the Notes. The Company paid the Payoff Amount to the Noteholder on October 9,2020. Pursuant to the Letter Agreement, the Noteholder and the Collateral Agent agree that, upon the Noteholder’s receiptof the Payoff Amount, the Notes and any other related documents and instruments will automatically terminate. Moreover, all ofthe obligations and liabilities of the Company and its affiliates under the Notes, the Purchase Agreement, and the Security Agreements,and any other related documents and instruments, will be automatically satisfied in full, and all related liens, mortgages orother security interests will be automatically released.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 48; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            48            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Product Research and Development        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We anticipate spending approximately $3,500,000 for productresearch and development activities during the next twelve months.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Off-Balance Sheet Arrangements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We do not have any off-balance sheet arrangements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Inflation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The effect of inflation on our revenueand operating results was not significant during the fiscal years ended September 30, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_011">           </a>           <b>            ITEM 7A.           </b>          </td>          <td>           <b>            QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Information requested by this Item is not applicable as weare electing scaled disclosure requirements available to Smaller Reporting Companies with respect to this Item.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_012">           </a>           <b>            ITEM 8.           </b>          </td>          <td style="text-align: justify">           <b>            FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="background-color: white">         Seepages F-1 through        </font>        <font>         F-30        </font>        <font style="background-color: white">         followingthe Exhibit Index.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_013">           </a>           <b>            ITEM 9.           </b>          </td>          <td style="text-align: justify">           <b>            CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 49; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            49            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="a_014">        </a>        <b>         ITEM 9A. CONTROLS AND PROCEDURES.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Management Report on Internal Controlover Financial Reporting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Evaluation of Disclosure Controls andProcedures        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Under the supervision and with the participation of our management,including, our Chief Executive Officer, along with the Chief Financial Officer, on September 30, 2020, we conducted an evaluationof the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) underthe Exchange Act, as of September 30, 2020. Disclosure controls and procedures are those controls and procedures designedto provide reasonable assurance that the information required to be disclosed in our Exchange Act filings is (1) recorded,processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (2) accumulatedand communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timelydecisions regarding required disclosure.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Based on that evaluation, our Chief ExecutiveOfficer and Chief Financial Officer concluded that, as of September 30, 2020, our disclosure controls and procedures wereeffective.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Management Report on Internal Controlover Financial Reporting        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our management is responsible for establishing and maintainingadequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f).Our internal control over financial reporting was designed to provide reasonable assurance to our management and board of directorsregarding the preparation and fair presentation of published consolidated financial statements. Internal control over financialreporting is promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executiveand principal financial officers and effected by our board of directors, management and other personnel, to provide reasonableassurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes inaccordance with generally accepted accounting principles. Internal control over financial reporting, no matter how well designed,has inherent limitations and may not prevent or detect misstatements. Therefore, even effective internal control over financialreporting can only provide reasonable assurance with respect to the financial statement preparation and presentation.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our management has conducted, with the participation of ourCEO and CFO, an assessment, including testing of the effectiveness, of our internal control over financial reporting as of September 30,2020. Management’s assessment of internal control over financial reporting was based on assessment criteria establishedin the        <i>         2013 Internal Control—Integrated Framework        </i>        issued by the Committee of Sponsoring Organizations of the TreadwayCommission (“COSO”). Based on such evaluation, management concluded that our internal control over financial reportingwas effective as of September 30, 2020.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Changes in Internal Control over Financial Reporting        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There were no changes in our internal control over financialreporting during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, ourinternal control over financial reporting.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_015">           </a>           <b>            ITEM 9B.           </b>          </td>          <td style="text-align: justify">           <b>            OTHER INFORMATION.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 50; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            50            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Part III        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_016">           </a>           <b>            ITEM 10.           </b>          </td>          <td>           <b>            DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_017">           </a>           <b>            ITEM 11.           </b>          </td>          <td>           <b>            EXECUTIVE COMPENSATION           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_018">           </a>           <b>            ITEM 12.           </b>          </td>          <td>           <b>            SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_019">           </a>           <b>            ITEM 13.           </b>          </td>          <td>           <b>            CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_020">           </a>           <b>            ITEM 14.           </b>          </td>          <td>           <b>            PRINCIPAL ACCOUNTANT FEES AND SERVICES           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The information called for by Items 10, 11, 12, 13 and 14 willbe included in our definitive proxy statement for the 2021 Annual Meeting of Stockholders, which will be filed with the SEC within120 days after September 30, 2020. The relevant portions of such definitive proxy statement are incorporated herein by reference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <a name="a_021">           </a>           <b>            ITEM 15.           </b>          </td>          <td style="text-align: justify">           <b>            EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           (a)          </td>          <td style="text-align: justify">           We have filed the following documents as part of this Form 10-K:          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           1.          </td>          <td style="text-align: justify">           Consolidated Financial Statements          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our consolidated financial statements at September 30,2020 and 2019 and for the years ended September 30, 2020 and 2019, and the notes thereto, together with the report of ourindependent registered public accounting firm on those consolidated financial statements, are hereby filed as part of this reportbeginning on page F-1.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           2.          </td>          <td style="text-align: justify">           Financial Statement Schedules          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All financial statement schedules have been omitted since therequired information is not applicable or is not present in amounts sufficient to require submission of the schedule, or becausethe information required is included in the consolidated financial statements and notes thereto.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           3.          </td>          <td style="text-align: justify">           Exhibits          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The information required by this itemis set forth on the exhibit index that follows the signature page of this report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 51; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            51            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SIGNATURES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Pursuant to the requirements of Section 13 or 15(d) ofthe Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,thereunto duly authorized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%">          </td>          <td style="width: 50%">           <b>            APPLIED DNA SCIENCES, INC.           </b>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           Date: December 17, 2020          </td>          <td style="border-bottom: black 1pt solid">           /s/ James A. Hayward          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: right">           By:          </td>          <td>           James A. Hayward          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <i>            President and Chief Executive Officer           </i>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Pursuant to the requirements of the SecuritiesExchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacitiesand on the dates indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 34%; border-bottom: black 1pt solid">           <b>            Name           </b>          </td>          <td style="width: 1%">          </td>          <td style="width: 36%; border-bottom: black 1pt solid; text-align: center">           <b>            Position           </b>          </td>          <td style="width: 1%">          </td>          <td style="width: 28%; border-bottom: black 1pt solid; text-align: center">           <b>            Date           </b>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           /s/           <b>            JAMES A. HAYWARD           </b>          </td>          <td>          </td>          <td>           Chief Executive Officer (           <i>            Principal Executive Officer           </i>           ),          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td>           James A. Hayward          </td>          <td>          </td>          <td>           President, Chairman of the Board of Directors and Director          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           /s/           <b>            BETH M. JANTZEN           </b>          </td>          <td>          </td>          <td rowspan="2">           Chief Financial Officer (           <i>            Principal Financial Officer and Principal Accounting Officer           </i>           )          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td>           Beth M. Jantzen          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           /s/           <b>            JOHN BITZER, III           </b>          </td>          <td>          </td>          <td>           Director          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td>           John Bitzer, III          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           /s/           <b>            ROBERT CATELL           </b>          </td>          <td>          </td>          <td>           Director          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td>           Robert Catell          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           /s/           <b>            JOSEPH D. CECCOLI           </b>          </td>          <td>          </td>          <td>           Director          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td>           Joseph D. Ceccoli          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           /s/           <b>            SCOTT L. ANCHIN           </b>          </td>          <td>          </td>          <td>           Director          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td>           Scott L. Anchin          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           /s/           <b>            YACOV A. SHAMASH           </b>          </td>          <td>          </td>          <td>           Director          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td>           Yacov A. Shamash          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           /s/           <b>            SANFORD R. SIMON           </b>          </td>          <td>          </td>          <td>           Director          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td>           Sanford R. Simon          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           /s/           <b>            ELIZABETH M. SCHMALZ FERGUSON           </b>          </td>          <td>          </td>          <td>           Director          </td>          <td>          </td>          <td>           December 17, 2020          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-top: black 1pt solid">           Betsy M. Schmalz Ferguson          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 52; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            52            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         EXHIBIT INDEX        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following exhibits are included as part of this Form 10-K.References to “the Company” in this Exhibit List mean Applied DNA Sciences, Inc., a Delaware corporation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: bottom; text-align: center">           <b>            Exhibit           </b>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td colspan="7" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">           <b>            Incorporated by Reference           </b>          </td>          <td colspan="2" style="vertical-align: bottom; text-align: center">           <b>            Filed or           </b>           <br/>           <b>            Furnished           </b>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1pt solid; text-align: center; width: 10%">           <b>            Number           </b>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="border-bottom: black 1pt solid; text-align: center; width: 35%">           <b>            Description           </b>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="border-bottom: black 1pt solid; text-align: center; width: 6%">           <b>            Form           </b>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="border-bottom: black 1pt solid; text-align: center; width: 13%">           <b>            Exhibit           </b>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="border-bottom: black 1pt solid; text-align: center; width: 10%">           <b>            File No.           </b>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="border-bottom: black 1pt solid; text-align: center; width: 10%">           <b>            Date Filed           </b>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="border-bottom: black 1pt solid; text-align: center; width: 10%">           <b>            Herewith           </b>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex4-1.htm" style="-sec-extract: exhibit">            3.1           </a>          </td>          <td>          </td>          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex4-1.htm" style="-sec-extract: exhibit">            Conformed version of Certificate of Incorporation of Applied DNA Sciences, Inc., as most recently amended by the    Fifth Certificate of Amendment, effective Thursday, September 17, 2020           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex4-1.htm" style="-sec-extract: exhibit">            S-8           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex4-1.htm" style="-sec-extract: exhibit">            333-249365           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex4-1.htm" style="-sec-extract: exhibit">            10/07/2020           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811209000105/ex3-2.htm" style="-sec-extract: exhibit">            3.2           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811209000105/ex3-2.htm" style="-sec-extract: exhibit">            By-Laws           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811209000105/ex3-2.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811209000105/ex3-2.htm" style="-sec-extract: exhibit">            3.2           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811209000105/ex3-2.htm" style="-sec-extract: exhibit">            002-90539           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811209000105/ex3-2.htm" style="-sec-extract: exhibit">            1/16/2009           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="tm2037742d1_ex4-1.htm">            4.1           </a>          </td>          <td>          </td>          <td>           <a href="tm2037742d1_ex4-1.htm">            Description of Securities           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>           <a href="tm2037742d1_ex4-1.htm">            Filed           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104914005563/t1401921_ex10-26.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.            </font>            2           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104914005563/t1401921_ex10-26.htm" style="-sec-extract: exhibit">            Form of Underwriter’s Warrant to be issued to Maxim Group LLC           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104914005563/t1401921_ex10-26.htm" style="-sec-extract: exhibit">            S-1/A           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104914005563/t1401921_ex10-26.htm" style="-sec-extract: exhibit">            10.26           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104914005563/t1401921_ex10-26.htm" style="-sec-extract: exhibit">            333-199121           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104914005563/t1401921_ex10-26.htm" style="-sec-extract: exhibit">            10/30/2014           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002402/t81896_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.            </font>            3           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002402/t81896_ex4-1.htm" style="-sec-extract: exhibit">            Form of Underwriter’s Warrant           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002402/t81896_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002402/t81896_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002402/t81896_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002402/t81896_ex4-1.htm" style="-sec-extract: exhibit">            3/27/2015           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.            </font>            4           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-1.htm" style="-sec-extract: exhibit">            Form of Purchase Warrant           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-1.htm" style="-sec-extract: exhibit">            11/23/2015           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.            </font>            5           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-2.htm" style="-sec-extract: exhibit">            Form of Placement Agent Warrant issued to Maxim Group LLC           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-2.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-2.htm" style="-sec-extract: exhibit">            4.2           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009521/t1502786_ex4-2.htm" style="-sec-extract: exhibit">            11/23/2015           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.            </font>            6           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex4-1.htm" style="-sec-extract: exhibit">            Form of Placement Agent Warrant issued to Maxim Group LLC and Imperial Capital, LLC           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex4-1.htm" style="-sec-extract: exhibit">            11/2/2016           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.            </font>            7           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex4-1.htm" style="-sec-extract: exhibit">            Form of Purchase Warrant           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex4-1.htm" style="-sec-extract: exhibit">            12/20/2017           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065827/tv509599_ex4-1.htm" style="-sec-extract: exhibit">            4.8           </a>          </td>          <td>          </td>          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065827/tv509599_ex4-1.htm" style="-sec-extract: exhibit">            Common Stock Purchase Warrant           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065827/tv509599_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065827/tv509599_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065827/tv509599_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065827/tv509599_ex4-1.htm" style="-sec-extract: exhibit">            12/21/2018           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex4-3.htm" style="-sec-extract: exhibit">            4.9           </a>          </td>          <td>          </td>          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex4-3.htm" style="-sec-extract: exhibit">            Form of pre-funded warrant.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex4-3.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex4-3.htm" style="-sec-extract: exhibit">            4.3           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex4-3.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex4-3.htm" style="-sec-extract: exhibit">            11/14/2019           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            4.10           </a>          </td>          <td>          </td>          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            Form of common warrant certificate (included in the Warrant Agreement, dated November 15, 2019)           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            4.2           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            11/18/2019           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920064735/tm2020582d1_ex4-1.htm">            4.11           </a>          </td>          <td>          </td>          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920064735/tm2020582d1_ex4-1.htm">            Form of Indenture           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920064735/tm2020582d1_ex4-1.htm">            S-3           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920064735/tm2020582d1_ex4-1.htm">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920064735/tm2020582d1_ex4-1.htm">            333-238557           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920064735/tm2020582d1_ex4-1.htm">            05/21/2020           </a>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">        <font style="font-size: 10pt">        </font>       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 53; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            53            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">        <font style="font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-3.htm" style="-sec-extract: exhibit">            4.12           </a>          </td>          <td style="width: 1%">          </td>          <td style="width: 35%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-3.htm" style="-sec-extract: exhibit">            Form of Common Stock Purchase Warrant           </a>          </td>          <td style="width: 1%">          </td>          <td style="text-align: center; width: 6%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-3.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="width: 1%">          </td>          <td style="text-align: center; width: 13%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-3.htm" style="-sec-extract: exhibit">            10.3           </a>          </td>          <td style="width: 1%">          </td>          <td style="text-align: center; width: 10%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-3.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="width: 1%">          </td>          <td style="text-align: center; width: 10%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-3.htm" style="-sec-extract: exhibit">            10/14/2020           </a>          </td>          <td style="width: 1%">          </td>          <td style="width: 10%">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex4-1.htm" style="-sec-extract: exhibit">            10.1†           </a>          </td>          <td>          </td>          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex4-1.htm" style="-sec-extract: exhibit">            <font style="background-color: white">             Form of employee stock option agreement under the Applied DNA Sciences, Inc. 2005 Incentive Stock  Plan            </font>           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex4-1.htm" style="-sec-extract: exhibit">            10-Q           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex4-1.htm" style="-sec-extract: exhibit">            002-90539           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex4-1.htm" style="-sec-extract: exhibit">            05/15/2012           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419018218/tv517608-def14a.htm" style="-sec-extract: exhibit">            10.2†           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419018218/tv517608-def14a.htm" style="-sec-extract: exhibit">            Applied DNA Sciences, Inc. 2005 Incentive Stock Plan, as amended and restated           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419018218/tv517608-def14a.htm" style="-sec-extract: exhibit">            DEF 14A           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419018218/tv517608-def14a.htm" style="-sec-extract: exhibit">            Appendix A           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419018218/tv517608-def14a.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419018218/tv517608-def14a.htm" style="-sec-extract: exhibit">            04/04/2019           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009962/t83787_ex10-1.htm" style="-sec-extract: exhibit">            10.3†           </a>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009962/t83787_ex10-1.htm" style="-sec-extract: exhibit">            Form of employee stock option agreement under the Applied DNA Sciences, Inc. 2005 Incentive Stock Plan, as amended           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009962/t83787_ex10-1.htm" style="-sec-extract: exhibit">            10-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009962/t83787_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009962/t83787_ex10-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009962/t83787_ex10-1.htm" style="-sec-extract: exhibit">            12/14/2015           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920089239/tm2024845-2_def14a.htm" style="-sec-extract: exhibit">            10.4†           </a>          </td>          <td>          </td>          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920089239/tm2024845-2_def14a.htm" style="-sec-extract: exhibit">            Applied DNA Sciences, Inc. 2020 Equity Incentive Plan           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920089239/tm2024845-2_def14a.htm" style="-sec-extract: exhibit">            DEF 14A           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920089239/tm2024845-2_def14a.htm" style="-sec-extract: exhibit">            Appendix A           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920089239/tm2024845-2_def14a.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920089239/tm2024845-2_def14a.htm" style="-sec-extract: exhibit">            08/03/2020           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex10-3.htm" style="-sec-extract: exhibit">            10.5†           </a>          </td>          <td>          </td>          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex10-3.htm" style="-sec-extract: exhibit">            Applied DNA Sciences, Inc. 2020 Equity Incentive Plan Stock Option Grant Notice and Award Agreement           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex10-3.htm" style="-sec-extract: exhibit">            S-8           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex10-3.htm" style="-sec-extract: exhibit">            10.3           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex10-3.htm" style="-sec-extract: exhibit">            333-249365           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex10-3.htm" style="-sec-extract: exhibit">            10/07/2020           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916016981/t1600484_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10.6†            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916016981/t1600484_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             Employment Agreement, dated July 1, 2016, between James A. Hayward and Applied DNA Sciences, Inc.            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916016981/t1600484_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             8-K            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916016981/t1600484_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10.1            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916016981/t1600484_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             001-36745            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916016981/t1600484_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             8/2/2016            </font>           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10.7            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             Software Distribution Agreement, dated as of January 25, 2012, by and between Applied DNA Sciences, Inc. and DivineRune, Inc.            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10-Q            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10.1            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             002-90539            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212001641/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             5/15/2012            </font>           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212003634/ex10-37.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10.8            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212003634/ex10-37.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             Form of Subscription Agreement dated June 21, 2012, by and among Applied DNA Sciences, Inc. and the investor named on the signature page thereto            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212003634/ex10-37.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10-K            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212003634/ex10-37.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10.37            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212003634/ex10-37.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             002-90539            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212003634/ex10-37.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             12/20/2012            </font>           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212002871/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10.9†            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212002871/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             Form of Indemnification Agreement dated as of September 7, 2012, by and between Applied DNA Sciences, Inc. and each of its directors and executive officers            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212002871/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             8-K            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212002871/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             10.1            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212002871/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             002-90539            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811212002871/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             9/13/2012            </font>           </a>          </td>          <td>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 54; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            54            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify; width: 10%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104914006670/t1402301_ex4-1.htm" style="-sec-extract: exhibit">            10.10           </a>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: left; width: 35%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104914006670/t1402301_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Warrant Agreement, dated November 20,    2014, between Applied DNA Sciences, Inc. and            </font>            American Stock Transfer &amp; Trust Company, LLC as warrant    agent           </a>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 6%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104914006670/t1402301_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 13%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104914006670/t1402301_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 10%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104914006670/t1402301_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 10%">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104914006670/t1402301_ex4-1.htm" style="-sec-extract: exhibit">            11/20/2014           </a>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="text-align: center; width: 10%">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002558/t81941_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            11           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002558/t81941_ex4-1.htm" style="-sec-extract: exhibit">            First Amendment to Warrant Agreement dated April 1, 2015    between Applied DNA Sciences, Inc. and American Stock Transfer &amp; Trust Company, LLC as warrant agent           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002558/t81941_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002558/t81941_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002558/t81941_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915002558/t81941_ex4-1.htm" style="-sec-extract: exhibit">            4/1/2015           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-4.htm" style="-sec-extract: exhibit">            10.12           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-4.htm" style="-sec-extract: exhibit">            Second Amendment to Warrant Agreement dated November 2,    2016           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-4.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-4.htm" style="-sec-extract: exhibit">            10.4           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-4.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-4.htm" style="-sec-extract: exhibit">            11/2/2016           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915007695/t83167_ex2-1.htm">            <font style="font-size: 10pt">             10.1            </font>            3           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915007695/t83167_ex2-1.htm">            Asset Purchase Agreement dated September 11, 2015 between    Applied DNA Sciences, Inc. and Vandalia Research, Inc.           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915007695/t83167_ex2-1.htm">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915007695/t83167_ex2-1.htm">            2.1           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915007695/t83167_ex2-1.htm">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915007695/t83167_ex2-1.htm">            9/17/2015           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t83701_ex10-1.htm" style="-sec-extract: exhibit">            10.14           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t83701_ex10-1.htm" style="-sec-extract: exhibit">            Placement Agency Agreement by and between Applied DNA Sciences, Inc.    and Maxim Group LLC, dated November 23, 2015           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t83701_ex10-1.htm" style="-sec-extract: exhibit">            8-K/A           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t83701_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t83701_ex10-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t83701_ex10-1.htm" style="-sec-extract: exhibit">            11/23/2015           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t1502786_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            15           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t1502786_ex10-2.htm" style="-sec-extract: exhibit">            Form of Securities Purchase Agreement           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t1502786_ex10-2.htm" style="-sec-extract: exhibit">            8-K/A           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t1502786_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t1502786_ex10-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104915009535/t1502786_ex10-2.htm" style="-sec-extract: exhibit">            11/23/2015           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            16           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-1.htm" style="-sec-extract: exhibit">            Placement Agency Agreement between Maxim Group LLC, Imperial    Capital, LLC and Applied DNA Sciences, Inc. dated November 2, 2016           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-1.htm" style="-sec-extract: exhibit">            11/2/2016           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            17           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-2.htm" style="-sec-extract: exhibit">            Securities Purchase Agreement dated November 2, 2016           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-2.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-2.htm" style="-sec-extract: exhibit">            11/2/2016           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            18           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-3.htm" style="-sec-extract: exhibit">            Registration Rights Agreement dated November 2, 2016           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-3.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-3.htm" style="-sec-extract: exhibit">            10.3           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-3.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000157104916019355/t1600699_ex10-3.htm" style="-sec-extract: exhibit">            11/2/2016           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417042045/v472281_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            19*           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417042045/v472281_ex10-1.htm" style="-sec-extract: exhibit">            License Agreement with Himatsingka America, Inc. dated    June 23, 2017           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417042045/v472281_ex10-1.htm" style="-sec-extract: exhibit">            10-Q           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417042045/v472281_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417042045/v472281_ex10-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417042045/v472281_ex10-1.htm" style="-sec-extract: exhibit">            8/10/2017           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-1.htm">            10.20           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-1.htm">            Placement Agency Agreement by and between Applied DNA Sciences, Inc.    and Maxim Group LLC, dated December 20, 2017.           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-1.htm">            <font style="font-size: 10pt">             8-K            </font>           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-1.htm">            10.1           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-1.htm">            <font style="font-size: 10pt">             001-36745            </font>           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-1.htm">            <font style="font-size: 10pt">             12/20/2017            </font>           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.2            </font>            1           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-2.htm" style="-sec-extract: exhibit">            Securities Purchase Agreement dated as of December 20,    2017, by and between Applied DNA Sciences, Inc. and the Purchasers named therein.           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-2.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420417064423/tv481658_ex10-2.htm" style="-sec-extract: exhibit">            12/20/2017           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            22           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-2.htm" style="-sec-extract: exhibit">            Registration Rights Agreement, dated November 29, 2018           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-2.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-2.htm" style="-sec-extract: exhibit">            12/6/2018           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 55; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            55            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify; width: 10%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.2            </font>            3           </a>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: left; width: 35%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-3.htm" style="-sec-extract: exhibit">            Securities Purchase Agreement, dated November 29,    2018           </a>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 6%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-3.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 13%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-3.htm" style="-sec-extract: exhibit">            10.3           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 10%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-3.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 1%">          </td>          <td style="padding-bottom: 1pt; text-align: center; width: 10%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063250/tv508537_ex10-3.htm" style="-sec-extract: exhibit">            12/6/2018           </a>          </td>          <td style="padding-bottom: 1pt; width: 1%">          </td>          <td style="text-align: center; width: 10%">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063812/tv508735_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            24           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063812/tv508735_ex10-2.htm" style="-sec-extract: exhibit">            Registration Rights Agreement, dated August 31, 2018           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063812/tv508735_ex10-2.htm" style="-sec-extract: exhibit">            8-K/A           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063812/tv508735_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063812/tv508735_ex10-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420418063812/tv508735_ex10-2.htm" style="-sec-extract: exhibit">            12/10/2018           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; text-align: justify">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065023/tv507795_ex10-45.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            25           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: left; padding-bottom: 1pt">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065023/tv507795_ex10-45.htm" style="-sec-extract: exhibit">            Securities Purchase Agreement, dated August 31, 2018           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065023/tv507795_ex10-45.htm" style="-sec-extract: exhibit">            10-K           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065023/tv507795_ex10-45.htm" style="-sec-extract: exhibit">            10.45           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065023/tv507795_ex10-45.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="padding-bottom: 1pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420418065023/tv507795_ex10-45.htm" style="-sec-extract: exhibit">            12/18/2018           </a>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 56; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            56            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419024873/tv520548_ex10-10.htm" style="-sec-extract: exhibit">            10.26+           </a>          </td>          <td style="width: 1%">          </td>          <td style="text-align: left; width: 35%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419024873/tv520548_ex10-10.htm" style="-sec-extract: exhibit">            Patent and Know-How License and Cooperation Agreement, dated March 28, 2019, between the Company, APDN (B.V.I.), Inc.,    and ETCH BioTrace S.A.           </a>          </td>          <td style="text-align: center; width: 1%">          </td>          <td style="text-align: center; width: 6%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419024873/tv520548_ex10-10.htm" style="-sec-extract: exhibit">            10-Q           </a>          </td>          <td style="text-align: center; width: 1%">          </td>          <td style="text-align: center; width: 13%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419024873/tv520548_ex10-10.htm" style="-sec-extract: exhibit">            10.10           </a>          </td>          <td style="text-align: center; width: 1%">          </td>          <td style="text-align: center; width: 10%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419024873/tv520548_ex10-10.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="text-align: center; width: 1%">          </td>          <td style="text-align: center; width: 10%">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419024873/tv520548_ex10-10.htm" style="-sec-extract: exhibit">            5/9/2019           </a>          </td>          <td style="width: 1%">          </td>          <td style="width: 10%">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-2.htm">            10.27           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-2.htm">            Registration Rights Agreement, dated July 16, 2019 by and among Applied DNA Sciences, Inc. and the investor    named on the signature page thereof.           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-2.htm">            8-K           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-2.htm">            10.2           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-2.htm">            001-36745           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-2.htm">            07/17/2019           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-3.htm" style="-sec-extract: exhibit">            10.28           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-3.htm" style="-sec-extract: exhibit">            Securities Purchase Agreement, dated July 16, 2019 by and among Applied DNA Sciences, Inc. and the investor    named on the signature page thereof.           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-3.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-3.htm" style="-sec-extract: exhibit">            10.3           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-3.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000114420419034946/tv525305_ex10-3.htm" style="-sec-extract: exhibit">            07/17/2019           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419039187/tv527257_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            29           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419039187/tv527257_ex10-1.htm" style="-sec-extract: exhibit">            Asset Purchase Agreement, dated July 29, 2019 by and between LineaRX, Inc. and Vitatex Inc.           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419039187/tv527257_ex10-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419039187/tv527257_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419039187/tv527257_ex10-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419039187/tv527257_ex10-1.htm" style="-sec-extract: exhibit">            8/12/2019           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419041661/tv528207_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.            </font>            30           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419041661/tv528207_ex10-1.htm" style="-sec-extract: exhibit">            Form of Subscription Agreement between investors and Applied DNA Sciences, Inc., dated August 22, 2019.           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419041661/tv528207_ex10-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419041661/tv528207_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419041661/tv528207_ex10-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000114420419041661/tv528207_ex10-1.htm" style="-sec-extract: exhibit">            8/26/2019           </a>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex1-1.htm" style="-sec-extract: exhibit">            10.31           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex1-1.htm" style="-sec-extract: exhibit">            Underwriting Agreement entered into by and between Applied DNA Sciences, Inc. and Maxim Group LLC, as Representative    of the Underwriters listed in Schedule I hereto, dated November 13, 2019.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex1-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex1-1.htm" style="-sec-extract: exhibit">            1.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex1-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919063574/tm1921482d3_ex1-1.htm" style="-sec-extract: exhibit">            11/14/2019           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            10.32           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            Warrant Agreement, dated November 15, 2019, between Applied DNA Sciences, Inc. and American Stock Transfer &amp;    Trust Company, LLC           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465919064931/tm1921482d4_ex4-1.htm" style="-sec-extract: exhibit">            11/18/2019           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-1.htm" style="-sec-extract: exhibit">            10.33†           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-1.htm" style="-sec-extract: exhibit">            Consulting Agreement, dated as of December 12, 2019, by and between Applied DNA Sciences, Inc. and Meadow Hill    Place, LLC           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-1.htm" style="-sec-extract: exhibit">            10.Q           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-1.htm" style="-sec-extract: exhibit">            08/06/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811213002398/ex10-2.htm" style="-sec-extract: exhibit">            10.34           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="text-align: left; vertical-align: bottom">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811213002398/ex10-2.htm" style="-sec-extract: exhibit">            Agreement of Lease dated June 14, 2013, between Applied DNA Sciences, Inc. and    Long Island High Technology Incubator, Inc.           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811213002398/ex10-2.htm" style="-sec-extract: exhibit">            10-Q           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811213002398/ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811213002398/ex10-2.htm" style="-sec-extract: exhibit">            002-90539           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/744452/000118811213002398/ex10-2.htm" style="-sec-extract: exhibit">            8/13/2013           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-2.htm" style="-sec-extract: exhibit">            10.35           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-2.htm" style="-sec-extract: exhibit">            Agreement of Lease, dated November 1, 2015, by and between Applied DNA Sciences, Inc. and Long Island High Technology    Incubator, Inc.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-2.htm" style="-sec-extract: exhibit">            10.Q           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-2.htm" style="-sec-extract: exhibit">            08/06/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104916015201/t1600281_ex10-2.htm" style="-sec-extract: exhibit">            10.36           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104916015201/t1600281_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Option Exercise Notice, dated December 3, 2015, Pursuant to Lease dated June 14,    2013, between Applied DNA Sciences, Inc. and Long Island High Technology Incubator, Inc.            </font>           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104916015201/t1600281_ex10-2.htm" style="-sec-extract: exhibit">            10.Q           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104916015201/t1600281_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104916015201/t1600281_ex10-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000157104916015201/t1600281_ex10-2.htm" style="-sec-extract: exhibit">            05/12/2016           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-3.htm" style="-sec-extract: exhibit">            10.37           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-3.htm" style="-sec-extract: exhibit">            Temporary Lease Extension Agreement, dated August 9, 2019, by and between Applied DNA Sciences, Inc. and Long    Island High Technology Incubator, Inc.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-3.htm" style="-sec-extract: exhibit">            10.Q           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-3.htm" style="-sec-extract: exhibit">            10.3           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-3.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-3.htm" style="-sec-extract: exhibit">            08/06/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-4.htm" style="-sec-extract: exhibit">            10.38           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-4.htm" style="-sec-extract: exhibit">            Amendment to Leases, dated November 4, 2019, by and between Long Island High Technology Incubator, Inc. and    Applied DNA Sciences, Inc.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-4.htm" style="-sec-extract: exhibit">            10.Q           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-4.htm" style="-sec-extract: exhibit">            10.4           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-4.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-4.htm" style="-sec-extract: exhibit">            08/06/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-5.htm" style="-sec-extract: exhibit">            10.39           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-5.htm" style="-sec-extract: exhibit">            Amendment to Leases, dated January 17, 2020, by and between Long Island High Technology Incubator, Inc. and    Applied DNA Sciences, Inc.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-5.htm" style="-sec-extract: exhibit">            10.Q           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-5.htm" style="-sec-extract: exhibit">            10.5           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-5.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920091414/tm2020564d1_ex10-5.htm" style="-sec-extract: exhibit">            08/06/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-1.htm" style="-sec-extract: exhibit">            10.40           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-1.htm" style="-sec-extract: exhibit">            Warrant Exercise Agreement, dated October 7, 2020, by and between Applied DNA Sciences, Inc. and Dillon Hill    Capital, LLC.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-1.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-1.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-1.htm" style="-sec-extract: exhibit">            10/14/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-2.htm" style="-sec-extract: exhibit">            10.41           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-2.htm" style="-sec-extract: exhibit">            Warrant Exercise Agreement, dated October 7, 2020, by and between Applied DNA Sciences, Inc. and Dillon Hill    Investment Company LLC.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-2.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-2.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-2.htm" style="-sec-extract: exhibit">            10/14/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-4.htm" style="-sec-extract: exhibit">            10.42           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-4.htm" style="-sec-extract: exhibit">            Registration Rights Agreement, dated October 7, 2020, by and between Applied DNA Sciences, Inc. and Dillon Hill    Capital, LLC.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-4.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-4.htm" style="-sec-extract: exhibit">            10.4           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-4.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-4.htm" style="-sec-extract: exhibit">            10/14/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-5.htm" style="-sec-extract: exhibit">            10.43           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-5.htm" style="-sec-extract: exhibit">            Registration Rights Agreement, dated October 7, 2020, by and between Applied DNA Sciences, Inc. and Dillon Hill    Investment Company LLC.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-5.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-5.htm" style="-sec-extract: exhibit">            10.5           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-5.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-5.htm" style="-sec-extract: exhibit">            10/14/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-6.htm" style="-sec-extract: exhibit">            10.44           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-6.htm" style="-sec-extract: exhibit">            Letter Agreement, dated October 9, 2020, by and among Applied DNA Sciences, Inc., Dillon Hill Capital, LLC,    and Delaware Trust Company, as Collateral Agent.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-6.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-6.htm" style="-sec-extract: exhibit">            10.6           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-6.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-6.htm" style="-sec-extract: exhibit">            10/14/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-7.htm" style="-sec-extract: exhibit">            10.45           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-7.htm" style="-sec-extract: exhibit">            Consent, dated October 9, 2020, from Dillon Hill Capital, LLC to Applied DNA Sciences, Inc.           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-7.htm" style="-sec-extract: exhibit">            8-K           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-7.htm" style="-sec-extract: exhibit">            10.7           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-7.htm" style="-sec-extract: exhibit">            001-36745           </a>          </td>          <td>          </td>          <td style="text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-7.htm" style="-sec-extract: exhibit">            10/14/2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="tm2037742d1_ex10-46.htm">            10.46+           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="tm2037742d1_ex10-46.htm">            Joint Development Agreement, dated September 11, 2018, between LineaRx, Inc., Takis S.R.L. and Evvivax S.R.L.,    as amended by that First Amendment, dated February 3, 2020           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           <a href="tm2037742d1_ex10-46.htm">            Filed           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="tm2037742d1_ex10-47.htm">            10.47           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="tm2037742d1_ex10-47.htm">            Animal Clinical Trial Agreement, dated September 14, 2020, between Applied DNA Sciences, Inc., Evvivax S.R.L.    and Veterinary Oncology Services, PLLC           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           <a href="tm2037742d1_ex10-47.htm">            Filed           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="tm2037742d1_ex21-1.htm">            <font style="font-size: 10pt">             21.1            </font>           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="tm2037742d1_ex21-1.htm">            <font style="font-size: 10pt">             Subsidiaries of Applied DNA Sciences, Inc.            </font>           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           <a href="tm2037742d1_ex21-1.htm">            <font style="font-size: 10pt">             Filed            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="tm2037742d1_ex23-1.htm">            <font style="font-size: 10pt">             23.1            </font>           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="tm2037742d1_ex23-1.htm">            <font style="font-size: 10pt">             Consent of Marcum LLP            </font>           </a>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           <a href="tm2037742d1_ex23-1.htm">            <font style="font-size: 10pt">             Filed            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="tm2037742d1_ex31-1.htm">            <font style="font-size: 10pt">             31.1            </font>           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="tm2037742d1_ex31-1.htm">            <font style="font-size: 10pt">             Certification of Chief Executive Officer, pursuant to Rules 13a-14(a) and 15d-14(a) of    the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <a href="tm2037742d1_ex31-1.htm">            <font style="font-size: 10pt">             Filed            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">        <font style="font-size: 10pt">        </font>       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 57; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            57            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">        <font style="font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a href="tm2037742d1_ex31-2.htm">            <font style="font-size: 10pt">             31.2            </font>           </a>          </td>          <td style="width: 1%">          </td>          <td style="width: 35%">           <a href="tm2037742d1_ex31-2.htm">            <font style="font-size: 10pt">             Certification of Chief Financial Officer, pursuant to Rules 13a-14(a) and 15d-14(a) of    the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            </font>           </a>          </td>          <td style="width: 1%">          </td>          <td style="width: 6%">          </td>          <td style="width: 1%">          </td>          <td style="width: 13%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%">          </td>          <td style="width: 1%">          </td>          <td style="text-align: center; width: 10%">           <a href="tm2037742d1_ex31-2.htm">            <font style="font-size: 10pt">             Filed            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="tm2037742d1_ex32-1.htm">            <font style="font-size: 10pt">             32.1            </font>           </a>          </td>          <td>          </td>          <td>           <a href="tm2037742d1_ex32-1.htm">            <font style="font-size: 10pt">             Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted    pursuant to Section 906 of the Sarbanes-Oxley Act of 2002            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <a href="tm2037742d1_ex32-1.htm">            <font style="font-size: 10pt">             F            </font>            urnished           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="tm2037742d1_ex32-2.htm">            <font style="font-size: 10pt">             32.2            </font>           </a>          </td>          <td>          </td>          <td>           <a href="tm2037742d1_ex32-2.htm">            <font style="font-size: 10pt">             Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted    pursuant to Section 906 of the Sarbanes-Oxley Act of 2002            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <a href="tm2037742d1_ex32-2.htm">            Furnished           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td>           101 INS          </td>          <td>          </td>          <td>           XBRL Instance Document          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           Filed          </td>         </tr>         <tr style="vertical-align: top">          <td>           101 SCH          </td>          <td>          </td>          <td>           XBRL Taxonomy Extension Schema Document          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           Filed          </td>         </tr>         <tr style="vertical-align: top">          <td>           101 CAL          </td>          <td>          </td>          <td>           XBRL Taxonomy Extension Calculation Linkbase Document          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           Filed          </td>         </tr>         <tr style="vertical-align: top">          <td>           101 DEF          </td>          <td>          </td>          <td>           XBRL Taxonomy Extension Definitions Linkbase Document          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           Filed          </td>         </tr>         <tr style="vertical-align: top">          <td>           101 LAB          </td>          <td>          </td>          <td>           XBRL Taxonomy Extension Labels Linkbase Document          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           Filed          </td>         </tr>         <tr style="vertical-align: top">          <td>           101 PRE          </td>          <td>          </td>          <td>           XBRL Taxonomy Extension Presentation Linkbase Document          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">           Filed          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        † Indicates a management contract or any compensatoryplan, contract or arrangement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        * A request for confidentiality has been granted for certainportions of the indicated document. Confidential portions have been omitted and filed separately with the SEC as required by Rule 24b-2promulgated under the Exchange Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        + Portions of this exhibit have been omitted because the informationis both not material and would likely cause competitive harm to the registrant if publicly disclosed. The omissions have beenindicated by bracketed asterisks (“[***]”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 58; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            58            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        INDEX TO FINANCIAL STATEMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 90%">          </td>          <td style="width: 10%; text-align: center">           <b>            Page           </b>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_022">            Report of Independent Registered Public Accounting Firm           </a>          </td>          <td style="text-align: center">           <a href="#a_022">            F-2           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_023">            Consolidated Balance Sheets as of September 30, 2020 and 201            <u>             9            </u>           </a>          </td>          <td style="text-align: center">           <a href="#a_023">            F-3           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_024">            Consolidated Statements of Operations for the Years Ended September 30, 2020 and 201            <u>             9            </u>           </a>          </td>          <td style="text-align: center">           <a href="#a_024">            F-4           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_025">            Consolidated Statements of Equity for the Years Ended September 30, 2020 and 201            <u>             9            </u>           </a>          </td>          <td style="text-align: center">           <a href="#a_025">            F-5           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_026">            Consolidated Statements of Cash Flows for the Years Ended September 30, 2020 and 201            <u>             9            </u>           </a>          </td>          <td style="text-align: center">           <a href="#a_026">            F-6           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_027">            Notes to Consolidated Financial Statements           </a>          </td>          <td style="text-align: center">           <a href="#a_027">            F-7           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 59 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="margin: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_022">        </a>        <b>         REPORT OF INDEPENDENT REGISTERED PUBLICACCOUNTING FIRM        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        To the Shareholders and Board of Directorsof       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Applied DNA Sciences, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Opinion on the Financial Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have audited the accompanying consolidatedbalance sheets of Applied DNA Sciences, Inc. (the “Company”) as of September 30, 2020 and 2019, and the relatedconsolidated statements of operations, equity (deficit) and cash flows for each of the two years in the period ended September 30,2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financialstatements present fairly, in all material respects, the financial position of the Company as of September 30, 2020 and 2019,and the results of its operations and its cash flows for each of the two years in the period ended September 30, 2020, inconformity with accounting principles generally accepted in the United States of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Explanatory Paragraph – Going Concern        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The accompanying consolidated financialstatements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note B, theCompany has recurring net losses. The Company incurred a net loss of $13,028,904 and generated negative operating cash flow of$11,143,059 for the fiscal year ended September 30, 2020 and has a working capital deficiency of $4,811,847. These conditionsalong with the COVID-19 risks and uncertainties raise substantial doubt about the Company's ability to continue as a going concern.Management's plans in regard to these matters are also described in Note B. The consolidated financial statements do not includeany adjustments that might result from the outcome of this uncertainty.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Basis for Opinion        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        These financial statements are theresponsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statementsbased on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (UnitedStates) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S.federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and thePCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We conducted our audits in accordance withthe standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whetherthe financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are requiredto obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on theeffectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our audits included performing proceduresto assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing proceduresthat respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosuresin the financial statements. Our audits also included evaluating the accounting principles used and significant estimates madeby management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide areasonable basis for our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        /s/ Marcum        <font style="font-variant: small-caps">         llp        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Marcum        <font style="font-variant: small-caps">         llp        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have served as the Company’s auditor since 2014.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Melville, NY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        December 17, 2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 60; Options: NewSection; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="a_023">         </a>         CONSOLIDATED BALANCE SHEETS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 AND 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         CONDENSED CONSOLIDATED BALANCE SHEETS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           September 30,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; font-weight: bold; text-align: center">           ASSETS          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Current assets:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left">           Cash and cash equivalents          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           7,786,743          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           558,988          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Accounts receivable, net of allowance of $11,968 and $4,500 at September 30, 2020 and 2019, respectively          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           194,319          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           839,951          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Inventories          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           497,367          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           142,629          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Prepaid expenses and other current assets          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           599,296          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           604,740          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Total current assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           9,077,725          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,146,308          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Property and equipment, net          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,277,655          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           226,221          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Other assets:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Deferred offering costs          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           109,698          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Deposits          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           95,083          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           62,351          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Goodwill          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           285,386          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           285,386          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Intangible assets, net          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           605,330          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           734,771          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Total Assets          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           11,341,179          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           3,564,735          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; font-weight: bold; text-align: center">           LIABILITIES AND EQUITY (DEFICIT)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Current liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Accounts payable and accrued liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           1,926,427          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           1,616,997          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Promissory notes payable-current portion          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           329,299          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Secured convertible notes payable , net of debt issuance costs          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,499,116          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Deferred revenue          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           511,036          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           628,993          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Total current liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           4,265,878          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,245,990          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Long term accrued liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           848,307          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           621,970          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Promissory notes payable-long term portion          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           517,488          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Secured convertible notes payable, net of debt issuance costs          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,442,497          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Secured convertible notes payable, recorded at fair value          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           102,777          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Total liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           5,631,673          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           4,413,234          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Commitments and contingencies (Note K)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Applied DNA Sciences, Inc. Stockholders’ Equity (Deficit) :          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2020 and 2019, respectively          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of September 30, 2020 and 2019, respectively          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of September 30, 2020 and 2019, respectively          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Common stock, par value $0.001 per share; 200,000,000 and 500,000,000 shares authorized as of    September 30, 2020 and 2019, respectively; 5,142,779 and 1,207,993 shares issued and outstanding as of September 30, 2020    and 2019, respectively          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           5,144          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,208          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Additional paid in capital          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           275,548,737          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           255,962,922          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Accumulated deficit          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (269,835,650          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (256,805,589          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Applied DNA Sciences, Inc. stockholders’ equity (deficit):          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           5,718,231          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (841,459          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Noncontrolling interest          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (8,725          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (7,040          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Total equity (deficit)          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           5,709,506          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (848,499          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Total liabilities and equity (deficit)          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           11,341,179          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           3,564,735          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See the accompanying notes to the consolidatedfinancial statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 61; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_024">        </a>        <b>         CONSOLIDATED STATEMENTS OF OPERATIONS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         YEARS ENDED SEPTEMBER 30, 2020 AND 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Revenues:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt">           Product          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           615,430          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           2,136,055          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 1pt">           Service          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,316,067          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           3,253,034          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Total revenues          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,931,497          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           5,389,089          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Cost of revenues          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           720,900          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           877,613          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Operating expenses:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Selling, general and administrative          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           10,138,103          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           10,278,045          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Research and development          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           3,321,763          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,967,278          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Depreciation and amortization          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           285,730          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           390,424          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Total operating expenses          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           13,745,596          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           13,635,747          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           LOSS FROM OPERATIONS          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (12,534,999          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (9,124,271          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Other (expense) income:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Interest expense (including related party interest of $46,586 for the year ended September 30, 2019)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (115,830          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (162,432          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Other expense, net          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (378,075          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (43,299          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Loss on extinguishment of debt          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1,260,399          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Unrealized gain on change in fair value of secured convertible notes payable          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,972,955          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Loss before provision for income taxes          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (13,028,904          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (8,617,446          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Provision for income taxes          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           15,000          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           NET LOSS          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (13,028,904          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (8,632,446          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Less: Net loss (income) attributable to noncontrolling interest          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,685          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           9,323          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           NET LOSS attributable to Applied DNA Sciences, Inc.          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (13,027,219          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (8,623,123          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Deemed dividend related to warrant modifications          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           2,842          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (309,607          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           NET LOSS applicable to common stockholders          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (13,030,061          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (8,932,730          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Net loss per share applicable to common stockholders-basic and diluted          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (3.32          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (9.69          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Weighted average shares outstanding-basic and diluted          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           3,919,072          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           921,809          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        See the accompanying notes to the consolidatedfinancial statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 62; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_025">        </a>        <b>         CONSOLIDATED STATEMENTS OF (DEFICIT)EQUITY        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         YEARS ENDED SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center; font-size: 8pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Common            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Common            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Additional            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Accumulated            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Noncontrolling            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Total            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center; font-size: 8pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Shares            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stock            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Paid                                         in            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Deficit            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Interest            </b>           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Amount            </b>           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Capital            </b>           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%; font-size: 8pt; font-weight: bold">           <font style="font-size: 10pt">            Balance October 1, 2018           </font>          </td>          <td style="width: 1%; font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 7%; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            752,802           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 7%; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            753           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 7%; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            249,119,833           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 7%; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (248,366,083           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="width: 1%; font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 7%; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 7%; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            754,503           </font>          </td>          <td style="width: 1%; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt">           <font style="font-size: 10pt">            Other           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            7,594           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            8           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (8           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Common stock issued in public offering, net of    offering costs           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            150,000           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            150           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            2,463,441           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            2,463,591           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Common stock issued in private placement, net of    offering costs           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            38,704           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            39           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            402,342           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            402,381           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Impact of adoption of new accounting pronouncements    included in accumulated deficit           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            493,224           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            493,224           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt">           <font style="font-size: 10pt">            Exercise of warrants           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            55,376           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            55           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            987,446           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            987,501           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt">           <font style="font-size: 10pt">            Exercise of warrants cashlessly           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            100,617           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            100           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (100           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Common stock issued in secured convertible note    conversion           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            102,900           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            103           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,440,402           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,440,505           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Deemed dividend, warrant repricing           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            309,607           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (309,607           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Investment in LineaRx, Inc.           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            110,849           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            2,283           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            113,132           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Stock based compensation           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,129,110           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,129,110           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">           <font style="font-size: 10pt">            Net loss           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (8,623,123           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (9,323           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (8,632,446           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt; font-weight: bold">           <font style="font-size: 10pt">            Balance, September 30, 2019           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,207,993           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,208           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            255,962,922           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (256,805,589           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (7,040           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (848,499           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Common stock issued in public offering, net of    offering costs           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            2,285,000           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            2,285           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            10,527,745           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-size: 10pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            10,530,030           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Deemed dividend - warrant repricing           </font>          </td>          <td style="font-size: 8pt; font-weight: bold">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; font-weight: bold; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; font-weight: bold; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; font-weight: bold; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            2,842           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (2,842           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt">           <font style="font-size: 10pt">            Exercise of warrants           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,649,786           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,651           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            8,054,146           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            8,055,797           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            Stock based compensation expense           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,001,082           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            1,001,082           </font>          </td>          <td style="font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">           <font style="font-size: 10pt">            Net loss           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (13,027,219           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (1,685           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 1pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (13,028,904           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">          <td style="font-size: 8pt; font-weight: bold; padding-bottom: 2.5pt">           <font style="font-size: 10pt">            Balance, September 30,    2020           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 2.5pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            5,142,779           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 2.5pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            5,144           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 2.5pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            275,548,737           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 2.5pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (269,835,650           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 2.5pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            (8,725           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="font-size: 8pt; padding-bottom: 2.5pt">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">           <font style="font-size: 10pt">            5,709,506           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">           <font style="font-size: 10pt">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See the accompanying notes to the consolidatedfinancial statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 63; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_026">        </a>        <b>         CONSOLIDATED STATEMENT OF CASH FLOWS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         YEARS ENDED SEPTEMBER 30, 2020 AND 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Cash flows from operating activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; width: 74%; font-size: 10pt; text-align: left">           Net loss          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           (13,028,904          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           (8,632,446          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Adjustments to reconcile net loss to net cash used in operating activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Depreciation and amortization          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           285,730          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           390,424          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Loss on extinguishment of debt          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,260,399          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Unrealized gain on change in fair value of senior secured convertible notes          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1,972,955          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Stock-based compensation          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,001,082          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,129,110          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Non-cash in process research and development          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           251,420          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Amortization of debt issuance costs          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           26,019          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           23,828          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Provision for bad debts          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           45,280          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           7,624          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Change in operating assets and liabilities           <i>            :           </i>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Accounts receivable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           600,352          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           638,339          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt">           Inventories          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (354,738          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           78,740          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Prepaid expenses and other current assets and deposits          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (27,288          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           23,767          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Accounts payable and accrued liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           427,365          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           667,898          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Deferred revenue          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (117,957          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (727,920          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Net cash used in operating activities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (11,143,059          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (6,861,772          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Cash flows from investing activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Purchase of property and equipment          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (1,063,698          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (67,438          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Net cash used in investing activities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (1,063,698          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (67,438          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Cash flows from financing activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Proceeds from secured convertible notes payable (including related parties of $550,000 for the year ended September 30, 2019)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,985,392          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Proceeds from Promissory notes          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           846,789          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Net proceeds from private placement          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           402,381          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Net proceeds from exercise of warrants          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           8,055,797          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           987,501          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Net proceeds from sale of common stock and warrants          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           10,639,728          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,463,591          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Repayment of convertible notes          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (107,802          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Capitalized offering costs          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (10,231          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Net cash provided by financing activities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           19,434,512          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           5,828,634          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Net increase (decrease) in cash and cash equivalents          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           7,227,755          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1,100,576          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Cash and cash equivalents at beginning of year          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           558,988          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,659,564          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Cash and cash equivalents at end of year          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           7,786,743          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           558,988          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Supplemental Disclosures of Cash Flow Information:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Cash paid during period for interest          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           45,354          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Cash paid during period for income taxes          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Non-cash investing and financing activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Public offering costs included in accounts payable and accrued liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           99,468          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Interest paid in kind (related party of $98,752 for the year ended September 30, 2019)          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           35,625          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           126,980          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Property and equipment acquired, and included in accounts payable          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           144,025          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Deemed dividend-warrant repricing          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           2,842          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           309,607          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Impact of adoption of new accounting pronouncements included in accumulated deficit          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           493,223          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Deferred offering costs reclassified to additional paid in capital          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           109,698          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Warrants exercised cashlessly          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           100          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Conversion of notes payable          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,440,505          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        See the accompanying notes to the consolidatedfinancial statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 64; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <a name="a_027">        </a>        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE A – NATURE OF THE BUSINESS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Applied DNA Sciences, Inc. (“AppliedDNA,” or the “Company”) develops and markets DNA-based technology solutions utilizing its LinearDNA        <sup>         TM        </sup>        large-scalepolymerase chain reaction (“PCR”) based manufacturing platform which is capable of producing large scale DNA. The Company’sproprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinicalnucleic-acid based drug development and manufacturing markets (“Biotherapeutic Contract Research and Manufacturing”)and for supply chain security, anti-counterfeiting and anti-theft technology purposes (“Non-Biologic Tagging”) applications.In response to the COVID-19 pandemic, the Company developed a PCR-based molecular diagnostic test for COVID-19, which was grantedEmergency Use Authorization (EUA) in May 2020. The Company currently manufactures and sells its EUA authorized COVID-19 moleculardiagnostic test kit under the Linea        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        COVID-19 Assay Kit trademark (“COVID-19Diagnostic Testing”). In addition, and in further response to the COVID-19 pandemic, the Company developed and is currentlyoffering non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations. The Company’sCOVID-19 pooled surveillance testing services are currently offered under the safeCircle        <sup>         TM        </sup>        trademark (“COVID-19Surveillance Testing”). The Company is also developing an invasive circulating tumor cell capture and identification technology(“iCTC Technology”) which uses a patented functional assay to capture live invasive circulating tumor cell and associatedlymphocytes that can be identified and expanded for further analysis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Applied DNA is currently engaged in thelarge scale production of DNA via its LinearDNA        <sup>         TM        </sup>        platform for two primary lines of services:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Biotherapeutic Contract Research andManufacturing        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s patented continuousflow PCR systems and other proprietary PCR-based production technologies and post-processing systems that comprise the LinearDNA        <sup>         TM        </sup>        platformallows for the large-scale production of specific DNA sequences. The LinearDNA        <sup>         TM        </sup>        platform allows for the large-scaleproduction of specific DNA sequences. The LinearDNA        <sup>         TM        </sup>        platform is currently being used for customers to manufactureDNA components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive celltherapies (CAR T and TCR therapies), (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromicrepeats (CRISPR) based therapies and gene therapies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company provides preclinical contractresearch and manufacturing services for the nucleic acid-based therapeutic markets. The Company works with biotech and pharmaceuticalcompanies to convert plasmid-based and/or viral transduction-based preclinical biotherapeutics into PCR-produced linear DNA-basedforms that can be produced on its LinearDNA        <sup>         TM        </sup>        platform. In addition, the Company provides contract research servicesto RNA based drug and biologic customers for preclinical studies. These services include the design, development and manufactureof PCR-produced DNA templates for RNA. In addition, the Company also uses its LinearDNA        <sup>         TM        </sup>        platform to produce verylarge gram-scale quantities of DNA for the in vitro diagnostic market where its DNA is used for both commercially available diagnosticsand diagnostics under development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company also seeks to develop, acquire,and commercialize, itself or with partners, a diverse portfolio of nucleic acid-based therapeutics based on PCR-produced linearDNA to improve existing nucleic acid-based therapeutics or to create new nucleic acid-based therapeutics that address unmet medicalneeds. The Company is currently directly engaged in preclinical drug candidate development activities focusing on therapeutically-relevantDNA constructs manufactured via its LinearDNA        <sup>         TM        </sup>        platform in the fields of DNA-based anti-viral and anti-cancervaccines, CAR-T cell immunotherapy and the manufacture of rAAV vectors for gene therapy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          COVID-19 Diagnostic Testing         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 13, 2020 the Companyreceived an EUA from the FDA for the clinical use of the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit for the qualitative detectionof nucleic acid from SARS-CoV-2 in respiratory specimens including anterior nasal swabs, self-collected at a healthcarelocation or collected by a healthcare worker, and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs,nasopharyngeal washes/aspirates or nasal aspirates, and bronchoalveolar lavage specimens collected by a healthcare workerfrom individuals who are suspected of COVID-19 by their healthcare provider. Under the EUA, testing is limited tolaboratories certified under the Clinical Laboratory Improvement Amendments of 1988 , 42 U.S.C. §263a, that meetrequirements to perform high complexity tests, which certification we have applied for but have not yet obtained.Subsequently, during July and November 2020, the Company was granted EUA amendments that expand the installed baseof PCR equipment platforms on which our Linea        <sup>         TM        </sup>        COVID-19 Assay Kit can be processed and significantlyincreased the daily testing capacity of the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit through the use of automation. Thescope of the EUA, as amended, is expressly limited to use consistent with the Instructions for Use by authorizedlaboratories, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity tests.The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use ofin vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated or until the EUA’s prior termination orrevocation. The Company’s Linea        <sup>         TM        </sup>        COVID-19 Assay Kit has not been FDA cleared or approved, and theEUA’s limited authorization is only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses orpathogens. The Company currently manufactures the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit at its facilities in Stony Brook, NewYork.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 65; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE A – NATURE OF THE BUSINESS, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          COVID-19 Surveillance Testing         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Starting in July 2020, the Companyunder its wholly-owned subsidiary, ADCL, began offering COVID-19 pooled surveillance testing to customers as a Testing-as-a-Service(TaaS) offering branded under the safeCircle        <sup>         TM        </sup>        trademark. Unlike diagnostic testing, which looks for the occurrenceof COVID-19 at the individual level, safeCircle        <sup>         TM        </sup>        surveillance testing looks for infections within a defined populationor community and can be used for making health management decisions at the population level. safeCircle        <sup>         TM        </sup>        surveillancetesting uses high-sensitivity pooled COVID-19 testing utilizing the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit. Under the safeCircle        <sup>         TM        </sup>        surveillance testing service, pooled test results are returned to the sponsoring organization in the aggregate only, not directlyto the participating individuals, and may be performed without CLIA certification. Once potentially infected portions of a definedpopulation are identified by the safeCircle        <sup>         TM        </sup>        surveillance testing service, the individuals comprising the potentiallyinfected portions of the defined population are referred to follow on diagnostic testing at a clinical lab to obtain individualresults. ADCL is offering its safeCircle        <sup>         TM        </sup>        surveillance testing in compliance with current CDC, FDA, CMS and New YorkState Department of Health recommendations. The use of pooled sampling procedures for the safeCircle        <sup>         TM        </sup>        surveillancetesting service has been internally validated by ADCL in compliance with current CDC guidance. The use of pooled sampling proceduresis not included in the Linea        <sup>         TM        </sup>        COVID-19 Assay Kit EUA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company seeks to commercialize thesafeCircle        <sup>         TM        </sup>        surveillance testing TaaS offering with institutional clients such as schools, colleges and businesses.The Company currently provides safeCircle        <sup>         TM        </sup>        surveillance testing to several private schools, New York State-based smallenterprises and college athletic programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Clinical Testing Laboratory         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Under its ADCL subsidiary, the Companyhas applied to the New York State Department of Health for all necessary licensing to operate a New York State clinical diagnosticslaboratory. These applications are currently pending. The New York State Department of Health performed its initial inspectionof our clinical laboratory and identified deficiencies in the clinical standard of practice. These deficiencies need to be rectifiedbefore we can submit a request for re-inspection. We are working to rectify these deficiencies now. Through ADCL, the Company seeksto further commercialize its EUA authorized Linea COVID-19 Assay Kit and its iCTC Technology. ADCL is also performing testing servicesin support of the Company’s safeCircle        <sup>         TM        </sup>        surveillance testing services in accordance with current CDC, FDA, CMSand New York State Department of Health recommendations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         i         <u>          CTC Technology         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company previously acquired technologythat uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. Currently, theCompany’s iCTC Technology is being used in a human cancer drug candidate clinical trial. The Company seeks to further developand commercialize this technology and to potentially integrate aspects of the iCTC Technology with the LinearDNA        <sup>         TM        </sup>        platformfor cancer research and nucleic-acid based drug development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Non-Biological Tagging and Related Services        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s supply chain securitybusiness allows its customers to use non-biologic DNA (molecular) tags, manufactured via its LinearDNA        <sup>         TM        </sup>        platform,to mark objects, and then identify these objects by detecting the absence or presence of the molecular tag. The Company’score products include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           SigNature® Molecular Tags produced by the Company’s LinearDNA           <sup>            TM           </sup>           platform,provide an approach to authenticate goods within large and complex supply chains for materials such as cotton, and leather, in-hometextiles and apparel, pharmaceuticals and nutraceuticals, cannabis and other products.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           SigNify® IF portable DNA readers and SigNify consumable reagent test kits provide definitivereal-time authentication of molecular tags in the field, providing a front-line solution for supply chain integrity backed withforensic-level molecular tag authentication. Applied DNA’ssoftware platform enables customers to track materials throughout a supply chain or product life.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           CertainT® trademark indicates the use of Applied DNA’s tagging, testing and trackingplatforms and solutions, enabling manufacturers, brands and trade organizations to convey proof of their product claims.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 66; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            8            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Split-Segment; Name: 2 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE B – GOING CONCERN AND MANAGEMENT’S PLAN        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Applied DNA Sciences, Inc. (the “Company”)has recurring net losses, which have resulted in an accumulated deficit of $269,835,650 as of September 30, 2020. The Companyincurred a net loss of $13,028,904 and generated negative operating cash flow of $11,143,059 for the fiscal year ended September 30,2020. At September 30, 2019 the Company had cash and cash equivalents of $7,786,743 and working capital of $4,811,847. Thesefactors, along with the COVID-19 risks and uncertainties detailed below, raise substantial doubt about the Company’s abilityto continue as a going concern for one year from the issuance of the financial statements. The ability of the Company to continueas a going concern is dependent on the Company's ability to further implement its business plan, raise capital, and generate revenues.The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a goingconcern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s current capital resources include cash andcash equivalents, accounts receivable and inventories. Historically, the Company has financed its operations principally from thesale of equity and equity-linked securities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         COVID-19 Risks and Uncertainties        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In March 2020, the World HealthOrganization declared the outbreak of a novel coronavirus (“COVID-19”) as a pandemic which continues to spreadthroughout the United States. The Company is monitoring this, and it is unable to predict the impactthat COVID-19 will have on the Company’s future financial position and operating results due to numerousuncertainties. The Company believes that the COVID-19 pandemic adversely impacted the global textile industry, which hasresulted in a reduction of textile related revenues, specifically as it relates to our cotton customer contract. OnMarch 7, 2020 the Governor of New York declared a health emergency and issued an order (as amended) to close allnonessential businesses, which was followed by a phased reopening. Portions of the Company’s business were deemed to bean essential business, such as its government and pharmaceutical contracts, as well as its vaccine and diagnostic candidatedevelopment. However, we have experienced, and may continue to experience in the future, facility closures related to our “nonessential” businesses, and pursuant to the government order, the Company reduced the scope of its operations.As discussed in Note G below, the Company received a loan of approximately $847 thousand on May 1, 2020 from Bank ofAmerica as lender pursuant to the Paycheck Protection Program (“PPP”) of the Coronavirus Aid, Relief, andEconomic Security Act (the “CARES Act”) (See Note G for further details).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As a result of COVID-19 the Company hasexperienced a decline in revenues from non-biological tagging and related services, primarily as it relates to our cotton customercontract. Historically revenues from our cotton customer contracts are seasonal and recognized primarily during the Company’sfirst and fourth fiscal quarters. However, due to the impacts of the COVID-19 global pandemic, the Company did not recognize revenuefor the shipment of DNA concentrate relating to its cotton customer contract during the twelve months ended September 30,2020. Due to the rapid development and fluidity of this situation, the magnitude and duration of the pandemic and its impact onthe Company's future operations and liquidity is uncertain as of the date of this Annual Report.  While there could ultimatelybe a material impact on operations and liquidity of the Company, at the time of issuance, the impact could not be determined.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE C – BASIS OF PRESENTATIONAND SUMMARY OF ACCOUNTING POLICIES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On September 16, 2002, the Companywas incorporated under the laws of the State of Nevada. Effective December 2008, the Company reincorporated from the Stateof Nevada to the State of Delaware. The Company is principally devoted to developing and marketing linear DNA technologysolutions in the United States, Europe and Asia. To date, the Company has produced limited recurring revenues from its productsand services; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherentin the establishment and development of a biotechnology company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Principles of Consolidation        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The consolidated financial statements include the accounts ofthe Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc., Applied DNA Sciences Europe Limited, and Applied DNA SciencesIndia Private Limited, Applied DNA Clinical Labs, LLC and its majority-owned subsidiary, LRx. Applied DNA Clinical Labs, LLC wasformed in Delaware on June 12, 2020. Significant inter-company transactions and balances have been eliminated in consolidation. Tofacilitate comparison of information across periods, certain reclassifications have been made to prior year amounts to conformto the current year’s presentation. To facilitate comparison of information across periods, certain reclassificationshave been made to prior year amounts to conform to the current year’s presentation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On October 31, 2019, the Company filed a Certificate ofAmendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-forty(1:40) reverse stock split of its common stock, par value $.001 per share, effective November 1, 2019. All warrant, option,share, and per share information in the consolidated financial statements gives retroactive effect to a one-for-forty reverse stocksplit that was affected on November 1, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Use of Estimates        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The preparation of the financialstatements in conformity with Accounting Principles Generally Accepted in the United States of America (“GAAP”)requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management basesits estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances,the results of which form the basis for making judgments about the carrying value of assets and liabilities that are notreadily apparent from other sources. The most complex and subjective estimates include revenue recognition, recoverability oflong-lived assets, including the values assigned to goodwill, intangible assets and property and equipment, fair valuecalculations for stock based compensation, contingencies, allowance for doubtful accounts and management’s anticipatedliquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in theconsolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ fromthose estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 67; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            9            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE C – BASIS OF PRESENTATIONAND SUMMARY OF ACCOUNTING POLICIES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Revenue Recognition        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We follow Financial Accounting StandardsBoard (“FASB”) issued accounting standard updates which clarify the principles for recognizing revenue arising fromcontracts with customers (“ASC 606” or “Topic 606”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The core principle of the revenue standardis that an entity recognizes revenue to depict the transfer of promised goods or services to clients in an amount that reflectsthe consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 applies a five-stepmodel for revenue measurement and recognition and also requires increased disclosures including the nature, amount, timing, anduncertainty of revenue and cash flows related to contracts with clients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        The Company measuresrevenue at the amounts that reflect the consideration to which it is expected to be entitled in exchange for transferring controlof goods and services to customers. The Company recognizes revenue either at the point in time or over the period of time thatperformance obligations to customers are satisfied. The Company’s contracts with customers may include multiple performanceobligations (e.g. taggants, maintenance, authentication services, research and development services, etc.). For such arrangements,the Company allocates revenues to each performance obligation based on their relative standalone selling price.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company recognizes revenue upon transferof control of promised goods or services to customers in an amount that reflects the consideration it expects to receive for thosegoods or services, including any variable consideration.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Due to the short-term nature of the Company’scontracts with customers, it has elected to apply the practical expedients under Topic 606 to: (1) expense as incurred, incrementalcosts of obtaining a contract and (2) not adjust the consideration for the effects of a significant financing component forcontracts with an original expected duration of one year or less.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <i>         Product Revenuesand Authentication Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s PCR-producedlinear DNA products, are manufactured in accordance with contracts with customers. The Company recognizes revenue uponsatisfying its promises to transfer goods or services to customers under the terms of its contracts. These performanceobligations are satisfied at the point in time the Company transfers control of the goods to the customer, which in nearlyall cases is when title to and risk of loss of the goods transfer to the customer. The timing of transfer of title and riskof loss is dictated by customary or explicitly stated contract terms. The Company does not consider payment terms of aperformance obligation for customers with contractual terms that are one year or less and has elected the practicalexpedient. Nearly all of the Company’s sales contracts reflect market pricing at the time the contract is executed, orare one year or less, and generally provide for shipment within 30 to 60 days after the price has been agreed upon with thecustomer. The Company invoices customers upon shipment, and its collection terms range, on average, from 30 to 60 days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <i>         Authentication Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company recognizes revenue for authenticationservices upon satisfying its promises to provide services to customers under the terms of its contracts. These performance obligationsare satisfied at the point in time the Company services are complete, which in nearly all cases is when the authentication reportis released to the customer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Clinical Laboratory Testing Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company records revenue for its clinical laboratory testingservice contracts, which includes its COVID-19 Surveillance Testing, upon satisfying its promise to provide services to customersunder the terms of its contracts. These performance obligations are satisfied at the point in time that Company services are complete,which is nearly all cases is when the testing results are released to the customer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Research and Development Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company records revenue for its researchand development contracts using the over-time revenue recognition model. Revenue is primarily measured using the cost-to-cost method,which the Company believes best depicts the transfer of control to the customer.  Under the cost-to-cost method, theextent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expectedupon satisfying the identified performance obligation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Revenues are recorded proportionally ascosts are incurred. For contracts where the total costs cannot be estimated, revenues are recognized for the actual costs incurredduring a period until the remaining costs to complete a contract can be estimated. The Company has elected to not disclose thevalue of unsatisfied performance obligations for contracts with an original expected duration of one year or less.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 68; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            10            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE C – BASIS OF PRESENTATIONAND SUMMARY OF ACCOUNTING POLICIES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Disaggregation of Revenue        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following table presents revenues disaggregatedby our business operations and timing of revenue recognition:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center">           Fiscal Years Ended:          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           September 30,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left">           Research and development services (over-time)          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           1,128,511          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           2,975,961          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Clinical laboratory testing services (point-in-time)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           81,947          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           --          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Product and authentication services (point-in-time):          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Supply chain          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           38,577          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,438,106          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Asset marking          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           400,491          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           587,012          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Large scale DNA production          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           281,971          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           388,010          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Total          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,931,497          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           5,389,089          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <i>         Contract balances        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        As of September 30, 2020, theCompany has entered into contracts with customers for which revenue has not yet been recognized. Consideration received from acustomer prior to revenue recognition is recorded to a contract liability and is recognized as revenue when the Company satisfiesthe related performance obligations under the terms of the contract. The Company’s contract liabilities, which are reportedas deferred revenue on the consolidated balance sheet, consist almost entirely of research and development contracts where considerationhas been received and the development services have not yet been fully performed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        The opening and closing balances ofthe Company’s contract balances are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Balance sheet classification          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           October 1,           <br/>           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           September 30,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           $           <br/>           change          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%; font-size: 10pt; text-align: left">           Contract liabilities          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 20%; font-size: 10pt; text-align: left">           Deferred revenue          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           628,993          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           511,036          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           ($          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           117,957          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        For the fiscal year ended September 30,2020, the Company recognized $591,360 of revenue that was included in Contract liabilities as of October 1, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Cash Equivalents        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the purpose of the accompanying consolidated financial statements,all highly liquid investments with a maturity of three months or less are considered to be cash equivalents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Accounts Receivable        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company provides an allowance for doubtful accounts equalto the estimated uncollectible amounts. The Company’s estimate is based on historical collection experience and a reviewof the current status of trade accounts receivable. It is reasonably possible that the Company’s estimate of the allowancefor doubtful accounts may change.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Trade accounts receivable are recorded at the invoiced amountand do not bear interest. The Company classifies receivable amounts as current or long-term based on expected payment and records long-termaccounts receivable when the collection period is expected to be greater than one year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At September 30, 2020 and 2019, the Company has an allowancefor doubtful accounts of $11,968 and $4,500, respectively. The Company writes-off receivables that are deemed uncollectible.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 69; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            11            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE C – BASIS OF PRESENTATIONAND SUMMARY OF ACCOUNTING POLICIES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Inventories        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Inventories, which consist primarily of raw materials, workin progress and finished goods, are stated at the lower of cost or net realizable value, with cost determined by using the first-in,first-out (FIFO) method.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Income Taxes        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company accounts for income taxes in accordance with ASC740, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for theexpected future tax consequences of events that have been included in the financial statement or tax returns. Under this method,deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assetsand liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differencesbetween taxable income reported for financial reporting purposes and income tax purposes include, but not limited to, accountingfor intangibles, equity based compensation and depreciation and amortization. The Company evaluates the recoverability of deferredtax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax assetwill not be realized. During the fiscal years ended September 30, 2020 and 2019, the Company incurred losses from operations.Based upon these results and the trends in the Company’s performance projected for fiscal year 2021, it is more likely thannot that the Company will not realize any benefit from the deferred tax assets recorded by the Company in previous periods. Managementmakes judgments as to the interpretation of tax laws that might be challenged upon an audit and cause changes to previous estimatesof tax liability. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxableincome by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary. The Companyhas identified its federal tax return and its state tax return in New York as “major” tax jurisdictions. Based on theCompany’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition inthe Company’s consolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company believes that its income tax positions and deductionswill be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.It is the Company’s policy to accrue interest and penalties on unrecognized tax benefits as components of income tax provision.The Company did not have any accrued interest or penalties as of September 30, 2020 and 2019. Tax years 2016 through 2019remain subject to future examination by the applicable taxing authorities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Property and Equipment        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Property and equipment are stated at cost and depreciated usingthe straight line method over their estimated useful lives. The estimated useful life for computer equipment, lab equipment andfurniture is 3 years and leasehold improvements are amortized over the shorter of their useful life or the remaining lease terms.Property and equipment consist of:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <b>            September 30,           </b>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2020           </b>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2019           </b>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 74%">           Computer equipment          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           $          </td>          <td style="width: 10%; text-align: right">           90,509          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           $          </td>          <td style="width: 10%; text-align: right">           90,509          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           Lab equipment          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           3,036,397          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           2,060,520          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           Furniture          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           74,781          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           74,781          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           Leasehold improvements          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           524,485          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           293,672          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 8.65pt">           Total          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           3,726,172          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           2,519,482          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           Accumulated depreciation          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           2,448,517          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           2,293,261          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">           Property and equipment, net          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           $          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           1,277,655          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           $          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           226,221          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of September 30, 2020 there was$214,101 and $571,440 of construction in progress that was included in lab equipment and leasehold improvements, respectively.Depreciation expense for the fiscal years ended September 30, 2020 and 2019 were $156,290 and $260,992, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 70; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            12            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE C – BASIS OF PRESENTATIONAND SUMMARY OF ACCOUNTING POLICIES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Impairment of Long-Lived Assets        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company evaluates its long lived assets for impairment wheneverevents or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverabilitymay include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-evenoperating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecastedundiscounted cash flows. Should impairment in value be indicated, the carrying value of long-lived assets will be adjusted, basedon estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Net Loss per Share        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company presents loss per share utilizing a dual presentationof basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weightedaverage number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable uponthe exercise of the Company’s stock options, warrants and secured convertible notes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the fiscal years ended September 30, 2020 and 2019,common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Securities that could potentially dilute basic net income pershare in the future that were not included in the computation of diluted net loss per share because to do so would have been antidilutivefor the fiscal years ended September 30, 2020 and 2019 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2020           </b>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2019           </b>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 74%">           Warrants          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           1,038,919          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           263,592          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           Options          </td>          <td style="padding-bottom: 1pt">          </td>          <td>          </td>          <td style="text-align: right">           291,035          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td>          </td>          <td style="text-align: right">           199,395          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           Secured convertible note          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           70,962          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           74,282          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           1,400,916          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           573,269          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Stock-Based Compensation        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company accounts for stock-based compensationfor employees, directors and nonemployees in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires allshare-based payments, including grants of employee stock options, to be recognized in the statement of operations based on theirfair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fairvalue of the award, and are recognized as expense over the requisite service period (generally the vesting period of the equitygrant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model withthe following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expensesstock-based compensation by using the straight-line method. In accordance with ASC 740, excess tax benefits realized from the exerciseof stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (includingtax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the consolidated statementsof operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Concentrations        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Financial instruments and related items, which potentiallysubject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Companyplaces its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of theFDIC insurance limit. As of September 30, 2020 the Company had cash and cash equivalents of approximately $7.3 million in excessof the FDIC insurance limit.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s revenues earned from sale of products andservices for the fiscal year ended September 30, 2020 included an aggregate of 13%, 12%, 11% and 10% respectively from fourcustomers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s revenues earned from sale of products andservices for the fiscal year ended September 30, 2019 included an aggregate of 27%, 26% and 15%, respectively from three customers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 71; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            13            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE C – BASIS OF PRESENTATIONAND SUMMARY OF ACCOUNTING POLICIES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Four customers accounted for 74% of the Company’s accountsreceivable at September 30, 2020 and one customer accounted for an aggregate of 77% of the Company’s total accountsreceivable at September 30, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Research and Development        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company accounts for research and development costs in accordancewith the ASC 730, Research and Development (“ASC 730”). Under ASC 730, all research and development costs must be chargedto expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research anddevelopment costs are expensed when the contracted work has been performed. Company-sponsored research and development costs relatedto both present and future products are expensed in the period incurred. During the fiscal years ended September 30, 2020and 2019, the Company incurred research and development expenses of $3,321,763 and $2,967,278, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Advertising        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company follows the policy of charging the costs of advertisingto expense as incurred. The Company charged to operations approximately $55,558 and $133,000, as advertising costs for the fiscalyears ended September 30, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Goodwill and Other Intangible Assets        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company amortizes its intangible assets using the straight-linemethod over their estimated period of benefit. All of the Company’s intangible assets, except for goodwill are subject toamortization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Goodwill arises as a result of business acquisitions. Goodwillconsists of the excess of the cost of the acquisitions over the tangible and intangible assets acquired and liabilities assumed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company evaluates goodwill for impairment at least annually.The Company qualitatively and quantitatively determines whether, more likely than not, the fair value exceeds the carrying amountof a reporting unit. There are numerous assumptions and estimates underlying the quantitative assessments including future earnings,long-term strategies, and the Company’s annual planning and forecasts. If these planned initiatives do not accomplish thetargeted objectives, the assumptions and estimates underlying the quantitative assessments could be adversely affected and havea material effect upon the Company’s financial condition and results of operations. As of September 30, 2020 and 2019,the Company performed its qualitative assessment of goodwill and indicated that there was no impairment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="background-color: white">         <u>          InternallyDeveloped Software         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="background-color: white">         Internally developed softwareproducts, consist of capitalized costs associated with the development of computer software to be sold, leased or otherwise marketed.Software development costs associated with new products are expensed as incurred until technological feasibility, as defined inFASB ASC Topic 985-20, has been established. Costs incurred thereafter are capitalized until the product is made generally available.The stage during the Company’s development process for a new product or new release at which technological feasibility requirementsare established affects the amount of costs capitalized. Annual amortization of internally developed software products is the greaterof the amount computed using the ratio that current gross revenues for a product bear to the total of current and anticipated futuregross revenues for that product or the straight-line method over the remaining estimated economic life of the software product,generally estimated to be 3 years from the date the product became available for general release to customers. The Companygenerally recognizes amortization expense for capitalized software costs using the straight-line method. Internally developed softwareproducts are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an assetmay not be recoverable and its carrying amount exceeds its fair value.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 72; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            14            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         NOTES TO CONSOLIDATEDFINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE C – BASIS OF PRESENTATIONAND SUMMARY OF ACCOUNTING POLICIES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <u>         ConvertibleInstruments        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        The Company accounts forconvertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their hostinstruments) in accordance with ASC 470-20, Debt with Conversion and Other Options. Accordingly, the Company records, whennecessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments basedupon the differences between the fair value of the underlying common stock at the commitment date of the note transaction andthe effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term ofthe related debt to their earliest date of redemption.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Fair Value of Financial Instruments        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The valuation techniques utilized are based upon observableand unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflectinternal market assumptions. These two types of inputs create the following fair value hierarchy:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">        Level 1 — Quoted prices in active markets for identical assets or liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 73; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE C – BASIS OF PRESENTATIONAND SUMMARY OF ACCOUNTING POLICIES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">        Level 2 — Observable inputsother than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not activeor other inputs that are observable or can be corroborated by observable market data for substantially the full term of the relatedasset or liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">        Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assetsor liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company utilizes observable marketinputs (quoted market prices) when measuring fair value whenever possible.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For fair value measurements categorized within Level 3 of thefair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determineits valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurementsand fair value calculations are the responsibility of the Company’s accounting and finance department and are approved bythe Chief Financial Officer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of September 30, 2020, there wereno transfers between Levels 1, 2 and 3 of the fair value hierarchy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Summary of Significant Valuation Techniques        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Level 3 Measurements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Secured convertible notes payable:        </u>        For the Existing Notes (as defined in Note G), the Company has elected to record them at fair value. The fair value for the ExistingNotes is estimated using the Monte Carlo simulation model. Significant observable and unobservable inputs include stock price,conversion price, annual risk free rate, term, likelihood of an event of default, and expected volatility. An increase or decreasein these inputs could significantly increase or decrease the fair value of the secured convertible notes payable (see Note G).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Recent Accounting Standards        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In August 2020, the FASB issuedASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives andHedging— Contracts in Entity’s Own Equity (Subtopic 815-40).” The objective of this update is to simplifythe accounting for convertible preferred stock by removing the existing guidance in ASC 470-20, “Debt: Debt withConversion and Other Options,”, that requires entities to account for beneficial conversion features and cashconversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the hostcontract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accountingin ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s ownstock and classified in stockholders’ equity, by removing certain criteria required for equity classification. Theseamendments are expected to result in more freestanding financial instruments qualifying for equity classification (and,therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the hostcontract. This amendment also further revises the guidance in ASU 260, “Earnings per Share,” to require entitiesto calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition,entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash orshares. The amendments in ASU 2020-06 are effective for fiscal years beginning after December 15, 2023, with earlyadoption permitted. The Company does not expect the adoption of ASU 2020-06 to have a significant impact on its consolidatedfinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In February 2016, the FASB issuedASU No. 2016-02, "Leases (Topic 842)." The objective of this update is to increase transparency and comparabilityamong organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information aboutleasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periodswithin those annual periods and is to be applied utilizing a modified retrospective approach. The Company adopted Topic 842 asof October 1, 2019 utilizing the modified retrospective approach. The adoption of Topic 842 did not have a significant impacton its consolidated financial statements, as the Company does not currently have any long-term lease obligations. The Company haselected the short-term lease measurement and recognition exemption as all of the Company’s leases are for twelve months orless.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 74; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            16            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE D– INVENTORIES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Inventories consist of the following at September 30, 2020and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2020           </b>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2019           </b>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%">           Raw materials          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           $          </td>          <td style="width: 10%; text-align: right">           387,815          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           $          </td>          <td style="width: 10%; text-align: right">           87,886          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Work in progress          </td>          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: right">           77,667          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           -          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           Finished goods          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           31,885          </td>          <td style="border-bottom: Black 1pt solid">          </td>          <td style="border-bottom: Black 1pt solid">          </td>          <td style="border-bottom: Black 1pt solid">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           54,743          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Total          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">           $          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           497,367          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">           $          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           142,629          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 75; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE E – INTANGIBLE ASSETS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Intangible assets at September 30, 2020 and 2019 are asfollows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left">           Internally developed software (5-year useful life)          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           157,221          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           157,221          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Customer relationships (10-year useful life)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           621,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           621,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Intellectual property (5-15 years)          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           917,350          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           917,350          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,695,571          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,695,571          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Less:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Accumulated amortization          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,090,241          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           960,800          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Intangible assets, net          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           605,330          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           734,771          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Total amortization expense charged to operationsfor the fiscal years ended September 30, 2020 and 2019 were $129,441 and $129,432, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table presents the estimated amortization expenseof the intangible assets for each of the five succeeding years as of September 30, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Amount          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 86%; font-size: 10pt; text-align: left">           2021          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           91,967          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           2022          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           91,967          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           2023          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           91,967          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           2024          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           91,967          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           2025          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           89,379          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Thereafter          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           148,083          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Total          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           605,330          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 76; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            18            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE F – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Accounts payable and accrued liabilities at September 30,2020 and 2019 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left">           Accounts payable          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           1,250,021          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           1,152,103          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Accrued salaries payable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           525,602          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           319,260          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Other accrued expenses          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           150,804          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           145,634          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Total          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,926,427          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,616,997          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE G –NOTES PAYABLE        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         CARES Act Loan        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company received a loan of approximately$847 thousand on May 1, 2020 from Bank of America as lender pursuant to the PPP of the CARES Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        All or a portion of the loan may be forgivenby the U.S. Small Business Administration (“SBA”) upon application by the Company beginning 60 days but not later than130 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act,loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and coveredutilities during the covered period as defined by the CARES Act. The Company used the proceeds from the loan to retain employees,maintain payroll and make lease and utility payments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For purposes of the CARES Act, payrollcosts exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 40% of the forgivenamount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employeeswith salaries of $100,000 or less annually are reduced by more than 25%. In the event the loan, or any portion thereof, is forgivenpursuant to the PPP, the amount forgiven is applied to outstanding principal.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The loan matures on May 1, 2022 andbears interest at a rate of 1% per annum. Payments of principal and interest commence in November 2020. The loan may be prepaidby the Company at any time prior to maturity with no prepayment penalties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Secured Convertible Notes Payable         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On August 31, 2018, the Company entered into a securitiespurchase agreement (the “Purchase Agreement”) with accredited investors and certain members of its management teamand Board of Directors (the “Purchasers”), pursuant to which the Company issued and sold an aggregate of $1,650,000in principal amount of secured convertible notes (the “August 2018 Notes”) bearing interest at a rate of 6% perannum. As part of the August 2018 Notes, the Company’s management and Board of Directors purchased August 2018Notes with a principal amount of $1,185,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The August 2018 Notes are convertible, in whole or inpart, at any time, at the option of the Purchasers, into shares of the Company’s common stock, in an amount determined bydividing the principal amount of each August 2018 Note, together with any and all accrued and unpaid interest, by the conversionprice of $100.00.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 77; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            19            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE G – NOTESPAYABLE, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The August 2018 Notes bear interest at the rate of 6% perannum, payable semi-annually in cash or in kind, at the Company’s option, and were due and payable in full on August 30,2021. Until the principal and accrued but unpaid interest under the August 2018 Notes is paid in full, or converted into sharesof common stock pursuant to their terms, the Company’s obligations under the August 2018 Notes were secured by a lienon substantially all assets of the Company (excluding certain cash accounts) and the assets of APDN (B.V.I.) Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On November 29, 2018, the Company closed a securities purchaseagreement with its chairman, president and chief executive officer and one member of the management team, pursuant to which theCompany issued and sold an aggregate of $550,000 in principal amount of secured convertible notes bearing interest at a rate of6% per annum (the “November 2018 Notes”). The November 2018 Notes are substantially similar to the Company’sAugust 2018 Notes except with respect to maturity date, which is November 29, 2021 The November 2018 Notes are securedon a        <i>         pari passu        </i>        basis with the same Company assets as the August 2018 Notes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On July 17, 2019, the Company closed $1.5 million in grossproceeds in July 2019 Notes, bearing interest at a rate of 6% per annum, in a non-brokered private placement with an accreditedinvestor, Dillon Hill Capital, LLC (“Dillon Hill”) and simultaneously amended the terms of the 2018 Notes and, (togetherwith the July 2019 Notes, the “Company Notes”) to, among other amendments, (i) reduce the conversion priceof the 2018 Notes to $21.60 to facilitate their conversion into equity and (ii) change the maturity date of the August 2018Notes to be November 28, 2021. In addition, Dillon Hill was granted a right to participate in certain future financing transactionsof the Company (each a “Subsequent Financing”) until July 16, 2020 equal to the amount required for Dillon Hillto maintain its pro rata ownership of the Company as if the July 2019 Notes had been fully converted into common stock. UntilJuly 16, 2020, Dillon Hill has the right to participate in full for the first $1 million of such Subsequent Financing. Thisright was exercised and Dillon Hill participated in the November 2019 underwritten public offering.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        After giving effect to the amendments to the 2018 Notes, theJuly 2019 Notes are substantially similar to the Existing Notes. The July 2019 Notes are secured on a        <i>         pari passu        </i>        basiswith the same Company assets as the 2018 Notes. In addition, on July 19, 2019, the Company also amended the security agreementsdated as of October 19, 2018, to among other amendments, exclude 20% of the Company’s equity interest in LRx from theassets securing the Company Notes. The July 2019 Notes are convertible, in whole or in part, at any time, at the option ofDillon Hill, into shares of common stock, in an amount determined by dividing the principal amount of the July 2019 Notes,together with any and all accrued and unpaid interest, by the conversion price of $21.60 (the “Conversion Price”).The July 2019 Notes are due and payable in full on November 28, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has the right to require DillonHill to convert all or any part of their Notes into shares of the Company’s common stock at the Conversion Price if theprice of the Common Stock remains at a closing price of $140.00 or more for a period of twenty consecutive trading days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 78; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            20            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE G – NOTESPAYABLE, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The amendments to the 2018 Notes resulted in a change in fairvalue of the conversion option that exceeded ten percent of the carrying amount of the 2018 Notes. Accordingly, the amendment wastreated as an extinguishment of the 2018 Notes and a corresponding loss on extinguishment of debt of $1,260,399. The fair valueof the 2018 Notes immediately after the amendments (“Amended 2018 Notes”) was $3,498,457. Going forward, the Companyhas elected to record the Amended 2018 Notes at fair value in accordance with ASC 825. As a result, the Company recorded a gainon the change in fair value of $65,576 for the year ended September 30, 2019. The July 2019 Notes are recorded at carryingvalue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During September 2019, a total of $2.2 million of the Amended2018 Notes was converted into 102,893 shares of the Company’s common stock. As part of the total amount converted, Dr. JamesA. Hayward, our Chairman, Chief Executive Officer and President (“CEO”), converted approximately $1.59 million of theAmended 2018 Notes, into approximately 73,400 shares of the Company’s common stock, and other directors, officers, and affiliatesof the Company converted approximately $409,000 of such 2018 Notes in September 2019 into 18,929 shares of the Company’scommon stock. The fair value of the Amended 2018 Notes was calculated immediately prior to conversion and resulted in a gain onthe change in fair value of the Amended 2018 Notes of approximately $1,907,379.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During December 2019, the remainingoutstanding balance of the 2018 Notes, for a total of $107,802, was repaid by the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the fiscal year ended September 30,2020 and 2019, the Company reclassified $35,625 and $126,980, respectively from accrued liabilities to senior secured notes payableto represent interest due to noteholders that was paid in kind and therefore increasing the convertible note balance outstandingat September 30, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        The Company incurred $64,848 to debt issuance costs based onthe cost incurred to complete the 2018 Notes financing, which was written off as part of the extinguishment accounting discussedabove. The Company incurred $64,608 to debt issuance costs based on the cost incurred to complete the July 2019 Notes. Duringthe fiscal years ended September 30, 2020 and 2019 the Company amortized $26,019 and $23,828, respectively, of debt issuancecosts resulting in unamortized debt issuance costs of $34,094 and the secured notes payable of $1,499,116 at September 30,2020. The debt issuance cost will be amortized over the life of the July 2019 Notes. During the fiscal years ended September 30,2020 and 2019, the Company incurred $116,786 and $138,604, respectively of interest expense. The effective interest rate for thefiscal years ended September 30, 2020 and 2019 was 8.0% and 7.5%, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As discussed more fully in Note O, the Company repaid the July 2019Notes in full during October 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 79; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            21            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE H – CAPITAL STOCK        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On October 31, 2019, the Company filed a Certificate ofAmendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-forty(1:40) reverse stock split of its common stock, par value $.001 per share, effective November 1, 2019. All warrant, option,share, and per share information in the consolidated financial statements gives retroactive effect to the one-for-forty reversestock split that was effected on November 1, 2019.        <i>        </i>        On September 16, 2020, the Company filed a Certificateof Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware that reduced its authorizedshares of common stock from 500,000,000 to 200,000,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Common Stock Transactions during the Fiscal Year Ended September 30,2020:        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On November 15, 2019, the Companyclosed an underwritten public offering (the “Offering”) in which, pursuant to the Underwriting Agreement datedNovember 13, 2019 by and between the Company and Maxim Group LLC (“Maxim”), as Representative of the Underwriters,the Company issued and sold 2,285,000 shares of the Company’s common stock and 2,285,000 accompanying warrants each withthe right to purchase one share of common stock at an exercise price of $5.25 per share (the “Common Warrants”). Theshares of common stock and accompanying Common Warrants were sold at a combined offering price of $5.25 before underwriting discounts.The common stock and the 2019 Warrants are collectively referred to herein as the “Securities.” As part of the Offering,the Company granted Maxim a 45-day option to purchase an additional 342,750 shares of common stock and/or additional Common Warrantsto purchase 342,750 shares of common stock (the “Option Warrants”, together with the 2019 Warrants, the “Warrants”)at the public offering price, less discounts and commissions, to cover any over-allotments made by the Underwriters in the saleand distribution of the Securities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The exercise price and number of the sharesof common stock issuable upon the exercise of the Common Warrant will be subject to adjustment in the event of any stock dividendsand splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As a result of this financing, the exerciseprice of the 8,375 remaining warrants issued during December 2018 was reduced to an exercise price of $5.60 per share in accordancewith the adjustment provision contained in the Warrant Agreement. The incremental change in fair value of these warrants as a resultof the triggering event was $2,842.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the fiscal year ended September 30,2020, 1,649,786 of the 2019 Warrants were exercised, resulting in net proceeds to the Company of approximately $8.1 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Subsequent to September 30, 2020,an additional 518,551 warrants were exercised for total net proceeds, of approximately $2.6 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 80; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            22            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE H – CAPITAL STOCK, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Common Stock Transactions during the Fiscal Year Ended September 30,2019:        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On August 22, 2019, the Company issued and sold 38,704shares of common stock at a price of $10.80 per share for total gross proceeds of $418,000 to a group of accredited investors,including its chief executive officer, president and chairman of the board of directors, its chief information officer, and a 5%or greater stockholder.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On December 21, 2018, the Company entered into an underwritingagreement (the “Agreement”) with Maxim , as the sole underwriter and book running manager, with respect to the issuanceand sale of an aggregate of 137,500 shares (the “Shares”) of common stock, together with warrants to purchase an aggregateof 137,500 shares of common stock (the “Warrants”) at an exercise price equal to $20.00 per share of common stock (the “Exercise Price”) in an underwritten public offering. The public offering price for each Share together with the accompanyingWarrant was $20.00. Pursuant to the Agreement, the Company also granted Maxim a 45-day option to purchase an additional 20,625Shares and/or additional Warrants to purchase 20,625 Shares to cover any over-allotments made by the underwriters in the sale anddistribution of the Shares and Warrants. The gross proceeds of the offering, before deducting underwriter discounts and commissionsand other offering expenses, were $2,750,000. The offering closed on December 26, 2018. On December 26, 2018, Maxim partiallyexercised its overallotment option and purchased an additional 20,000 Warrants at a price of $0.0000004 per Warrant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        After deducting underwriting discounts and commissions and otherexpenses related to the offering, the aggregate net proceeds were approximately $2,262,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On January 25, 2019, the Company closed on the underwriters’partial exercise of its over-allotment option for 12,500 shares of common stock for gross proceeds of $250,000. After deductingunderwriting discounts and commissions and other expenses related to the over-allotment option, the aggregate net proceeds wereapproximately $201,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The total number of common stock and Warrants issued under thisoffering, including the exercise of the over-allotment option was 150,000 and 157,500, respectively. The gross proceeds to us wereapproximately $3.0 million and net proceeds after deducting underwriting discounts and commissions and other estimated offeringexpenses was approximately $2.5 million.       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Warrants are immediately exercisablebeginning on the date of issuance (the “Initial Exercise Date”). The Warrants will be exercisable for five years fromthe Initial Exercise Date, but not thereafter.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Warrants include an adjustmentprovision that, subject to certain exceptions, reduces their exercise price if the Company issues common stock or commonstock equivalents at a price lower than the then-current exercise price of the Warrants, subject to a minimum exercise priceof $5.60 per share. The exercise price and number of the shares of the Company’s common stock issuable upon theexercise of the Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split,recapitalization, reorganization or similar transaction, as described therein. In addition, on or after any trading day 75days after the closing date of the offering, if the daily volume weighted average price of the Company’s common stockfails to exceed the Exercise Price, the aggregate number of warrant shares issuable in a cashless exercise shall equal theproduct of (i) the aggregate number of warrant shares that would be issuable upon exercise of the Warrants if suchexercise were by means of a cash exercise and (ii) 0.70.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As a result of the 2019 private placement offering of the Company’scommon stock, the exercise price of these warrants was reduced to $12.00 per share. The incremental change in fair value of thesewarrants as a result of the triggering event was $78,785. Subsequently, as a result of the underwritten public offering on November 15,2019, the exercise price of these warrants was further reduced to $5.60 per share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As a result of the Company’s stock price falling below$20.00, 143,252 warrants have been cashlessly exercised. These exercises resulted in the issuance of 100,617 shares of the Company’scommon stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As a result of this financing, the exercise price of the 68,375warrants issued during December 2017 was reduced to an exercise price of $17.60 per share in accordance with the adjustmentprovision contained in the warrant agreement. The incremental change in fair value of these warrants as a result of the triggeringevent was $281,042.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 81; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            23            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE I – STOCK OPTIONS AND WARRANTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Warrants        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Transactions involving warrants (see Note H) are summarizedas follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Number of           <br/>           Shares          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Weighted Average           <br/>           Exercise Price Per           <br/>           Share          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt">           Balance at October 1, 2019          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           263,592          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           131.12          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Granted          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,636,125          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           5.25          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Exercised          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1,649,786          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (5.25          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Cancelled or expired          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (211,012          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (135.01          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Balance, September 30, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,038,919          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           10.83          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Stock Options        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During June 2020, the Board of Directors and subsequentlyduring September 2020, the holders of a majority of the outstanding shares of common stock approved the 2020 Equity IncentivePlan (the “2020 Incentive Plan”). The 2020 Incentive Plan, among other things, reserves an additional 3,500,000 sharesof the Company’s common stock for issuance in the form of equity-based awards to employees, directors, consultants, and otherservice providers, and those of the Company’s affiliates. The maximum total grant date fair value of awards granted underthe 2020 Incentive Plan to individuals in their capacity as non-employee directors may not exceed $250,000 in any single calendaryear. The 2020 Incentive Plan’s expiration date is September 15, 2030.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The 2020 Incentive Plan is designed toretain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company'ssuccess with an award of options to purchase shares of common stock. As of September 30, 2020, a total of 6,894 shares havebeen issued and options to purchase 303,911 shares have been granted under the Company’s Incentive Plans.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In 2005, the Board of Directors and the holders of a majorityof the outstanding shares of common stock approved the 2005 Incentive Stock Plan, as amended and restated as of January 21,2015 (the “2005 Incentive Plan”, collectively with the 2020 Incentive Plan, the “Company’s Incentive Plans”).Effective as of September 16, 2020, no further awards will be made under the Company’s 2005 Incentive Stock Plan, asamended and restated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 82; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            24            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE I – STOCK OPTIONS AND WARRANTS, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Stock Options        </u>        , continued       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Transactions involving stock options issued are summarized asfollows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Number of           <br/>           Shares          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Weighted Average           <br/>           Exercise Price Per           <br/>           Share          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Aggregate           <br/>           Intrinsic           <br/>           Value          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Contractual           <br/>           Life (years)          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 48%; font-size: 10pt">           Outstanding at October 1, 2019          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           199,395          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           99.68          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Granted          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           155,395          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           8.45          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Exercised          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Cancelled or expired          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (63,755          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           42.08          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Outstanding at September 30, 2020          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           291,035          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           63.25          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 1pt">           Vested at September 30, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           200,407          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           87.22          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           6.67          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Non-vested at September 30, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           90,628          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           10.25          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           9.61          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the fiscal year ended September 30, 2020, the Companyissued an aggregate of 155,395 options to employees and non-employee board of director members and consultants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the fiscal year ended September 30, 2019, the Companyissued an aggregate of 86,349 (including award modifications of 35,040) options to employees, consultants, members of the strategicadvisory board and non-employee board of director members.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The fair value of options granted during the fiscal years endedSeptember 30, 2020 and 2019 was determined using the Black Scholes Option Pricing Model. For the purposes of the valuationmodel, the Company used the simplified method for determining the granted options expected lives. The simplified method is usedsince the Company does not have adequate historical data to utilize in calculating the expected term of options. The fair valuefor options granted was calculated using the following weighted average assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt">           Stock price          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           8.40          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           32.82          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Exercise price          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           8.45          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           100.65          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Expected term          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           6.85          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           4.40          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Dividend yield          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Volatility          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           136          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           89          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Risk free rate          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           0.86          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2.43          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company recorded $1,001,082 and $1,129,110as stock compensation expense within selling, general and administrative for fiscal years ended September 30, 2020 and 2019,respectively. Included in this amount is $221,046 for the fiscal year ended September 30, 2019 for employee stock optionmodifications. As of September 30, 2020, unrecorded compensation cost related to non-vested awards was $540,594 which isexpected to be recognized over a weighted average period of approximately 0.79 years. The weighted average grant date fair valueper share for options granted during the fiscal years ended September 30, 2020 and 2019 was $7.49 and $11.51, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 83; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            25            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE J – INCOME TAXES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The income tax provision (benefit) for the fiscal years endedSeptember 30, 2020 and 2019 consists of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Federal:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Current          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; padding-bottom: 1pt">           Deferred          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (2,914,000          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (1,658,000          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (2,914,000          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1,658,000          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           State and local:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Current          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 1pt">           Deferred          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (591,000          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           308,000          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (591,000          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           308,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Foreign:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Current          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           15,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 1pt">           Deferred          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           15,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Change in valuation allowance          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           3,505,000          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,350,000          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Income tax provision (benefit)          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           15,000          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        The provision for income taxes differs from the amount of incometax determined by applying the applicable U.S. statutory rate to losses before income tax expense for the years ended September 30,2020 and 2019 as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Statutory federal income tax rate          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           21.00          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           %          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           21.00          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Statutory state and local income tax rate (1%, as of September 30, 2019 and 2018), net of federal benefit          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2.26          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           0.52          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Stock based compensation          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1.60          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1.62          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Other permanent differences          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           3.83          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (3.15          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Change in deferred tax rate          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1.66          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (2.33          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">           Change in valuation allowance          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (27.15          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )%          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (14.42          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">           Effective tax rate          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           0.00          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           0.00          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Deferred income taxes result from temporary differences in therecognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differencesrepresenting deferred tax asset and liabilities result principally from the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           September 30,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Deferred tax assets (liabilities):          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 74%; font-size: 10pt; text-align: left">           Stock based compensation          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           2,120,000          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           1,960,000          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Depreciation and amortization          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           232,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           277,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Net operating loss carry forward          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           17,499,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           14,091,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Tax credits          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,227,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,171,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Other          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           355,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           397,000          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Less: valuation allowance          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (21,433,000          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (17,896,000          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Net deferred tax asset          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 84; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            26            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE J– INCOME TAXES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of September 30, 2020, the Companyhas approximately $72,475,000 of Federal and $46,066,000 of State net operating loss “NOL” carryforwards availablewhich begin to expire after 2022. Pursuant to Internal Revenue Code Section 382, the Company’s ability to utilize theNOLs is subject to certain limitations due to changes in stock ownership in prior years as well as during the fiscal year endedSeptember 30, 2020. The annual limitation ranges between $94,000 and $1,103,000 and any unused amounts can be carried forwardto subsequent years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has provided a full valuation allowance againstall of the net deferred tax assets based on management’s determination that it is more likely than not that the net deferredtax assets will not be realized in the future. The valuation allowance increased by $3,537,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has Federal research and development credits ofapproximately $840,000 that will begin to expire after 2034. The Company also has state investment tax credits of $345,000 thatwill begin to expire after 2029.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE K – COMMITMENTS AND CONTINGENCIES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Operating leases        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company leases office space under an operating lease inStony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commencedon June 15, 2013 and expired on May 31, 2017, with the option to extend the lease for two additional three-year periods.The Company has exercised its option to extend the lease for one additional three-year period ending May 31, 2019. The baserent during the additional three-year period is $458,098 per annum. During November 2019, the Company extended this leaseuntil January 15, 2020. In addition to the office space, the Company also has 2,200 square feet of laboratory space. On January 20,2020, the Company entered into an agreement to amend both of these leases, extending the term for the corporate headquarters aswell as the laboratory space until January 15, 2021, with a one-year renewal option. During October 2020, the Companyexercised the one-year renewal option, extending the term for this lease until January 15, 2022. The Company also has a satellitetesting facility in Ahmedabad, India, which occupies 1,108 square feet for a three-year term beginning November 1, 2017.During September 2020, the Company renewed this lease with a new expiration date of September 30, 2021. The base rentis approximately $6,500 per annum. The Company’s total short-term lease obligation as of September 30, 2020 is $596,273.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Total rent expense for the fiscal years ended September 30,2020 and 2019 were $585,189 and $516,988, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Future minimum rental payments (excludingreal estate tax and maintenance costs) as of September 30, 2020 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        For the fiscal year ending September 30,       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 98%; border-collapse: collapse; margin-left: 0.25in">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 86%">           2021          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           $          </td>          <td style="width: 10%; text-align: right">           570,207          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           2022          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           188,261          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">           Total          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           $          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           758,468          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Employment and Consulting Agreements        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Employment agreements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 11, 2011, the Company’sBoard of Directors approved the terms of employment for Dr. James A. Hayward, the Company’s CEO.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The CEO’s employment agreement provides that he willbe the Company’s CEO, and will continue to serve on the Company’s Board of Directors. On July 28, 2017, anew employment agreement was entered into with the CEO effective July 1, 2017. The initial term was from July 1,2017 through June 30, 2018, with automatic one-year renewal periods. As of June 30, 2020, the employment contractrenewed for an additional year. Under the new agreement, the CEO will be eligible for a special cash incentive bonus of up to$800,000, $300,000 of which is payable if and when annual revenue reaches $8 million and $100,000 of which would be payablefor each $2 million of annual revenue in excess of $8 million. Pursuant to the contract, the CEO’s annual salary is$400,000. The Board of Directors, acting in its discretion, may grant annual bonuses to the CEO. The CEO will be entitled tocertain benefits and perquisites and will be eligible to participate in retirement, welfare and incentive plans available tothe Company’s other employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 85; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            27            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE K – COMMITMENTS AND CONTINGENCIES, continued        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The agreement with the CEO also provides that if he is terminatedbefore the end of the initial or a renewal term by the Company without cause or if the CEO terminates his employment for good reason,then, in addition to previously earned and unpaid salary, bonus and benefits, and subject to the delivery of a general releaseand continuing compliance with restrictive covenants, the CEO will be entitled to receive a pro rata portion of the greater ofeither (X) the annual bonus he would have received if employment had continued through the end of the year of terminationor (Y) the prior year’s bonus; salary continuation payments for two years following termination equal to the greaterof (i) three times base salary or (ii) two times base salary plus bonus; company-paid COBRA continuation coverage for18 months post-termination; continuing life insurance benefits (if any) for two years; and extended exercisability of outstandingvested options (for three years from termination date or, if earlier, the expiration of the fixed option term). If terminationof employment as described above occurs within six months before or two years after a change in control of the Company, then, inaddition to the above payments and benefits, all of the CEO’s outstanding options and other equity incentive awards willbecome fully vested and the CEO will receive a lump sum payment of the amounts that would otherwise be paid as salary continuation.In general, a change in control will include a 30% or more change in ownership of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Upon termination due to death or disability, the CEO will generallybe entitled to receive the same payments and benefits he would have received if his employment had been terminated by the Companywithout cause (as described in the preceding paragraph), other than salary continuation payments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Effective March 15, 2018, the Compensation Committee ofthe Company’s Board of Directors, approved a bonus of $121,125 that would be payable to the CEO when the Company reaches$3,000,000 in revenues for two consecutive quarters or $12,000,000 in revenues for a fiscal year, provided that the CEO is stillemployed by the Company on such date (the “Revenue Bonus”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Effective May 2, 2018, the Compensation Committee of theCompany’s Board of Directors, increased the amount of the Revenue Bonus to $403,623. Effective December 27, 2018, thecompensation committee approved an additional bonus opportunity of $150,000 for the calendar year-ended December 31, 2019that would be payable to the CEO under the same terms as described above.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The accrual for the Revenue Bonus of $816,840 is recorded tolong term accrued liabilities on the balance sheet as of September 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The CEO voluntarily reduced his salary for the fiscal yearsended September 30, 2020 and 2019. His base salary for the majority of the 2019 fiscal year was $250,000. During September 2019,the CEO further voluntarily reduced his salary from the then-current rate of $250,000 to $50,000. The CEO’s salary was subsequentlyincreased to $150,000 during December 2019. The Company has as of October 3, 2020 re-affirmed the employment agreement’sannual salary of $400,000, and from that date the CEO’s salary will be paid at such rate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On October 19, 2020, the Company awarded the CEO, a one-timediscretionary bonus, to be paid in cash, of $250,000, in recognition of his contributions to the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Litigation        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        From time to time, the Company maybecome involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company isaware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss willresult and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In additionto the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim orpotential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arisefrom time to time that may harm the Company’s business. There is no pending litigation involving the Company atthis time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         NOTE L – GEOGRAPHIC AREA INFORMATION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company attributes net revenues from external customersaccording to the geographic location of the customer. Net revenues by geographic location of customers are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <b>            Year Ended September 30,           </b>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2020           </b>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2019           </b>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 74%">           Americas          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           $          </td>          <td style="width: 10%; text-align: right">           1,165,320          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           $          </td>          <td style="width: 10%; text-align: right">           4,166,315          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           Europe          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           266,701          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           600,374          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           Asia and other          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           499,476          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           622,400          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt">           Total          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           $          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           1,931,497          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           $          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           5,389,089          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 86; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            28            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         APPLIED DNA SCIENCES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SEPTEMBER 30, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note M – FAIR VALUE OF FINANCIAL INSTRUMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        The Company's financial instruments at fair value are measuredon a recurring basis. Related unrealized gains or losses are recognized in unrealized gain on change in fair value of secured convertiblenotes payable in the consolidated statements of operations. For additional disclosures regarding methods and assumptions used inestimating fair values of these financial instruments, see Note C.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        The following table presents carrying amounts and fair valuesof the Company's financial instruments as of September 30, 2019 and summarizes the significant unobservable inputs infair value measurement of Level 3 financial assets and liabilities as of September 30, 2019. The Company did not have anyassets or liabilities categorized as Level 1 or 2 as of September 30, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Fair value at            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             September 30,            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             2019            </b>           </p>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Carrying value at            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             September 30,            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             2019            </b>           </p>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">           Valuation           <br/>           Technique          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">           Unobservable           <br/>           Input          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">           Range          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">           Weighted           <br/>           Average          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; font-weight: bold">           Liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-left: 5.4pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-left: 5.4pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; width: 26%; font-size: 10pt; text-align: left">           Secured Convertible Notes (“2018 Notes”)          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           102,777          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           104,482          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 10%; font-size: 10pt; text-align: left">           Monte Carlo simulation          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 10%; font-size: 10pt; text-align: left">           Annualized volatility          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           87.22% - 92.66%          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           87.39          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE N — RELATED PARTY TRANSACTIONS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 12, 2019, the Companyentered into a consulting agreement, with Meadow Hill Place, LLC (“Meadow Hill”), a company wholly owned by Scott L.Anchin (“Mr. Anchin”), a board member, whereby Meadow Hill will provide certain advisory services to the Company.The initial term of the agreement ended on June 12, 2020. The agreement provided for compensation in the form of both cashand equity. Meadow Hill was eligible to receive $125,000 for the initial six month term. In addition, in satisfaction of the equitycompensation portion of the agreement, (i) the Company granted an option to purchase 20,834 shares of its common stock toMr. Anchin on December 12, 2019 at an exercise price equal to $4.26 per share, which vested on June 12, 2020, and(ii) the Company granted an option to purchase 20,786 shares of its common stock to Mr. Anchin on January 2, 2020at an exercise price equal to $4.43 per share, of which 9,121 vested on July 2, 2020. The consulting agreement was completedon June 12, 2020 in full satisfaction of all obligations. As a result, the agreement was not extended and therefore expiredon June 12, 2020. As a result, 11,665 of the options granted on January 2, 2020, which were related to the extensionperiod, did not vest and were cancelled on June 12, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On each of December 9 and 10, 2020, the Investors exercised100,000 of their 2019 Warrants, for an aggregate exercise of 200,000 of their 2019 Warrants, resulting in total net proceeds tothe Company of approximately $1.1 million. As a result of these exercises, we issued to the Investors an aggregate of 100,000 additionalreplacement warrants, which are substantially similar to the Replacement Warrants described above except that 50,000 of the newly-issuedreplacement warrants have an exercise price of $6.57 and 50,000 of such replacement warrants have an exercise price of $6.46.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         NOTE O – SUBSEQUENT EVENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Warrant Exercise Agreement        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On October 7, 2020, the Company enteredinto Warrant Exercise Agreements with Dillon Hill and its affiliate, Dillon Hill Investment Company LLC (together, the “Investors”),whereby 318,000 of the 2019 Warrants with an exercise price of $5.25 per share were exercised. The gross proceeds to the Companyfrom this partial exercise of the 2019 Warrants is $1,669,500. Approximately 661,000 2019 Warrants currently remain outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In consideration of this partialexercise of the 2019 Warrants and of the consent to repayment of the July 2019 Notes, as described below, the Companyagreed to issue, 159,000 replacement warrants (the “Replacement Warrants”) to the Investors, which is an amountequal to one-half the amount of the 2019 Warrants exercised pursuant to the Warrant Exercise Agreements. The ReplacementWarrants have an exercise price of $7.54. In addition, until January 5, 2021, if the Investors exercise additional 2019Warrants, the Company will issue to the applicable Investor additional Replacement Warrants in an amount equal to one-halfthe amount of such exercised 2019 Warrants with each such Replacement Warrant having an exercise price equal to the closingprice on The Nasdaq Capital Market of the Company’s common stock on such date that the related 2019 Warrants areexercised.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Each Replacement Warrant will be exercisablebeginning on the date of issuance thereof and ending on the five year anniversary of such date. The exercise price and number ofshares of common stock issuable upon exercise of the Replacement Warrants will be subject to adjustment in the event of any stockdividend, split, recapitalization, reorganization or similar transaction, as described in the Replacement Warrant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On each of December 9 and 10, 2020, the Investors exercised100,000 of their 2019 Warrants, for an aggregate exercise of 200,000 of their 2019 Warrants, resulting in total net proceeds tothe Company of approximately $1.1 million. As a result of these exercises, we issued to the Investors an aggregate of 100,000 additionalreplacement warrants, which are substantially similar to the Replacement Warrants described above except that 50,000 of the newly-issuedreplacement warrants have an exercise price of $6.57 and 50,000 of such replacement warrants have an exercise price of $6.46.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Repayment of the July 2019 Notes        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On October 9, 2020, the Company enteredinto a letter agreement (the “Letter Agreement”) with Dillon Hill, as sole holder of the July 2019 Notes forthe repayment in full of the July 2019 Notes, in an aggregate amount of $1,665,581 (the “Payoff Amount”), representingthe outstanding principal amount of the July 2019 Notes plus accrued but unpaid interest through the scheduled maturity ofthe July 2019 Notes. The Company paid the Payoff Amount to Dillon Hill on October 9, 2020. As of October 9, 2020,all of the obligations and liabilities of the Company and its affiliates under the July 2019 Notes, the Purchase Agreement,and the Security Agreements, and any other related documents and instruments, was automatically satisfied in full, and all relatedliens, mortgages or other security interests were automatically released. Dillon Hill is a greater than 5% shareholder in theCompany’s common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 87; Options: Last -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            29            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>